





THE RELATIONSHIP BETWEEN QUALITY OF LIFE (EORTC QLQ C-30) AND 
















Submitted to the University of Glasgow 
for the Degree of Master of Science (Medical Science) 
in the Faculty of Medicine 
 
from research conducted in 
 
The University Department of Surgery 






        ©Margaret McKernan      
  2 
І.  CONTENTS                   PAGE 
І.  LIST OF CONTENTS           2 
ІІ.  LIST OF TABLES             4 
ІІІ.  LIST OF FIGURES             5 
ІV.  LIST OF ABBREVIATIONS         6 
V.  ACKNOWLEDGEMENTS          7 
VІ.  DECLARATION            8 
VІІ.  SUMMARY              9 
 
 
1.  INTRODUCTION AND AIMS 
1.1.1  Worldwide incidence and mortality        12 
1.1.2    United Kingdom incidence and mortality    13 
1.2  Pathology              16 
1.3  Aetiology              18 
1.3.1    Genetics            18 
1.3.2    Environment            18 
1.3.3    Inflammation            23 
1.4  Staging of disease            25 
1.4.1    Diagnosis            25 
1.4.2    Assessment and staging        25 
1.4.3    Symptom staging          27 
1.5  Treatment              28 
1.6  Weight loss, body composition and the systemic  
inflammatory response          33 
1.7  Quality of life             39 
1.8  Definitions and dimensions of quality of life     41 
1.9  Quality of life assessments          43 
1.9.1    Karnofsky performance scale       43 
1.9.2    Zubrod performance scale        44 
1.9.3    General health questionnaire        44 
1.9.4    SF-36              45 
1.9.5    WHOQOL-100          45 
1.9.6    Dysphagia score          45 
1.10  EORTC QLQ C-30            47 
1.11  Quality of life summary          49 
1.12  Aims of thesis             50 
 
 
2.  PATIENT STUDIES: THE RELATIONSHIP BETWEEN QUALITY OF LIFE 
(EORTC QLQ-C30) AND SURVIVAL IN PATIENTS WITH GASTRO-
OESOPHAGEAL CANCER 
2.1  Introduction              52 
2.2  Patients and Methods           54 
2.3  Statistics              56      
  3 
2.4  Results               57 
2.5  Discussion              60 
 
 
3.  PATIENT STUDIES: A PROSPECTIVE LONGITUDINAL STUDY OF THE 
IMPACT OF TREATMENT ON QUALITY OF LIFE (EORTC QLQ-C30) IN 
PATIENTS WITH GASTRIC AND OESOPHAGEAL CANCER 
3.1  Introduction              69 
3.2  Patients and Methods           71 
3.3  Statistics              73 
3.4  Results               74 
3.5  Discussion              76 
 
 
4.  CONCLUSIONS 
 
4.1  Introduction              90 
4.2  Aim 1                90 
4.3  Aim 2                91 
 
REFERENCES              93 
APPENDICES 
  Appendix A  TNM Classification        110 
  Appendix B  Quality of life assessment tools    113 
  Appendix C  Scoring methods for EORTC     118 
  Appendix D  EORTC tables         120      
  4 
ІІ.  List of Tables 
Table 2.1:  The relationship between clinico-pathological characteristics,  
quality of life and cancer specific survival in patients with  
gastro-oesophageal cancer            62 
 
Table 2.2:  The relationship between tumour site, clinico-pathological  
characteristics and quality of life in patients with gastro-oesophageal  
cancer                  63 
 
Table 2.3:  The relationship between TNM stage and clinico-pathological  
characteristics and quality of life in patients with gastro-oesophageal  
cancer                  64 
 
Table 2.4:  The relationship between appetite loss, clinico-pathological  
characteristics and quality of life in patients with gastro-oesophageal  
cancer                  65 
 
Table 2.5:  The relationship between systemic inflammatory response, as  
evidenced by elevated C-reactive protein, clinico-pathological and  
quality of life characteristics in patients with gastric-oesophageal  
cancer                  66 
 
Table 3.1:  The relationship between clinico-pathological and quality of life  
(EORTC QLQ-C30) characteristics in patients with operable gastric  
and oesophageal cancer and inoperable gastric and oesophageal cancer 
                    78 
 
Table 3.2:  Longitudinal dysphagia score and quality of life EORTC QLQ-C30  
in patients after gastrectomy at baseline, 3 and 6 months, 1, 2, 3 and  
4 years                  79 
 
Table 3.3:  Longitudinal dysphagia score and quality of life EORTC QLQ-C30  
in patients after oesophagectomy at baseline, 3 and 6 months,1, 2, 3  
and 4 years                80 
 
Table 3.4:  Longitudinal dysphagia score and quality of life EORTC QLQ-C30  
in patients with gastro-oesophageal cancer receiving oncological  
treatment at baseline, 3 and 6 months          81 
 
Table 3.5:  Longitudinal dysphagia score and quality of life EORTC QLQ-C30  
in patients with gastro-oesophageal cancer receiving supportive care  
at baseline, 3 and 6 months            82      
  5 
ІІІ.  LIST OF FIGURES  
Figure 2.1:  The relationship between appetite loss and cancer specific  
  survival in patients with gastro-oesophageal cancer.      67 
 
Figure 3.1:  Changes in quality of life following gastrectomy; 
social functioning               83 
 
Figure 3.2:  Changes in quality of life following gastrectomy; pain     83 
 
Figure 3.3:  Changes in quality of life following oesophagectomy; 
                   physical functioning              84 
 
Figure 3.4:  Changes in quality of life following oesophagectomy; 
        role functioning                84 
 
Figure 3.5:  Changes in quality of life following oesophagectomy; 
social functioning               84 
 
Figure 3.6:  Changes in quality of life following oesophagectomy; 
global quality of life              85 
 
Figure 3.7:  Changes in quality of life following oesophagectomy; 
dysphagia                 85 
 
Figure 3.8:  Changes in quality of life following oesophagectomy; 
 Fatigue                  85 
 
Figure 3.9:  Changes in quality of life following oesophagectomy; 
 nausea/vomiting               86 
 
Figure 3.10:  Changes in quality of life following oesophagectomy; 
dyspnoea                86 
 
Figure 3.11:  Changes in quality of life following oesophagectomy; 
diarrhoea                86 
 
Figure 3.12:  Changes in quality of life following oncological treatment; 
physical functioning              87 
 
Figure 3.13:  Changes in quality of life following oncological treatment; 
fatigue                  87 
 
Figure 3.14:  Changes in quality of life following oncological treatment; 
dysphagia                87 
 
Figure 3.15:  Changes in quality of life during supportive care; 
cognitive functioning              88 
 
Figure 3.16:  Changes in quality of life during supportive care; dysphagia    88      
  6 
ІV.  LIST OF ABBREVIATIONS 
AJCC    American Joint Committee on Cancer 
ASCO   American Society Clinical Oncology 
AUGIS  Association of Upper Gastrointestinal Surgeons 
BMI    Body Mass Index 
CRP    C-reactive protein 
CT    Computer Tomography 
ECOG   Eastern Co-operative Oncology Group 
EORTC  European Organisation for Research and Treatment of Cancer 
KPS    Karnofsky Performance Status Scale Index 
SAGOC  Scottish Audit of Gastric and Oesophageal cancer 
SD    Standard Deviation 
SIGN    Scottish Intercollegiate Guidelines Network 
TNM    Tumour, Node, Metastases 
QoL    Quality of Life 
QLQ-C30  Quality of Life Questionnaire-Core 30 
QLQ-OES18  Quality of Life Questionnaire-Oesophageal module 18 
UICC    Union International Centre of Cancer 
WHO    World Health Organisation 
WHOQOL  World Health Organisation Quality of Life      
  7 
V.  ACKNOWLEDGEMENTS 
I owe my most grateful thanks to Dr Donald McMillan, senior lecturer in the University 
Department of Surgery, Glasgow Royal Infirmary University NHS Trust for his invaluable 
support, encouragement, guidance and patience while writing this thesis. 
I am grateful to Mr Robert Stuart, Department of Surgery, Glasgow Royal Infirmary 
University NHS Trust for the opportunity to work with him over the years and his 
supervision, guidance and financial support to ensure its completion. 
I also wish to thank Mr John Anderson for allowing me to study his patients within the 
Southern General Hospital, Glasgow. 
I am extremely grateful to the patients who willingly participated in my studies. 
I am indebted to Dr Wilson Angerson for statistical assistance and the librarians in the 
medical library, Glasgow Royal Infirmary University NHS Trust for their help. 
Finally, I would like to thank my family and friends, particularly Connor my son, for his 
patience and unending help around the house!      
  8 
VІ  DECLARATION 
The studies presented in this thesis reflect work carried out by myself except where 
indicated below, over the period of 1997-2005, whilst working as a research nurse in the 
Department of Surgery, Glasgow Royal Infirmary. 
Routine measurements of serum albumin, C-reactive protein and white cell count were 
performed in the Institute of Biochemistry and Department of Haematology in Glasgow 
Royal Infirmary and the Southern General Hospital. 
Pathology reports were discussed at the multi-disciplinary meeting and were forwarded to 
me by the pathology departments within Glasgow Royal Infirmary and the Southern 
General Hospital. 
The statistical analysis was performed with the assistance of Dr Donald McMillan and Dr 
Wilson Angerson, University Department of Surgery, Glasgow Royal Infirmary, Glasgow. 
List of publications arising from this thesis 
1. M. McKernan., D.C. McMillan., J. Anderson., W. Angerson., R. Stuart. (2008).  The 
relationship between quality of life (EORTC QLQ-C30) and survival in patients with 
gastro-oesophageal cancer.  British Journal of Cancer, 98, 888-893 
 
2. M. McKernan., R. Stuart., J. Anderson., D.C. McMillan. (2008).  A prospective 
longitudinal study of the impact of treatment on quality of life (EORTC QLQ-C30) in 
patients with gastric and oesophageal cancer.  (Submitted to European  Journal of 
Cancer, March 2008). 
      
  9 
VІІ.  SUMMARY 
Gastro-oesophageal cancer is the third commonest cause of cancer death in the UK.  Each 
year, there are approximately 16,500 new cases diagnosed and over 13,000 deaths 
attributable to the disease.  Overall survival is poor with the majority of patients presenting 
with advanced, inoperable disease and less than 15% surviving 5 years, therefore ensuring 
the best quality of life is paramount for these patients. 
The traditional end points of tumour response, toxicity and survival are limited in 
discerning differences between the various treatments for gastro-oesophageal cancer.  
Irrespective of treatment, the majority of patients with advanced disease do not achieve a 
response to treatment or an increased survival.  Consequently, in the last decade, there has 
been considerable interest in including some measure of quality of life in the assessment of 
patients with cancer and their continuing aftercare, as it provides information on the 
patient’s perception of their health and the effectiveness and side effects of their treatment. 
Quality of life has been an implied outcome since the earlier days of health care.  In 1947, 
the World Health Organisation defined health as “a state of complete physical, mental and 
social well-being and not merely the absence of disease”.  The first scale to quantify 
patient’s activity level and capability was developed in 1948 by Karnofsky.  Since that 
time, numerous scales have been developed to assess an individual’s physical, 
psychological and social response to disease and its treatment. 
The aim of this thesis is to examine the baseline relationship between clinico-pathological 
characteristics and quality of life in gastro-oesophageal cancer patients and to further 
assess the long-term effect of treatment (surgery, oncological treatment or supportive care). 
For this study we have used the EORTC QLQ-C30, the ECOG performance status scale 
and the dysphagia score. 
In Chapter 2, an assessment of quality of life, clinical and pathological variables was 
undertaken on 152 patients.  This study demonstrated there were major differences in 
quality of life and symptom scores with increasing stage of disease.  In particular, social 
functioning, fatigue, appetite loss and global quality of life were all impaired with 
increasing tumour stage.  As might be expected in view of these associations, the majority      
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of quality of life and symptom scores predicted survival on univariate analysis.  It was of 
interest, however, that appetite loss remained an independently significant prognostic 
factor even after adjustment for TNM stage and treatment. 
Furthermore in the present study C-reactive protein concentrations were available in 94 
(62%) patients, at the time of quality of life assessment.  An elevated C-reactive protein 
concentration was associated with increased appetite loss and when included in the 
multivariate analysis, an elevated C-reactive protein concentration was independently 
associated with poorer cancer specific survival.  However, even those patients without an 
elevated C-reactive protein concentration, reported some appetite loss and the independent 
prognostic value of appetite loss remained, thus confirming the importance of appetite loss 
in the multifactorial nature of weight loss and poor outcome in these patients. 
The effect of treatment on aspects of quality of life including appetite loss has rarely been 
examined.  Furthermore, there are, to our knowledge, no studies which have examined the 
effect of surgery on quality of life beyond 3 years.  Therefore in Chapter 3 we examined 
the effect of treatment (surgery, oncological treatment or supportive care) on quality of life 
(EORTC QLQ-C30) for up to fours years post treatment in 160 patients.  Patients who 
underwent surgery had, at study entry, better global quality life including better physical 
and role functioning and less fatigue and appetite loss compared with those patients who 
did not receive surgery.  Furthermore, the effect of oesophageal surgery on global quality 
of life appeared to be more profound and persistent.  In contrast, in patients with 
inoperable disease, the poor quality of life measures at study entry remained poor on 
follow-up whether patients received oncological input or supportive care. 
In conclusion, the results of the present studies have indicated that appetite loss is 
important in determining quality of life in gastro-oesophageal cancer patients and is 
independently associated with poor survival.  Furthermore, the effect of surgery has a long 
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1.  INTRODUCTION AND AIMS  
1.1  Incidence and mortality of gastro-oesophageal cancer 
1.1.1  Incidence and mortality world wide 
In 2002, there were an estimated 11 million newly diagnosed cancer cases and 7 million 
cancer deaths reported worldwide.  Furthermore, there were nearly 25 million persons 
living with cancer.  Cancers of the lung, stomach, colon and rectum, liver and oesophagus 
are associated with the highest incidence worldwide; cancers of the lung, liver and 
oesophagus are associated with the highest mortality and are indicative of poor survival 
(Kamangar et al., 2006; Parkin et al., 2005).  Lung, colorectal, stomach and breast cancers 
account for nearly all cancer deaths in Europe (Boyle and Ferlay, 2005; Parkin et al., 
2005). 
Worldwide gastric cancer was the fourth most common cancer with approximately 600,000 
new cases among men and 330,000 new cases among women in 2002.  It is the second 
most common cause of cancer death with approximately 700,000 deaths annually.  Across 
continents incidence rates vary from 3.4 per 100,000 per year among females in North 
America to 26.9 per 100,000 per year among males in Asia.  Overall the 5-year survival 
rates are approximately 20% in most areas of the world, except Japan where there are mass 
screening programs and survival rates are approximately 60% (Parkin et al., 2005). 
Gastric cancer is declining in Switzerland and neighbouring countries, and the mortality 
fell by 60 % within one generation.  It is said that if this trend continues, gastric cancer 
may in some world regions become a rare disease within the next 30 years (WHO global 
cancer rates, 2003).  The incidence of non-cardia gastric cancer has declined in more 
developed countries over the last decade; this may be due to improved sanitation and 
improved diet and the decline of helicobacter infection.  In contrast the incidence of cardia 
cancers have increased or remained constant, this may be due to smoking, the rise in 
obesity and reflux disease (Blot et al., 1991; Munoz and Francesci, 1997). 
Worldwide oesophageal cancer is the eighth most common cancer and accounted for 
approximately 320,000 new cases among men and 150,000 new cases among women in 
2002, it is the sixth most common cause of cancer death with approximately 386,000 Created by Margaret McKernan     
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deaths annually (Parkin et al., 2005).  Overall incidence rates are two-fold higher in less 
developed countries compared with more developed countries (Kamangar et al., 2006).  
The majority of cases (80-85%) are diagnosed in developing countries where it is the 
fourth most common cancer in men and in most cases are squamous cancers (Brown and 
Devesa, 2002).  It has also been reported that the highest incidence for oesophageal cancer 
is in the so-called Asian ‘oesophageal cancer belt’ which stretches from Turkey through 
Iran, Afghanistan and Russia to China, and where incidence rates rise steadily with age 
(Parkin, 2004).  Oesophageal cancer tends to occur more often in the elderly, with the male 
to female ratio 3:1 (Keighley, 2003). 
Over the last three decades the incidence of adenocarcinoma in the lower part of the 
oesophagus has been rising steadily, in contrast there has been a decline in squamous 
cancers.  Wide variation has been reported both between countries and in different ethnic 
groups and populations within a country.  For example, in the USA the incidence of 
squamous cancers is almost six times higher in black men than in white, and the incidence 
of adenocarcinoma is almost four times higher in white men than black men.  It has been 
reported that the decline in the prevalence of squamous cancers is due partly to the decline 
in smoking and drinking, especially among men, and with the increased intake of fresh 
fruits and vegetables (Brown and Devesa, 2002).  It has also been reported that the 
increasing incidence of adenocarcinoma is partly due to reflux disease and Barretts 
oesophagus (Blot et al., 1991). 
Survival is universally poor worldwide, the majority of patients present with advanced or 
inoperable disease and mortality figures occasionally exceed the number of newly 
diagnosed cases per year.  Furthermore, it has been reported that less than 15% of the 
people survive for at least five years after initial diagnosis (Keighley, 2003). 
1.1.2  Incidence and mortality in the United kingdom 
In 2002, in the United Kingdom there were approximately 17,000 new cases of gastro-
oesophageal cancers diagnosed, and combined gastro-oesophageal cancer was the third 
most common cause of cancer death (Cancer Research UK, Information Resource Centre 
2004 and Welsh Cancer Intelligence), with over 13,000 deaths attributed to the disease 
(Office for National Statistics, Cancer Statistics).  Overall survival is poor with the Created by Margaret McKernan     
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majority of patients presenting with advanced disease and less than 15% surviving 5 years 
(Cancer Research UK). 
Gastric cancer accounted for 9,500 new cases and occurs more commonly in men, the 
male/ female ratio being 2:1, and has been reported to be the sixth most common cancer.  
Incidence rates rise steeply with increasing age, with the majority of cases being diagnosed 
from 60 years onwards. 
Fifty years ago gastric cancer was reported to be the leading cause of death in Britain, 
since then there has been a dramatic decline in incidence and mortality, with current rates 
less than half of the 1950’s.  In addition there is evidence of increasing adenocarcinoma in 
the gastric cardia.  It has been reported that this may be due to the rise in obesity and reflux 
disease, and in contrast there has been a decline in distal cancers, similar to the reported 
worldwide figures (Cancer Research UK). 
The 5 year survival rate for advanced gastric cancer has increased over the last twenty 
years in many countries, figures from the United Kingdom are still poor compared to other 
countries and only 12% survive 5 years.  Unfortunately, the majority of patients are 
diagnosed with advanced inoperable disease and the number of deaths per year is 15% less 
than the number of new cases diagnosed (Keighley, 2003). 
Rates for oesophageal cancer in the United Kingdom are significantly higher than the 
European average, with the highest incidence occurring in Scotland and rank 34
th out of 
172 countries (Boyle and Ferlay, 2005).  In 2002, oesophageal cancer accounted for 7,500 
new cases, the male/ female ratio was 3:2, and has been reported to be the fifth most 
common cancer.  Less than 10% of cases are diagnosed before the age of 55 and the rates 
increase steeply from the age of 60 onward.  Unfortunately, even when diagnosed at an 
early stage, cancer of the oesophagus has a poor prognosis.  Furthermore, adenocarcinoma 
is rising rapidly, partly due to reflux disease and Barretts oesophagus, particularly in men. 
Oesophageal cancer has been reported to be the fourth most common cause of death in 
men and sixth in women and mortality rates have risen sharply over the last thirty years 
(Cancer Research UK).  The 5-year survival rate for oesophageal cancer has recently been 
reported to be 9%.  Similar to gastric cancer, the majority of patients are diagnosed with Created by Margaret McKernan     
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advanced inoperable disease and the number of deaths per year is 9% less than the number 
of new cases diagnosed (Keighley, 2003). 
Based on current evidence, both gastric and oesophageal cancer will remain as commonly 
fatal cancers with incidence only just greater than the mortality (Scottish Audit of Gastric 
and Oesophageal Cancer, 1997-2000).  Furthermore, areas with high levels of deprivation 
are strongly associated with high rates of oesophageal cancer in men, and of gastric cancer 
in both men and women (McKinney et al., 1995). 
From the above data it is evident that overall gastro-oesophageal cancer has a high 
incidence and mortality rate, as the majority are diagnosed at an advanced stage ensuring 
the best quality of life is paramount for these patients. Created by Margaret McKernan     
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1.2  Pathology 
The vast majority of gastric cancers within the United Kingdom are adenocarcinomas.  
Rare tumours such as adenosquamous or lymphomas are not considered typical and are not 
included in this thesis. 
Jarva and Lauren (1951), established that the histological structure of gastric 
adenocarcinoma often displays features characteristic of intestinal mucosa and reported 
that at least 50% of gastric cancers arise from intestinal metaplasia in the stomach; gastric 
adenocarcinoma can also be described as a solid tumour.  Lauren (1965) reported that 
gastric cancers could be divided into those with gland formation (intestinal type) and those 
without glandular characteristics (diffuse type).  Intestinal type cancer occurs more 
commonly in older male patients, whereas diffuse type cancer has a constant rate 
worldwide and occurs in a younger age group (Lauren Classification, 1965).  Lo and co-
workers (1996) reported that the diffuse type tumours are predominate in younger patients 
and are associated with a worse prognosis (Lo et al., 1996).  Early gastric cancer (EGC) 
was first defined in 1962 by the Japanese’s Society of Gastroenterological Endoscopy, as 
adenocarcinoma confined to the mucosa or submucosa without penetration through the 
muscularis propria, irrespective of lymph node involvement (Murakami, 1971). 
Tumours are also classified according to the Japanese Research Society Committee and are 
divided into papillary/well differentiated and tubular/moderately differentiated 
adenocarcinoma.  It has been reported that the degree of differentiation is closely related to 
the depth of invasion, with poorer differentiation evident in submucosal and advanced 
cancers (Ferrari et al., 1992). 
There are two main types of oesophageal cancer, squamous and adenocarcinoma due to the 
marked differences in the pathogenesis, tumour biology and characteristics of the affected 
patients they are treated as separate entities.  Squamous cell cancer continues to be the 
most common histology and occurs more frequently in the upper two-thirds of the 
oesophagus, macroscopically there are ulcerated, polypoid and diffusely infiltrating forms, 
differentiation can differ in this tumour type (Vellone et al., 2006).  However, in the last 
few years adenocarcinoma involving the distal oesophagus and gastro-oesophageal 
junction has increased in frequency. Created by Margaret McKernan     
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Following a consensus conference of the International Gastric Cancer Association and 
International Society for Diseases of the Esophagus all participating experts agreed that 
there should be a clear definition and classification of tumours arising within the 
oesophagogastric junction (Siewert and Stein, 1998).  Type; I/II/III, the most common is 
type I, adenocarcinoma of the distal oesophagus which can arise in Barretts oesophagus; 
and contains glandular epithelium, of which there are three types (metaplastic columnar, 
metaplastic glandular and metaplastic intestinal).  Type II arises within the cardiac 
epithelium (cardia) or can be short segments with intestinal metaplasia at the gastro-
oesophageal junction.  Type III infiltrates the oesophagogastric junction and distal 
oesophagus from below.  Dysplasia is more likely to develop in intestinal type mucosa 
(Siewert and Stein, 1998; Stein et al., 2001). Created by Margaret McKernan     
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1.3  Aetiology 
The large majority (approximately 90%) of gastric and oesophageal cancers are believed to 
be due to environmental factors and the remaining 10% having been linked to genetic 
factors. 
1.3.1  Genetics 
Researchers are beginning to identify genetic factors that contribute to the development of 
stomach cancer.  Patients with blood relatives who have been diagnosed with stomach 
cancer are more likely to develop the disease, two Italian studies estimated that 8% of 
stomach cancer cases are due to inherited factors (Encyclopaedia of genetic disorders, 
2006; Cancer consultants.com).  In the United Kingdom approximately 10% of gastric 
cancers cluster in families, a family history of gastric cancer has been shown to marginally 
increase the risk of relatives developing cancer compared to that of the general population.  
Furthermore, it has been reported that environmental factors shared by family members 
may explain the clustering effect in families (Cancer Research UK). 
A previous study in the USA reported that the risk of developing gastric cancer was 
elevated in patients who had a family history of the disease; in contrast there was no 
association to any form of oesophageal cancer.  The authors have stated that the study has 
a number of limitations, most importantly that the potential for recall bias from patients 
can be poor and inaccurate (Dhillon et al., 2001). 
1.3.2  Environment 
In 2002 the World Health Organization and Food and Agriculture Organization stated that 
eating habits were the main factor involved in gastric and oesophageal cancer risk.  
Furthermore, as developing countries become urbanised the patterns of cancer shift 
towards those of more developed countries (WHO, 2003).  There are geographic and 
ethnic differences in the incidence around the world.  Furthermore, incidence patterns 
observed among immigrants change according to where they live (Tsugane and Sasazuki, 
2007).  All of these factors serve to indicate the close association of gastric and 
oesophageal cancer with factors such as diet and lifestyle changes. Created by Margaret McKernan     
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Several case-controlled studies have been undertaken over the years to study the 
association between a poor diet and the diagnosis of gastric cancer.  Low consumption of 
vegetables and fruits and a high intake of processed foods and salts have been highlighted 
as being predisposing factors in gastric cancer.  One study by Tajima and Tominaga (1985) 
from Japan, reported that in gastric and colorectal cancer patients, a fondness for salty 
tastes, especially salted foods such as pickled hakusai (vegetable) and dried salted fish, 
which are typical traditional Japanese foods, showed a significantly positive association 
with gastric cancer.  Conversely, the habit of eating a western style breakfast for greater 
than 10 years made a greater contribution to colon cancer, but a decreased risk in gastric 
cancer (Tajima and Tominaga, 1985). 
Another study from Italy by Buiatta and co-workers (1989) reported on diet, between 
known gastric cancer patients and the general population, that a significant trend of 
increasing gastric cancer was found with an increased consumption of traditional soups, 
meats, salted/dried fish and a combination of cold cuts and seasoned cheeses.  The habit of 
adding salt to food and the preference for salty foods were associated with an elevated risk 
of gastric cancer, while storing foods in the refrigerator and the availability of the freezer 
to store fresh unsalted foods lowered the risk, along with increasing the intake of raw 
vegetables and fresh fruit (Buiatti et al., 1989). 
A case controlled study by Cook-Mozaffari and co-workers (1979) on oesophageal cancer 
patients in Iran, reported that there was a strong association between low-socio-economic 
class and a low intake of fresh fruit and vegetables.  Furthermore, a second potential factor 
associated with socio-economic class is the continued use of traditional outmoded 
agricultural practices in separating and storing wheat, which could lead to a contamination 
of bread.  The study concluded that a high-fat, low protein diet, low intake of fresh fruit 
and vegetables and also excessive drinking of hot liquids have also been shown to increase 
the risk of oesophageal cancer (Cook-Mozaffari et al., 1979). 
Wu and co-workers (2007) reported recently that the intake of fibre had a significant 
impact on risk of oesophageal and gastric cardia adenocarcinoma.  The study reported on 
dietary factors in oesophageal (n=206), gastric cardia (n=257), distal gastric (n=366) 
adenocarcinoma patients and 1,308 control subjects in Los Angeles.  The study concluded 
that a high intake of fibre was associated with significant reduced risks of oesophageal and 
gastric cardia adenocarcinoma (Wu et al., 2007). Created by Margaret McKernan     
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The incidence of oesophageal and gastric cardia adenocarcinoma has been rising steadily 
since the 1970’s in obese patients.  It is unclear to what extent the two are related; several 
authors have looked at the relation.  One possible relation could be that patients with an 
increased girth are more susceptible to reflux; in turn this is known to predispose the risk 
of Barretts metaplasia.  Vaughan and co-workers in the USA, (1994) undertook two case 
controlled studies on 404 gastric and oesophageal cancer patients.  They reported that high 
body mass index was associated with an increase in adenocarcinomas of the oesophagus 
and cardia in 18% of patients, in contrast, patients with squamous cancer had consistently 
lower body mass indices than controls (Vaughan et al., 1994). 
A further study by Lagergren and co-workers on Swedish patients (1999) measured 
patients BMI at diagnosis, and enquired about body weight 20 years before diagnosis, to 
assess latency between the critical effect of BMI on carcinogenics and the clinical 
manifestation of the tumours.  The study concluded that the association between BMI and 
oesophageal adenocarcinoma was strong, and was independent of the presence of reflux 
symptoms or of Barretts metaplasia, furthermore the mechanism that would fully explain 
the carcinogenic effect remained to be identified (Lagergren et al., 1999). 
In contrast, a study from China by Zhang and co-workers (2003) compared a healthy 
population of subjects and operable gastric cardia adenocarcinoma patients, BMI was 
recorded and it was reported that patients diagnosed were underweight.  Furthermore, no 
underweight subject was found in the healthy cohort of patients.  The study reported that 
the differences in results might be due to the genetic background of Chinese people, which 
differs greatly from Westerners (Zhang et al., 2003). 
(Kubo and Corley, 2006) undertook a systematic review of observational studies from 
1966 to 2005 and found 14 relevant studies which filled their criteria, which included body 
mass index and oesophageal and cardia cancers.  The pooled results supported a positive 
association between increased BMI and the risk of oesophageal adenocarcinoma.  The 
strength of the association increased with increasing BMI and there was a trend towards 
men compared with women.  The results on gastric cardia association were weaker; 
furthermore, there was no clear association in cancer patients from China. 
Another possible factor involved in the development of gastric cancer is Helicobacter-
pylori (a spiral-shaped gram-negative bacillus) found in the stomach, which causes Created by Margaret McKernan     
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inflammation of the mucous membrane, and is more often associated with diffuse and 
intestinal gastric cancers.  In 1994, the International Agency for Research on Cancer, as 
part of the World Health Organization identified H-pylori as a definite biological 
carcinogen (Schwesinger, 1996).  In 20% of patients this can induce gastric ulcers 
(Parsonnet, 1998), numerous studies have looked closely at the link to H-pylori and gastric 
adenocarcinoma, and there are conflicting outcomes to these studies.  El-Omar and co-
workers (2000), reported that helicobacter was present in approximately 50% of the 
world’s population and infected patients have an increased risk of developing gastric 
cancer due to the histological and functional changes it causes, such as atrophic gastritis 
and hypochlorhydria.  The study also reports that relatives of Scottish gastric cancer 
patients with H-pylori infection also have an increased prevalence of atrophy (52%) and 
hypochlorhydria (40%) and therefore an increased chance of them developing the disease 
(El-Omar et al., 2000).  Ye and co-workers (2004) reported a reduced risk of oesophageal 
adenocarcinoma in Swedish patients with H-pylori and suggested that the H-pylori 
infection may have a protective effect in respect of this cancer (Ye et al., 2004). 
A possible factor involved in the development of oesophageal cancer is chronic irritation 
of the mucosa related to acid reflux, which has been recognised to be a factor in 
developing Barretts oesophagus.  Barretts oesophagus as detailed above develops in the 
distal part of the oesophagus in a subset of patients (approximately 1%) with chronic 
reflux.  The epithelial surface is altered to become more like the lining of the stomach; a 
process called intestinal metaplasia, this condition requires endoscopic surveillance to 
detect any pre-cancerous changes (National Cancer Institute).  In Scotland approximately 
14% of oesophageal cancer patients had previously been diagnosed with Barretts 
oesophagus (SAGO C, 2002).  A study by Chak and co-workers (2002) reported that 
patients with Barretts oesophagus or oesophageal adenocarcinoma are 12 times more likely 
to have a first or second degree relative with a history of Barretts and /or oesophageal 
adenocarcinoma and concluded that it is important to gather careful family history when 
screening patients with Barretts oesophagus for surveillance (Chak et al., 2002). 
Toxins and chemicals have been reported to be significant in both gastric and oesophageal 
cancer.  O’Neill and co-workers (1980) reported that there was a high incidence of 
oesophageal cancer in north-east Iran, where there is contaminated flour originating from a 
fine fibrous silica which is found in the weeds that contaminate the wheat (O’Neill et al., 
1980). Created by Margaret McKernan     
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Several studies regarding cigarette smoking and alcohol have been undertaken to 
demonstrate the association with gastro-oesophageal adenocarcinoma.  Squamous cell 
cancers of the oesophagus have been long associated with cigarette smoking and/or 
excessive alcohol intake.  Studies undertaken in Japan and Italy looked at gastric cancer 
patients and reported that there was no positive link between drinking and gastric cancer 
(Tajima and Tominaga, 1985; Buiatti et al., 1989).  A more recent study, reported that 
combined high levels of tobacco and alcohol were more prevalent in patients with cardia, 
proximal and distal gastric cancers (Sung et al., 2007). 
Vaughan and co-workers (1994) reported in their study of oesophageal cancer patients that 
cigarette smoking and alcohol accounted for 50% of adenocarcinomas and an elevated risk 
was found in patients who drank straight liquor.  In comparison, cigarette smoking and 
alcohol alone accounted for 87% of the squamous cancers; the study concluded that there 
was no reason to believe that cigarettes and alcohol were associated with the rise in 
adenocarcinomas (Vaughan et al., 1994).  A French study reported that for a given lifetime 
consumption of alcohol, a high intake during a shorter period carries a higher risk than a 
moderate intake during a longer period.  Furthermore, the risk varied greatly according to 
the type of alcoholic beverage, the higher risks were associated with aniseed aperitifs, beer 
and hot spirits (especially hot Calvados) the study further suggested that 2⁄3 of the high 
incidence in the west of France and in rural populations could be due to the specific habit 
of drinking hot spirits (Launoy et al., 1997; Launoy et al., 1997). 
The risk of gastric and oesophageal cancer in the workplace has been
 the focus of 
significant research, studies have looked at the exposure to toxins and chemicals in 
employees.  The IARC recently considered
 that there is evidence, although not definitive, 
of an association
 between gastric cancer and coal, rubber, and leather industries
 and asphalt 
workings (International Agency for Research on Cancer, 1981). 
A Danish study by Raaschou-Nielsen and colleagues (2003) reported that 1:8 of employees 
working with Trichloroethylene went on to develop oesophageal cancer.  A further study 
by Yu and colleagues (2005) examined the relationship between silicosis and oesophageal 
cancer in Hong Kong and concluded that there was a greater risk in employees who 
worked in underground caissons after adjusting for cigarette smoke and alcohol 
(Raaschou-Neilsen et al., 2003; Yu et al., 2005).  Raj and co-workers (2003) reviewed 
several previous studies and concluded, that it would be difficult
 to judge with confidence Created by Margaret McKernan     
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whether some people are more at risk
 as a result of their occupation or their social class, 
when
 some occupations attract workers from certain classes and indeed
 occupations can 
define social classes (Raj et al., 2003). 
Worldwide low socio-economic class has also been reported to be a risk factor in the 
development of gastric and oesophageal cancer and is more obvious in squamous 
oesophageal cancer, where environmental issues associated with poor housing, 
overcrowding and inadequate/unsanitary food preparation areas play an important role.  
Data from the United Kingdom also shows a strong association with social deprivation and 
gastric cancer and oesophageal squamous cancer, but no clear association with 
oesophageal adenocarcinoma (Cancer Research UK, 2004; SAGO C, 2002). 
1.3.3  Inflammation 
There is increasing evidence that the systematic inflammatory response, as evidenced by 
elevated circulating concentrations of C-reactive protein, often acts as a tumour promoter, 
resulting in aggressive cancerous growth and spread, normally the inflammation response 
is self limiting and ceases when healing occurs.  However, continuing inflammatory 
response may occur in response to a tumour, releasing a number of substances, including 
pro-inflammatory cytokines (Argyles and Lopez-Soriano, 1998; MacDonald, 2007).  A 
further study from Japan identified a decrease in survival in oesophageal cancer patients 
with an elevated C-reactive protein at the time of diagnosis (Nozoe et al., 2001).  Recent 
studies by (Crumley et al., 2006; Deans et al., 2006; Wong et al., 2007) showed that the 
presence of an elevated C-reactive protein and hypoalbuminaemia, (using the Glasgow 
Prognostic score) highlighted that a systematic inflammatory response appears to be a 
useful outcome measurement of survival in patients with operable and inoperable gastric-
oesophageal cancer.  Furthermore, Crumley and co-workers (2007) reported in patients 
undergoing platinum based treatment that the presence of systemic inflammatory response 
appears to be superior to the subjective assessment of performance status (Crumley et al., 
2007). 
In summary, it would appear a healthy lifestyle i.e. not smoking, not consuming excess 
alcohol, avoiding obesity and maintaining a good dietary intake of fibre, fruit and 
vegetables is associated with reduced risk of both oesophageal and gastric cancer and 
should be encouraged (SIGN 87, 2006 Recommendation).  It may be that such lifestyle Created by Margaret McKernan     
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factors are associated with the elaboration of an inflammatory response that, in turn, 
promotes tumour formulation and progression (McMillan et al., 2006).Created by Margaret McKernan     
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1.4  Staging of disease 
Tumour staging is a method of describing cancer development.  Gastric and oesophageal 
cancers are diagnosed and staged after a number of investigations are performed; accurate 
staging is essential in planning the surgical approach or oncological input and in 
determining the risk of tumour recurrence and overall prognosis.  The Association of 
Upper Gastrointestinal Surgeons of Great Britain and Ireland, (AUGIS, 2002) and more 
recently the Scottish Intercollegiate Guidelines Network (SIGN, 2006) developed 
guidelines after they undertook a systematic review of relevant literature. 
1.4.1  Diagnosis 
Initially, an endoscopy (flexible telescope is passed through the mouth into the stomach) 
should be performed and multiple biopsies taken for a pathological diagnosis.  At the time 
of endoscopy, location, size and appearance of the tumour can also be ascertained.  This 
procedure can be undertaken with or without a mild sedative.  In some cases barium meals 
or swallows are still performed, as part of the diagnostic workup.  In recent years 
endoscopy has become the preferred choice of initial assessment.  Dooley and co-workers 
(1984) reported on randomly selected patients (n=100) who were examined with both 
double-contrast barium meal and endoscopy in a blinded prospective fashion and 
concluded, that endoscopy was reported to be more sensitive and specific than the double-
contrast barium meal and further reported that endoscopy should be recommended for 
initial assessment (Dooley et al., 1984).  AUGIS (2002) and SIGN (2006) guidelines 
recommended that the diagnosis of malignancy should be confirmed by endoscopy and 
pathologically (Alum et al., 2002; www.sign.ac.uk). 
1.4.2  Assessment and staging 
After histological confirmation the next step is to assess the depth and spread of the 
tumour.  Accurate staging is achieved by a combination of techniques.  The recommended 
initial preferred mode of non invasive investigation staging assessment should include 
contrast enhanced computerised tomography scan of the thorax and abdomen to determine 
the presence or absence of metastatic disease.  The neck and pelvis should be imaged at the 
same time to provide adequate staging.  If at this time advanced or metastatic disease is Created by Margaret McKernan     
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confirmed then no further investigation is required (Allum et al., 2002 and 
www.sign.ac.uk). 
More recently, in the absence of metastatic disease, assessment of operability is preferably 
made by endoscopic ultrasound (EUS); which is performed with a small high frequency 
probe incorporated into the distal end of the endoscope.  This technique more accurately 
assesses the depth of penetration of the tumour, but the ability to accurately stage nodal 
involvement is dependant upon the site of the tumour.  Local nodes are usually well seen, 
but detection of more distant nodes is reduced by the limited ultrasound penetration 
(McLean and Fairclough, 1996).  Endoscopic ultrasound also allows fine needle aspiration 
(FNA) of suspicious lymph nodes; this also improves the accuracy of nodal staging. 
Magnetic resonance imaging (MRI) and Positron emission tomography (PET) are accurate 
for TNM staging, but are not routinely used, as CT and EUS can be as accurate in staging 
(www.sign.ac.uk). 
Patients with gastric cancer and oesophageal tumours with a gastric component, if suitable 
for anaesthetic, will have a laparoscopy to detect any peritoneal deposits.  Laparoscopy can 
be performed with or without ultrasound, and a peritoneal lavage will be carried out and 
sent to cytology to detect any peritoneal metastasis.  Molloy and co-workers (1995) 
reported on the role of laparoscopy to detect inoperable advanced disease or to determine 
patients suitable for further resection, laparoscopy was performed on 244 patients and 
concluded that laparoscopy was a valuable investigation when used to assess the feasibility 
of resection (Molloy at al., 1995). 
Patients with upper third oesophageal cancer may have a bronchoscopy to assess 
tracheobronchial invasion, again washings may be sent to cytology to assess any spread to 
the lung. 
Tumours are then staged using TNM, edition of the international union against cancer 
(UICC) classification of malignant tumours, which defines the anatomical extent of the 
disease, (see appendix A 1.4).  The (T) category is the depth of tumour infiltration and the 
relationship with neighbouring structures.  The (N) category determines regional lymph 
node metastases and the (M) category reports on distant metastases or lymphatic invasion 
(UICC, 1997). Created by Margaret McKernan     
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1.4.3  Symptom staging 
Gastric and oesophageal cancer is often asymptomatic or causes mild symptoms in its early 
stages i.e. heartburn, indigestion and loss of appetite.  It is usually only in later stages 
symptoms are more severe i.e. abdominal pain, nausea, vomiting, weight loss, weakness, 
fatigue, bleeding and dysphagia.  A muticentre study of oesophageal cancer patients 
(n=5000) by Daly and co-workers between 1994-1997 reported that at diagnosis patient’s 
most common symptoms were dysphagia (74%) and weight loss (57%).  They concluded 
that patients tend to modify their diets for a long time before seeking attention and 
dysphagia may progress rapidly to a stage where patients are unable to swallow fluids or 
saliva (Daly et al., 2000).  Therefore, the disease is usually advanced when the diagnosis is 
made.  However, several studies have reported that the duration of symptoms does not 
predict survival (SAGOC 2002; Martin et al., 1997). 
In potentially curative cancer patients the main symptom tool used is the ECOG 
performance status, lung function tests and, in some centres, the POSSUM score.  A 
retrospective study of patients who underwent oesophagectomy reported that age, lung 
function, and performance status could be used to select patients who would benefit from 
pre-operative cardio pulmonary rehabilitation (Ferguson and Durkin, 2002).  McCulloch 
and co-workers (2003) reported that after initial assessment 57% of gastric and 
oesophageal patients assessed for surgery were unfit for surgery due to chronic respiratory 
and cardiac conditions (McCulloch et al, 2003).  One American study reported a stair 
climbing exercise offers an inexpensive means to predict potential post-operative 
cardiopulmonary complications after high-risk surgery (Girish et al, 2001).  Therefore, 
TNM staging, age, performance status and co-morbidity need to be taken into 
consideration before deciding on the best treatment for the patient. Created by Margaret McKernan     
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1.5  Treatment 
Like any cancer, treatment is adapted to fit each person’s individual needs and depends on 
tumour size, location, and extent of the tumour, the stage of disease and the patients 
general health, well being and patient preference to options available.  Gastric and 
oesophageal cancer is difficult to cure unless it diagnosed at an early stage, unfortunately 
the majority of these cancers are advanced at time of presentation.  Treatment options 
include surgery, chemotherapy, radiation therapy, endoscopic therapy, multimodality 
therapy, or palliative care. 
Alici and co-workers (2006) reported that in patients with gastric cancer, the ideal 
approach to patient’s treatment choice is to establish as many prognostic factors as possible 
before administering therapy, furthermore knowing the prognostic factors could therefore 
aid the physician in improving prognosis.  Surgical complications and chemotherapy 
toxicity can also have an impact on overall survival time (Alici et al., 2006). 
There are various treatments that can be offered to patients once prognostic factors have 
been determined.  In patients who have potentially curable disease, the majority of cases 
will be offered surgery if fit enough.  The extent of the resection undertaken will depend 
on tumour site, histology and stage.  Although surgery confers the greatest chance of long-
term cure and aims to maintain long-term quality of life it may be associated with 
significant morbidity. 
 
Surgery for gastric cancer has the best chance of cure, two studies comparing distal 
gastrectomy and total gastrectomy for non cardia gastric cancers reported similar results on 
5 year survival, morbidity and mortality and concluded that sub total gastrectomy was 
associated with a better nutritional status and quality of life and should be the procedure of 
choice, provided that the proximal margin of the resection falls in healthy tissue, the only 
adverse outcome of this type of operation is the chance of recurrence in the remaining 
stump (Gouzi et al., 1989; Bozzetti et al., 1999; Bae et al., 2006).  (Hundahi et al., 2000) 
reported that in Japanese proximal and distal cancers, the patient’s 5 year survival rate was 
approximately 20%/34% respectively five years after resection. 
 
Surgery for oesophageal cancer is extensive and there is a greater chance of operative 
mortality and very seldom performed on patients with upper third cancer, Daly and co-Created by Margaret McKernan     
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workers (2000) reported that on comparing transthoracic and transhiatal oesophagectomy, 
that hospital stay was similar, but post operative complications were more frequent in the 
later, furthermore at least one major postoperative complication occurred in 46% of 
patients (Daly et al., 2000).  The 5-year survival rate for oesophageal cancer patients that 
undergo potentially curative resection has recently been reported to be 40% (Stein et al., 
2005).  Ancona and co-workers (2006) reported that postoperative complications after 
oesophagectomy did not affect the patient’s long-term prognosis (Ancona et al., 2006).  
Important postoperative complications in both tumour sites include anastomotic leak, 
wound infection, cardiac and pulmonary complications and pneumonia. 
If unfit for surgery but stage of disease is amenable for cure then chemotherapy agents can 
be administered, normally (ECF) Epirubicin, Cisplatin and 5-Fluorouracil (5-FU).  Side 
effects (usually temporary) of chemotherapy may include a low blood count, hair loss, 
vomiting and diarrhoea and skin irritation.  Chemotherapy can be combined with 
radiotherapy, particularly when cure is being sought in oesophageal cancer; Ross and co-
workers reported an improved outcome in patients with loco-regional oesophageal disease 
(Ross et al., 1998). 
Several studies have reported on the use of neo-adjuvant chemotherapy to downstage 
tumour.  The United Kingdom MAGIC (MRC adjuvant gastric infusional chemotherapy) 
trial randomised gastric and oesophageal cancer patients (n=503) to pre-operative and post 
operative chemotherapy versus surgery alone, with a follow up period of three years.  The 
results demonstrated a significant difference in favour of the surgery plus chemotherapy 
group with respect to resection rate and survival (Cunningham and W.A.S.S.S.W, 2005). 
Radiotherapy may be used as a single modality radical treatment for patients with a small 
length of oesophageal cancer, to relieve dysphagia and control local disease.  The main 
disadvantage of radiotherapy is the development of an oesophageal stricture or 
oesophagitis. 
Endoscopic treatments offer an alternative to surgery, endoscopic mucosal resection 
(EMR) can be undertaken to remove an early tumour of less than 3cm in diameter in 
gastric and oesophageal cancer patients.  The resected specimen will be sent to pathology 
where they will check the depth of invasion and if the margins are clear.  EMR is suitable 
for elderly patients who are not fit enough to undergo surgery or able to cope with the side Created by Margaret McKernan     
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effects of chemotherapy, this is performed under sedation at time of endoscopy; therefore 
the patient will not be subjected to a general anaesthetic.  EMR has an advantage of low 
morbidity and mortality.  A recent Japanese study reported that the 3 year 
residual/recurrence free survival rate after EMR was 92.5% and concluded should be the 
standard treatment for early cancers (Oda et al., 2006). 
Patients who have advanced/metastatic disease will be offered palliative therapies directed 
towards alleviating symptoms.  These palliative treatments can include surgery or by-pass 
but this is associated with high mortality and morbidity and less invasive options are 
currently used.  There are a wide variety of palliative therapies suitable for this cohort of 
patients as outlined below.  Daly (2000) reported that after clinical staging over 60% of 
patients had advanced disease and went on to receive palliative input (Daly et al., 2000).  
This result was replicated in another study by (Schlansky et al., 2005) where 89% of 
patients were clinically staged as advanced disease. 
Palliative chemotherapy may be given with the intent to increase survival, sustain quality 
of life and improve dysphagia.  Ross and co-workers (1998) reported that gastric cancer 
was one of the most chemo sensitive solid tumours of the gastrointestinal tract with the 
majority of patients being suitable for palliative chemotherapy.  The ECF regimen was 
developed in the gastrointestinal unit of the Royal Marsden Hospital and first reported in 
1991, in a prospective randomised trial.  ECF was compared with the standard combination 
of 5-Fluorouracil, Adriamycin and Methotrexate (FAMTX) in patients with previously 
untreated gastric cancer, it was reported that the response rate and overall survival was 
significantly improved with the ECF regime (Ross et al., 1998).  In recent years Mitomycin 
had been substituted for Epirubicin in the hope to reduce toxicity, Ross (2002) reported 
that on comparing ECF with MCF that there was a higher response rate and less toxicity 
with ECF and recommends that ECF should still be the treatment of choice for advanced 
gastro-oesophageal cancers (Ross et al., 2002).  Currently there is limited evidence to 
support the efficacy of chemotherapy alone in oesophageal cancer patients (Conroy, 2006). 
Palliation of advanced oesophageal cancer will be the main goal of treatment and will offer 
relief of mechanical obstruction and swallowing function (Kelsen, 1982), thus allow 
improved food intake.  Caspers and co-workers (1988) reported that oesophageal cancers 
are often responsive to radiotherapy and has been shown to palliate symptoms of 
dysphagia, the study concluded that 70% of patients showed improvement in dysphagia Created by Margaret McKernan     
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and furthermore, 54% remained palliated until time of death (Caspers et al., 1998).  The 
potential side effect from this mode of treatment may be severe oesophagitis.  There are no 
studies evaluating the use of radiotherapy alone in patients with gastric cancer, but it can 
be useful for pain control in patients with proven bone metastatic disease. 
Palliation of dysphagia in oesophageal cancer patients is of high importance and there is a 
range of different endoscopic modalities that involve ablation or stenting.  Ablation 
techniques include laser, argon plasma coagulation, alcohol injection and photodynamic 
therapy.  The side effects from these treatments include perforation, haemorrhage, fistulas 
and stricture; these treatments are repeated until the patients’ swallowing has improved.  In 
a study by Mellow and Pinkas (1985) it was reported that 97% of oesophageal patients 
achieved luminal patency after an average of three laser treatments over seven days.  
Furthermore, there was also a marked improvement in nutritional input and performance 
status (Mellow and Pinkas, 1985). 
Laser treatments are also extensively used in the treatment of gastric cancers and can 
provide good palliative results and contribute to a good quality of life (Wu et al., 1989).  
Mathus-Vliegen and Tytgat (1990), reported in patients with gastro-oesophageal cancer 
(n=42) who were mainly referred for bleeding or obstruction that laser palliation was 
successful in 81% and 86% of patients respectively.  Argon plasma coagulation (APC) in 
which a current is applied to tissues by means of ionised argon gas was developed by 
Grund and co-workers (1991) in Germany and initially piloted on patients (n=102) with 
highly effective results and in Germany has became the preferred mode of ablation therapy 
(Grund et al., 1994). 
The placement of a plastic or metal stent, offers rapid relief of dysphagia, although there 
can be retrosternal pain for the first few days, there can also be recurrent dysphagia due to 
stent migration or bolus obstruction.  Dilatation with bougies or balloon can also relieve 
dysphagia temporarily and can, be repeated as required; it can also be used to allow access 
for laser therapy or the placement of the stent.  The main complications from repeated 
dilatation are perforation and haemorrhage (Kavic and Basson, 2001). 
Studies have compared laser treatment with stent placement; the results which have been 
reported are variable, Dallal and co-workers (2001) reported that survival was greater in 
patients who underwent laser ablation compared to patients who stent placement.  Created by Margaret McKernan     
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However, dysphagia relief was disappointing in both groups and overall deterioration of 
quality of life was more noticeable in the stent group.  The aim of the above treatments are 
to restore and/or maintain an as normal as possible food intake and improve quality of life.  
These procedures avoid immediate morbidity associated with surgery, but should only be 
applied if they are effective in disease control and/or symptom control. 
For some patients there is no appropriate treatment that can be offered or the patient may 
refuse treatment.  McMillan nurses; clinical nurse specialists and hospices can offer 
supportive care to the patients and their families.  This has been defined by (Ahmeddzai, 
2001) as “Supportive care for cancer patients is the multi professional attention to the 
individual’s overall physical, psychological, spiritual and cultural needs, and should be 
available at all stages of the illness, for patients of all ages regardless of the current 
intention of anti-cancer treatment”.  The philosophy as seeing the patient as a whole person 
is an acknowledgement that the effect of the disease will also impact on other parts of the 
patient’s life and support needs to be offered. 
It is acknowledged increasingly that in the process of weighing the benefits and side effects 
of treatment, the patient’s perspective is of prime concern.  Some patients are willing to go 
to extreme lengths to prolong survival, accepting treatments that severely impair quality of 
life.  Other patients feel that they want to make the most of their remaining time and are 
unwilling to risk an inferior quality of life.  A study by Voogt and co-workers (2005) 
concluded that attitudes toward medical treatment vary in cancer patients in whom the 
cancer is, in principle incurable.  One third of the patients can be classified as striving for 
length of life, one third strived for quality of life and one third seemed unwilling or unable 
to express preference (Voogt et al., 2005). 
In summary, the majority of patients with gastric and oesophageal cancer present late with 
a multitude of problems, some related to and some independent of the underlying disease 
and treatment should be adapted to fit each person’s needs.  Despite the advances of cancer 
therapy, cancer continues to be a life threatening illness with a poor survival rate and the 
newly diagnosed patient faces a crisis that emphasizes his or her mortality. Created by Margaret McKernan     
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1.6  Weight loss, body composition and the systemic inflammatory response 
The general poor outcome observed in patients with gastric and oesophageal cancer is 
related to the fact that most patients have locally/regionally advanced or disseminated 
disease at diagnosis (Blot and McLaughlin, 1999). 
Malnutrition, weight loss, cachexia, reduced calorie intake and multiple vitamin 
deficiencies are a few of the symptoms often seen in patients with advanced cancer.  Due 
to anorexia, maintaining and attaining a good nutritional state is frequently difficult to 
overcome (Laszlo and Spencer, 1953) all of these symptoms can in some way be related to 
one another. 
Belghiti and co-workers (1987) conducted a study of squamous oesophageal cancer 
patients (n=50) and reported that 42% suffered from anorexia and further reported that 
malnutrition can be attributed to mechanical obstruction, widespread tumour or 
disseminated cancer.  Therefore, nutritional status should be evaluated while evaluating for 
the suitability of surgery (Belghiti et al., 1987). 
Fearon (1992) reported that patients with advanced cachexia are characterized by anorexia, 
early satiety and marked weight loss.  The majority of patients present with advanced 
disease and it was recognised that morbidity and mortality are associated with cachexia 
(Fearon, 1992).  Furthermore, Ovesen and co-workers (1993) noted that a deteriorating 
nutritional status and insufficient food intake in cancer patients with solid tumours, 
compromised their physical functional status even if the weight loss was minor to 
moderate and concluded that it was not possible to ascertain which symptom came first 
(Ovesen et al., 1993). 
Bruera (1997) reported that more than 80% of patients with cancer develop cachexia 
before death and furthermore, 80% of patients with gastrointestinal cancers will have 
cachexia at the time of diagnosis.  In general, patients with solid tumours (with the 
exception of breast cancer) have a higher frequency of cachexia and can become more 
pronounced as disease progresses.  Patients with oesophageal cancer may suffer greatly 
from dysphagia, abnormalities of taste or chronic nausea, resulting in reduced caloric 
intake and anorexia (Bruera, 1997). Created by Margaret McKernan     
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Argiles and Lopez-Soriano reported similar observations in that cachexia occurs because 
of alterations in metabolism caused by the tumour and that the body uses calories faster 
than they can be replaced, due to this the weight loss cannot be reversed simply by 
increasing calories.  They suggested that appropriate treatment at onset of tumour growth, 
could improve on the patients clinical state and quality of life (Argilies and Lopez-Soriano, 
1998). 
Furthermore, Goldberg and Loprinzi, (1999) reported that cancer associated causes of 
reduced caloric intake can be separated into direct and indirect tumour effects.  A direct 
tumour effect is a consequence of the presence of a tumour mass or tumour infiltration, 
from tumour encroachment of the gastrointestinal tract.  The remote effects from 
treatments such as surgery, radiotherapy or chemotherapy are exemplified and the 
disinterest in food and reduced appetite can be due to poorly controlled pain, depression or 
from the oesophageal pain of mucositis, and that in patients with several months to live, 
therapy with progestational agents may be of benefit to aid an increase in appetite 
(Goldberg and Loprinzi, 1999). 
Argiles and co-workers (2002) reported that the most relevant characteristics of cachexia is 
that of asthenia (or lack of muscle strength), which reflects the great muscle wasting that 
takes place, it is also characterized by general weakness as well as physical and mental 
fatigue (Argiles et al., 2002). 
Although there is good evidence that weight loss, appetite loss, cachexia, performance 
status and the systemic inflammatory response in gastro-intestinal cancer patients are 
associated, it is also important to note that not all patients with weight loss demonstrate 
evidence of a systemic inflammatory response.  Several authors have studied the potential 
relationship between the variables and concluded that although they are all related; the 
relationship remains complex and unclear (Fearon et al., 2006).  Furthermore, it has also 
been reported that the loss of adipose tissue constitutes for the majority of weight loss; and 
it is thought that the depletion of skeletal muscle, which occurs later, is more significant in 
the survival of cancer patients.  The development of nutritional therapies should aim at 
increasing weight gain and the preservation of skeletal mass and in turn improve the 
quality of life in these patients (McMillan et al., 1994; O’Gorman et al., 1999; Kotler, 
2000; McMillan et al., 2001; Delano et al., 2006). Created by Margaret McKernan     
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Persson and co-workers (2002) reported that gastric cancer patients who had nutritional 
support during their illness gained weight.  Furthermore, appetite loss and fatigue 
decreased in the same cohort of patients.  A further study undertaken by (Hopkinson et al., 
2006) found that patients with advanced cancers, 17% of whom were gastrointestinal, had 
experienced weight loss and a decline in food intake and were concerned about their 
quality of life. 
The majority of patients with oesophageal cancer suffer from dysphagia, which will 
normally be due to obstruction caused by the neoplasm.  Dysphagia can occur at anytime 
during their illness and this can also result in marked weight loss.  Palliation of dysphagia 
can be offered and relieving the dysphagia will help to improve quality of life. 
Belghiti and co-workers (1987) conducted a study of squamous oesophageal cancer 
patients (n=50) and reported that all patients suffered from dysphagia with or without 
anorexia at some stage during their disease (Belghiti et al., 1987). 
Spencer and Laszlo (1953) reported that contrary to the common belief, pain is not always 
associated with advanced cancer and pain medication is not a treatment for cancer.  
Furthermore, anxiety and fear are often mistaken for pain and are often treated with 
analgesics.  A survey of advanced cancer patients reported that more than 50% of patients 
with advanced cancer were not in need of analgesics (Spencer and Laszlo, 1953). 
(Foley, 1985) reported that severe intense and poorly controlled pain may be a primary 
reason for patients to abandon treatment.  Furthermore, poorly controlled pain also impacts 
on mood, appetite and overall quality of life.  Proper management of pain control should 
be sufficient to allow them to carry on with their daily activities and to die relatively free 
from pain.  Two studies undertaken by Cleeland and Ryan (1989 and 1994) reported that 
many adults including patients with cancer function effectively with mild pain, as pain 
increases it can no longer be ignored as it may affect general well being.  Many patients 
may not report an increase in pain as they would then have to acknowledge the spread of 
disease and they may be concerned that their physician will be diverted from the task of 
curing the tumour, it was also reported that 36% of patients with metastatic disease 
reported significant pain (Cleeland & Ryan, 1989; Cleeland et al., 1994). Created by Margaret McKernan     
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A study was undertaken in the general population in primary care centres for the World 
Health Organization to assess the association between persistent pain and psychological 
illness, showed a 4-fold increase in patients also suffering with depression, anxiety and 
difficulty in coping with daily activities over those patients not affected by persistent pain 
(Gureje et al., 1998).  It was reported that when pain is ongoing and uncontrolled it has a 
detrimental and deteriorative effect and it is apparent that it has a diminishing effect on 
quality of life; it produces emotional distress, undermines well being and interferes with 
general daily functioning.  For patients with chronic pain opioid analgesics can improve 
quality of life (Katz, 2002). 
Cancer related fatigue is an important rarely treated symptom in cancer today; this fact is 
probably due to improved management options for other symptoms associated with 
cancers and its treatment such as pain, depression, nausea and vomiting.  However, though 
the problem is real, both patients and physicians may review cancer related fatigue as 
something to be endured, as treatment for cancer is foremost in the physicians and patients 
minds. 
It has been reported that for most individuals fatigue is a protective response to physical 
and psychological stress, for patients with chronic disease it can become a distressing 
symptom with negative effects on daily functioning and quality of life (Glaus et al., 1994). 
A panel of experts of the National Comprehensive Cancer Network (NCCN) defined 
fatigue as “a persistent subjective sensation of fatigue related to cancer and its treatments 
that interfere with the daily life activities of the patient” (Mock et al., 2000).  Furthermore, 
cancer related fatigue has been described by Romanelli (2004) as general weakness, limb 
weariness and difficulty in finishing the daily activities, diminished concentration, sleep 
disturbances and a marked emotional reaction to fatigue (Romanelli et al., 2004). 
(Servaes et al., 2000) reported in their study that one fifth of disease free patient’s still 
suffered from fatigue, psychological and physical problems long after treatment.  It is 
frequently one of the initial symptoms experienced by patients and it tends to increase with 
the progression of cancer and its treatment.  Furthermore, it is possible that fatigue is 
related to the psychological and physical problems.  It has been reported that cancer related 
fatigue differs from normal fatigue, which can be due to overexertion or lack of sleep.  In 
contrast, cancer related fatigue is characterized by feelings of tiredness and weakness Created by Margaret McKernan     
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despite adequate amounts of sleep.  In a study by Cella and co-workers (2001), 17% of 
patients who had completed treatment for more than 1 year, reported ongoing fatigue 
(Cella et al., 2001). 
(Persson et al., 2002) reported that fatigue and appetite loss were closely linked with 
depression and anxiety, in which order they appear is more difficult to report, patients may 
worry over treatment and the anxiety and depression affect their appetite and contribute to 
the fatigue, or the fatigue may have compromised the ability to buy and cook food and 
adversely promote appetite loss. 
Prue and co-workers (2006) undertook a literature search with fatigue and cancer as the 
main criteria, and reported that cancer related fatigue has a major impact on a sufferer’s 
life with devastating social and economical consequences and can persist for months or 
even years following completion of treatment (Prue et al., 2006). 
Depression and anxiety can be quite variable in cancer patients and may also be related to 
pain, reduced performance status and other physical symptoms such as dysphagia, which 
are difficult to palliate.  Patients deal with depression in various ways depending on 
personality and coping ability and in some cases can improve and as their depression is 
appropriately treated. 
A study undertaken by Schag and Heinrick (1989) reported that adults with cancer were 
subjected to a variety of potentially stressful medical situations, yet little attention has been 
paid to the impact of these situations on them.  Anxiety and poor communication skills was 
an important finding; it could not be decided if anxiety was a consequence of a patient’s 
inability to communicate effectively with physicians or whether the anxiety makes it more 
difficult to communicate (Schag and Heinrick, 1989). 
In one study, patients who were deemed suitable for radiotherapy, were asked to complete 
a quality of life questionnaire, the study reported that 69% of patients had psychological 
distress, social dysfunction and reduced well being at onset of treatment; furthermore 
distress can evolve from unresolved symptoms and be associated with increased depression 
(Kaasa et al., 1993).  Servaes and co-workers (2000) also reported that patients were still 
clinically depressed long after treatment had completed and this could be as a result of Created by Margaret McKernan     
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being confronted with a life threatening illness or be anxious of disease recurrence 
(Servaes et al., 2000). 
A study undertaken by (Lloyd-Williams et al., 2004) of patients attending a palliative care 
day unit, reported that depression is a symptom affecting approximately one in four 
patients receiving palliative care and that it is significantly associated with general quality 
of life and the presence of immobility, tiredness and pain in this population.  Yan and 
Sellick, (2004) reported similar results in patients diagnosed with gastro-intestinal cancer, 
that 27% of patients suffered from depression and that depression and quality of life were 
strongly associated, particularly during the time of diagnosis and the commencement of 
treatment.  This study further reported that younger patients demonstrated a higher level of 
depression (Yan and Sellick, 2004). 
In summary, cancer is now often classified as a chronic illness and increasing survival can 
be accompanied by increased numbers of hospitalisations, complications and expense, 
furthermore symptom control and the dying process can be prolonged and arduous for all 
concerned.  A number of publications have concluded that cancer and cancer treatments 
may affect the way in which patients perceive their quality of life and in particular, a 
deteriorated state of health and the adverse effects of treatments may influence reduced 
physical functioning. Created by Margaret McKernan     
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1.7  Quality of life 
Quality of life has been an implied outcome since the earlier days of health care.  The 
ethical basis for cancer care treatment is provided by the well-known dictum primum non-
nocere, which translated means first do no harm.  Furthermore, the benefit of the treatment 
proposed must be greater than the suffering it entails; one of medicines time honoured 
precepts is to treat the patient and not only the disease (Greer, 1984). 
The ethics of cancer treatment was summarised by Dr Neil Fiore, who had developed 
metastatic cancer as: “Fighting cancer must come to mean more than excising a tumour 
and focusing the latest weapon on the metastases.  It must include recognition, by both the 
medical professionals and the patient, that the patient’s mind and body are powerful factors 
in this fight.  Failure to use these potential allies can mean losing them to the ‘enemy’ 
through patient resistance to treatment, depression and loss of the will to live.  Effective 
cancer therapy must treat the healthy portion of the patient’s body as well as combat the 
diseased cells” (Fiore, 1979). 
(Slevin, 1992) reported that cancer and its treatment can create distress to the patient and 
their families, furthermore patients are often told “there is nothing we can do for you”, it is 
therefore not surprising that patients with cancer often feel miserable and despondent and 
maintaining quality of life then becomes an issue. 
Tradeoffs between quality of life and quantity of life are often found to be necessary in 
decision making Stiggelbout and co-workers (1996) found that younger cancer patients 
were more likely to strive for length of life, whereas older patients were more likely to 
strive for quality of life.  Cancer patients who thought they would survive for at least 6 
months were more likely to favour life-prolonging therapy over comfort care, than cancer 
patients who thought they had at least 10% chance of not surviving the next six months 
(Stiggelbout et al., 1996). 
Quality of life is a phrase that covers a multitude of factors each contributing to the value 
of life perceived by the patient during their illness and treatment.  Health-related quality of 
life is largely based upon a multidimensional perspective of health as physical, 
psychological, social functioning and general well being.  In recent years improvements in 
cancer treatment have emphasised the importance to the short and long term implications Created by Margaret McKernan     
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of therapy and it is important to the cancer patient that quality of life is maintained.Created by Margaret McKernan     
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1.8  Definitions and dimensions of quality of life 
There are differing opinions regarding what concepts of quality of life are important and 
this has hindered an agreement of the definition of “quality of life”. 
In 1947, the World Health Organisation defined health as “a state of complete physical, 
mental and social well-being and not merely the absence of disease” (World Health 
Organisation Constitution, 1947).  In 1978 they reiterated, that individuals were entitled to 
an adequate quality of life, but they did not elaborate on what constituted an “adequate 
quality of life” (International Conference on Primary Health Care: WHO and UNICEF, 
1978). 
Gough and co-workers (1983) reported that the effectiveness for cancer treatment was 
usually measured on tumour response, toxicity and overall survival and the concept of 
quality of life had been too complex to be quantified, in their study of 100 advanced 
metastatic gastrointestinal and breast cancer patients, using 4 different questionnaires, they 
advocated that only one question need be asked to assess quality of life- on a ten 
centimetre analogue scale –“How would you rate your quality of life today?”.  They 
support their claim with evidence of a strong correlation between scores on this scale and 
on more elaborate sets of quality of life assessments and concluded that this question could 
be advocated for periodic assessment of patients with cancer, particularly in clinical trials 
(Gough et al., 1983). 
Calman stated that quality of life was a difficult concept to define and to measure.  It was 
suggested that quality of life should measure the difference, or the gap, at a particular 
period of time between the hopes and expectations of the individual and the individual’s 
present experiences.  Furthermore, it can only be described by the individual and must take 
into account many aspects of life.  Quality of life extends not only to the impact of 
treatment and side effects but also to the recognition of the patient as an individual and as a 
whole person, body, mind and spirit (Calman, 1984). 
Ware (1987) attempted to bring some order to the range of variables employed in health 
and quality of life and stated standards would need to be adhered to for judging the content 
validity.  Five generic health concepts were defined as: physical health, mental health, 
social functioning, and role functioning and general health perceptions.  Items from widely Created by Margaret McKernan     
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used health measures were presented to clarify distinctions among these concepts and the 
different health states they encompass.  It was recommended that labels be assigned to 
health measures in a manner consistent with their content and other evidence of validity 
(Ware, 1987). 
In 1993, the Health Services Research Committee of the American Society of Clinical 
Oncology (ASCO) organised a working group to define outcomes, focusing on cancer 
treatments and concluded that survival should be the most important final outcome of 
cancer treatment.  In contrast, patients with metastatic disease should still be offered 
treatment if it improves quality of life, and should encompass physical, psychological and 
social dimensions.  Cancer related quality of life is important because it is the patient’s 
evaluation of how cancer and its treatment affect the physical, psychological and social 
aspects of their life and concluded that reliable, valid measurements must be used (ASCO, 
1996). 
The need to objectively measure quality of life is now widely recognised as being an 
important outcome in clinical trials, several authors have highlighted the importance of 
outcome measures in addition to the traditional end points, such as survival time, 
morbidity, nutritional function and relief of dysphagia, as they fail to take into account the 
broader effects of both the illness and intervention on the patient with gastric and 
oesophageal cancer.  More recently, quality of life has become an outcome measure for 
patients after the diagnosis and treatments in and out with trials (Blazeby et al., 1995; 
O’Hanlon et al., 1995; Coates et al., 1997; Zieren et al., 1998; Vickery et al., 2000). 
The fundamental question of who should measure quality of life remains.  Quality of life is 
an individual and personal experience; clinicians prefer scales where they can use their 
clinical judgement.  However, when patients complete the questionnaires results may differ 
from a clinician’s perspective, a study reported by Slevin and co-workers found a poor 
correlation between patients and doctors quality of life scores and led him to believe that 
assessments should be completed by patients themselves (Slevin et al., 1988). 
 Created by Margaret McKernan     
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1.9  Quality of life assessments 
There is no gold standard measure of quality of life; several authors have highlighted the 
importance of establishing the validity and reliability of any assessment tool being used.  
Validity reflects the degree to which the tool measures what it claims to measure and it 
must cover construct, content and criterion validity, this can be assessed by comparing the 
results with another accepted tool.  Reliability reflects the consistency of the information 
being collected.  There are numerous quality of life tools available, which measure aspects 
of quality of life in relation to health care.  However, there is no agreement on which tools 
are most effective.  No single tool satisfies all dimensions for assessing quality of life and 
the use of numerous assessments can be impractical for seriously ill patients.  Investigators 
need to clearly define the aims of their investigation and use the most appropriate 
assessment tool available. 
Outlined below are some of the instruments used on assessing patient’s performance 
status/quality of life. 
1.9.1  Karnofsky Performance Scale 
The Karnofsky performance scale (KPS) is a widely accepted tool, it was originally 
developed by Karnofsky and co-workers in 1948 to document physical function and the 
need for assistance in advanced lung cancer patients, it assesses the patient’s performance 
on a numerical scale from 0-100 representing a patient’s ability to perform normal activity, 
the ability to do normal work and the need for assistance with daily living (Karnofsky et 
al., 1949).  The performance status is assessed by direct observation; the same observer 
should complete the scale to confirm continuity.  It is also used to evaluate response to 
treatment.  Studies evaluating the reliability of the scale came to different conclusions; 
Conill (1990) reported significant correlation between physician’s scores and also between 
physician and patient score.  Schagg (1984) reported that physician’s reported higher 
scores than mental health professionals and concluded that further research was required 
(Schag et al., 1984; Conill et al., 1990).  The major disadvantages of the KPS are that it has 
a limited content and is normally scored by a physician and it is subjective in nature, which 
does not reflect the patients’ attitude. Created by Margaret McKernan     
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1.9.2  Zubrod Scale, or the Eastern Cooperative Oncology Group Performance Scale: 
(ECOG) 
A condensed version of the Karnofsky scale was developed in 1960 for use with cancer 
patients, and is known as the Zubrod Scale or the Eastern Cooperative Oncology Group 
Performance Scale (ECOG) (Zubrod et al., 1960).  It is a measure of performance and a 
predictor of functional outcome of tumour treatment.  It is an observer- rated scale that 
ranges from 0 to 4 (see appendix B 2.2).  A study by (Verger et al., 1992) compared 
Karnofsky with ECOG in 150 cancer patients and reported that both scales where highly 
correlated, but caution should be used when using either scale as there is a wide spread in 
the lower performance status range. 
Karnofsky and ECOG performance scales are both widely accepted tools, but neither scale 
measures any psychosocial indices (Bowling, 1995).  Furthermore, disease specific aspects 
of a questionnaire would provide detailed information about the patients’ perception of 
their health. 
1.9.3  General Health Questionnaire 
The General Health Questionnaire was first published in 1972, as a 60 item questionnaire 
(Goldberg, 1972) and subsequently shorter versions have been introduced.  The version 
most frequently used is the 28 item version (GHQ-28), it has four subscales assessing 
somatic or physical symptoms, anxiety / insomnia, depression and social dysfunction, and 
it is a self report questionnaire in which patients are asked to respond to each question by 
comparing their present experience to their usual state.  Four possible response options are 
provided and can be scored in two ways, firstly by employing the Likert type severity 
score, which is a psychometric response scale and is most widely used in survey research 
(Likert, 1932) or by using the general health questionnaire scoring.  Goldberg and Hillier 
(1979) tested the validity of this assessment to discriminate between patients with and 
without mental illness and reported no advantage in using the Likert scale; however it is 
useful for indicating patients with severe psychological disturbance.  This questionnaire 
was developed for research purposes (Goldberg, 1991; Bowling, 1991).  There would 
appear to be no reliability testing reported on the use of the GHQ-28. Created by Margaret McKernan     
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1.9.4  SF-36 
The SF-36 was developed in 1988, as a multi-purpose, short-form health survey with 36 
questions, it is suitable for self-administration or by a trained interviewer; it was 
constructed to satisfy minimum psychometric standards necessary for group comparisons, 
it is a generic measure, as opposed to one that targets a specific disease.  Eight health 
concepts were chosen from a possible 40, those chosen represent the most frequently 
measured concepts used that can measure health affected by disease and treatment, these 
include: physical, role, social and emotional functioning, bodily pain, general health, 
vitality and mental health.  Reliability has been estimated using both internal consistency 
and test-re-test measures; with rare exceptions published material has exceeded the 
minimum standard of 0.70 (McHorney et al., 2000). 
1.9.5  WHOQOL-100 
In 1991 the WHOQOL-group launched a program to define and measure the quality of life 
and proceeded to develop an instrument to assess overall quality of life and general health, 
it consists of six broad domains: physical, psychological, environmental, spiritual, levels of 
development and social relationships, there are a total of 100 items in the assessment and 
all items are rated on a five point scale.  The WHO groups’ initiative to develop a quality 
of life assessment, arose from a need for an international measure, and the commitment to 
the continued promotion of a holistic approach to health and health care.  The WHOQOL-
group undertook a pilot study and reliability studies during the development process.  In 
1998 the development of the WHOQOL-BREF, an abbreviated version of the WHOQOL-
100 was constructed and validated as a reliable alternative to the previous assessment.  It 
was envisaged that the WHOQOL-BREF would be most useful in large epidemiological 
studies and clinical trials.  In addition, the WHOQOL-BREF may be of use to health 
professionals in the assessment and evaluation of treatment efficacy (WHOQOL, 1999). 
1.9.6  Dysphagia Score 
The first formal attempt to measure dysphagia was not made until 1976 when DeMeester 
devised a simple classification system, based on patients swallowing abilities (DeMeester 
et al., 1976).  There have been attempts by other authors to further express dysphagia in 
numerical terms using a dysphagia scale graded from 1 to 5, (see appendix B 2.3) as well Created by Margaret McKernan     
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as a diet scale (Goldschmid et al., 1989).  (Van Knippenberg et al., 1992) adapted the 
Rotterdam Symptom check list to include dysphagia and eating scale for Dutch patients 
undergoing oesophageal surgery.  The M. D. Anderson Dysphagia Inventory (MDADI) 
also included global, emotional, functional, and physical subscales.  The MDADI was the 
first validated and reliable self-administered questionnaire designed specifically for 
evaluating the impact of dysphagia on the quality of life of patients with head and neck 
cancer (Chen et al., 2001).  More recently a site specific oesophageal questionnaire module 
was developed by the EORTC (QLQ-OES18) to measure dysphagia in an objective 
fashion, and test its correlation with subjective estimates of dysphagia, the OES18 
demonstrated good psychometric and clinical validity and should be used with the core 
C30 questionnaire (Blazeby et al., 2003). Created by Margaret McKernan     
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1.10  EORTC QLQ-C30 
(Aaronson, 1991) reported that at that time there was a large pool of instruments available 
for assessing health related quality of life and suggested that additional efforts at re-
inventing the wheel might not be particularly useful, rather it would be more fruitful to 
maximise existing tools and apply modifications where needed.  Furthermore, future 
efforts for designing assessments should be directed towards examining the relevance of 
the instruments in the clinical setting.  The most serious limitation of a generic 
measurement, that when applied in the oncology setting, fails to address the disease 
specific aspects of treatment. 
In 1986, the European Organisation for Research and Treatment of Cancer (EORTC) 
initiated a research programme to develop an integrated, modular approach for evaluating 
the quality of life of patients participating in international clinical trials.  The 36 item 
version (see appendix B 2.1) was widely tested in 1991 and was shortened to 30 items.  
The QLQ-C30 incorporates nine multi-item scales: five functional scales (physical, role, 
cognitive, emotional and social); three symptom scales (fatigue, pain, and 
nausea/vomiting); and a global health and quality of life scale.  Several single item 
symptom measures are also included.  The response to questions are in the format of 
dichotomous (yes-no) and Likert-scale and asks patients to respond to items using a time 
frame of the “the past week”.  The average time to complete the questionnaire is 10-12 
minutes and no significant difference has been reported in the results whether it has been 
self completed or completed by interview. 
Validity and reliability was performed following an international field study on the initial 
core questionnaire, with 300 non-resectable lung cancer patients from 13 countries.  
Clinical variables assessed included; weight loss, performance status and stage of disease.  
The internal consistency of the items produced reliability coefficients of 0.52-0.89.  With 
the exception of role function status, the EORTC tool was shown to be reliable in assessing 
many dimensions of quality of life and it has been proposed that quality of life assessment 
promotes a patient centred approach and has the ability to influence cancer care.  The 
results of the study concluded that the tool was reliable and a valid measure of quality of 
life in clinical research settings (Aaronson et al., 1993). Created by Margaret McKernan     
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The EORTC study group provides written guidelines, which details the scoring procedure 
required (see appendix C 3.1).  Once the questionnaire has been completed the sum of 
items in each category is added and the total divided by the number of questions in the 
category.  A linear transformation is then undertaken to convert this to a percentage scale 
with a higher score representing a higher response level.  Thus a high score for functional 
scale represents a high/healthy level of functioning.  A high score for the global health 
status/ quality of life represents a high quality of life.  In reverse a high score for the 
symptom scale represents a higher level of symptoms / problems (Aaronson et al., 1993). 
The EORTC QLQ-C30 was recommended by Bowling (1995) as the best developed 
quality of life measures for use with cancer patients (Bowling, 1995). 
The QLQ-C30 has been widely applied, during the year 2000 alone; 590 academic users 
and 45 pharmaceutical companies signed agreements with EORTC to use the questionnaire 
(EORTC, 2001).  Several authors have looked at quality of life in reference to gastro-
oesophageal cancer, in surgical and palliative patients in the short term. There are, to our 
knowledge, no studies which have examined the effect of surgery on quality of life beyond 
3 years.  A number of workers (Blazeby et al., 2000; 2001; 2005: Chau et al., 2004; Vigano 
et al., 2004; Reynolds et al., 2006; Viklund et al., 2006; Avery et al., 2007) have reported 
that the EORTC QLQ-C30 measurement of quality of life may have prognostic value in 
patients with gastro-oesophageal cancer and furthermore, a decrease in functional scales in 
the short term have been reported. Created by Margaret McKernan     
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1.11  Quality of life summary 
No single quality of life tool satisfies all dimensions for assessing quality of life and the 
use of numerous assessments can be impractical for seriously ill patients.  Investigators 
need to clearly define the aims of their investigation and use the most appropriate 
assessment tool available. 
For this study we have used the EORTC QLQ-C30 (Aaronson et al., 1993) as outlined 
above as it has passed numerous validity and reliability tests, the ECOG performance 
status scale (Zubrod, 1960) and the dysphagia score. Created by Margaret McKernan     
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1.12  Aims of thesis 
The prognosis of patients with gastric and oesophageal cancer remains poor and are 
commonly fatal cancers with incidence only just greater than the mortality.  Traditionally 
various factors have been linked to poor survival rate; these include stage of disease, 
performance status, weight loss and inflammatory response, as the majority of patients are 
diagnosed at an advanced stage.  Therefore, ensuring the best quality of life is paramount.  
Aaronson (1993) and Vickery (2000) reported the importance of quality of life as an 
outcome in addition to survival as debilitating problems with nutrition; pain and fatigue are 
predominant after surgery.  Furthermore, in patients undergoing palliative treatment, 
symptom relief must be weighed against treatment toxicity and therefore recording 
ongoing quality of life in these patients is of considerable importance (Aaronson et al., 
1993; Vickery et al., 2000). 
It has also been reported that, in a few studies, the EORTC QLQ-C30 measurement of 
quality of life may have prognostic value in patients with gastro-oesophageal cancer 
(Conroy et al., 2006). 
Clearly, further investigation is required in this area and this thesis will examine:- 
1. The relationship between quality of life (EORTC QLQ-C30) and survival in patients 
with gastro-oesophageal cancer. 
2. The longitudinal impact of treatment on quality of life (EORTC QLQ-C30) in patients 
with gastric and oesophageal cancer. 
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2.  The relationship between quality of life (EORTC QLQ-C30) and survival in patients 
with gastro-oesophageal cancer 
2.1  Introduction 
Gastro-oesophageal cancer is the third commonest cause of cancer death in the UK.  Each 
year, there are approximately 16,500 new cases and over 13,000 deaths attributable to the 
disease.  Overall survival is poor with the majority of patients presenting with advanced, 
inoperable disease and less than 15% surviving 5 years (Cancerstats, 2004;).  Although 
there have been improvements in survival following surgery (Ando et al., 2000; Hundahl et 
al., 2000; Hofstetter et al., 2002; von Rahden et al., 2004), for the majority of patients 
current treatment offers little in terms of improved survival.  As a result quality of life in 
these patients is likely to be of considerable importance (Aaronson, Bullinger and 
Ahmedzai, 1988; Aaronson et al., 1993). 
The European Organisation for Research and Treatment of Cancer have developed and 
validated the EORTC-QLQ-C30 questionnaire designed to assess the quality of life of 
cancer patients (Aaronson et al., 1993).  Disease specific aspects of the questionnaire 
provide detailed information about the patients’ perception of their health.  Moreover, it 
has been reported that, in a few studies, the EORTC QLQ-C30 measurement of quality of 
life may have prognostic value in patients with gastro-oesophageal cancer (Conroy et al., 
2006). 
Blazeby and co-workers (2001) reported that, in addition to age and TNM stage, physical 
function or emotional function had independent prognostic value in 92 patients with 
oesophageal cancer.  However, treatment (whether or not the patient underwent surgery) 
was not included in the model (Blazeby et al., 2001). 
Fang and co-workers (2003) studied 110 patients with squamous oesophageal cancer and 
concluded that there was evidence to support the correlation of patient-reported QOL 
scores with survival; therefore, pre-treatment physical functioning might be a surrogate 
marker of an unrecognised biological prognostic factor.  Although performance status was 
significant on univariate analysis it was not significant on multivariate analysis, whereas 
physical functioning was significant (Fang et al., 2003).  
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In contrast, in a study of more than 1000 patients with inoperable gastro-oesophageal 
cancer, entering 3 randomised clinical trials, Chau and colleagues (2004) reported that no 
aspect of the QLQ-C30 had independent prognostic value when performance status was 
considered.  However, physical function, role function and global quality of life were 
associated with survival on univariate analysis.  There were no survival differences among 
patients with oesophageal or gastric cancer (Chau et al., 2004).  However, this study was 
retrospective and included selected cohorts of patients. 
Therefore, from the above it remains unclear whether any aspect of quality of life other 
than physical function has a role in predicting survival in an unselected cohort of patients 
with gastro-oesophageal cancer.  The aim of the present study was to examine the 
relationship between quality of life (EORTC QLQ-C30), clinico-pathological 
characteristics and survival in patients with gastro-oesophageal cancer.  
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2.2  Patients and Methods 
Patients 
Patients presenting with adenocarcinoma or squamous carcinoma of the gastric or 
oesophageal tract at the Royal Infirmary and Southern General Hospital, Glasgow between 
November 1997 and December 2002 (n=152) participated in a quality of life study, using 
the EORTC QLQ-C30 core questionnaire. 
The extent of tumour spread was recorded using the TNM 5th edition classification (Sobin 
and Wittekind, 1997).  Tumours around the gastro-oesophageal junction were further 
classified according to tumour site, using the Siewert system; type 1 and 2 lesions of the 
gastro-oesophageal junction were designated as cancers of the oesophagus.  Type 3 
tumours of the cardia were designated as gastric cancers (Siewert and Stein, 1998). 
For gastric cancers, tumour node metastasis (TNM) stage I–III tumours were considered to 
be potentially amenable to curative surgical resection.  For oesophageal cancers, TNM 
stage I–III tumours, excluding T4, were deemed to be potentially amenable to curative 
surgical resection.  Patients who had stage 1 and 2 disease but whose performance status 
was poor or who had significant co-morbidity were deemed not suitable for surgery and 
went forward for active palliative treatment or supportive care.  There were 152 patients 
included in the study, 69 patients underwent surgery and 83 patients received active 
palliative treatment or supportive care. 
The study was approved by the Research Ethics Committee of the Royal Infirmary and 
Southern General Hospital, Glasgow.  
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Methods 
Clinical and demographic variables were recorded at the patient’s initial presentation and 
included age, sex, tumour type, site and length, TNM stage, ECOG performance status, 
weight loss and dysphagia. 
Following diagnosis but prior to treatment the lead clinician approached patients as to 
whether they would participate in a study to examine their quality of life.  If they gave 
informed consent they were given the EORTC QLQ-C30 questionnaire to complete. 
Different aspects of quality of life were assessed using this cancer specific 30-item 
questionnaire, which has six functional scales (physical, role, emotional, cognitive, social, 
global health status) and several questions relating to a range of physical symptoms 
(Aaronson et al., 1993).  Patients marked to what extent each statement applied to them.  A 
number of patients were excluded because they were unlikely to understand the 
questionnaire either due to language, brain metastases, delirium or confusion.  Neither age 
nor performance status were considered when offering the patient questionnaire.  Few 
subjects were excluded (less than 10 patients) and therefore in those patients offered the 
questionnaire the bias was likely to be small.  
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2.3  Statistics 
Scoring algorithms have been produced by the EORTC Quality of Life Study Group.  The 
sum of items in each category is added and the total divided by the number of questions in 
the category.  A linear transformation is then undertaken to convert this to a percentage 
scale with a higher score representing a higher response level.  Thus a high score for 
functional scale represents a high/healthy level of functioning.  A high score for the global 
health status/quality of life represents a high quality of life.  In contrast, a high score for 
the symptom scale represents a higher level of symptoms / problems (Aaronson et al., 
1993). 
Data are presented as the median and range.  Survival was determined from the time of 
biopsy proven diagnosis, and the endpoint for survival analysis was cancer-specific death.  
Patients were followed up at their clinic or endoscopy appointments and information on 
date and cause of death was checked with that received by the cancer registration system 
through the Registrar General (Scotland).  Deaths up to the end of April 2007 were 
included in the analysis. 
Univariate and multivariate survival analysis and calculation of hazard ratios (HR) were 
performed using a Cox regression model.  For simplicity of presentation, a single hazard 
ratio was calculated for each ordered categorical variable, corresponding to the relative risk 
between adjacent categories.  Hazard ratios for EORTC quality of life and symptom scores 
relate to a one-percentage point increase in the score.  Owing to the large number of 
covariates examined, only those that were significant on univariate analysis were included 
in the multivariate analysis, and only main effects were considered.  The analysis was 
performed using a backward stepwise procedure to derive a final model of the variables 
that had a significant relationship with survival.  To remove a variable from the model, the 
corresponding P-value had to be greater than 0.05.  The proportional hazards assumption 
was checked using log minus log plots. 
Comparison of the association between tumour site, TNM stage, treatment and the 
functional (physical, role, emotional, cognitive, social, global health status) and physical 
symptoms (fatigue, pain and appetite loss) scales of the EORTC-QLQ-C30 quality of life 
questionnaire was carried out using the X
2-test or Mann-Whitney U-test where appropriate.  
Analysis was performed using SPSS software (SPSS Inc, Chicago, IL, USA). 
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2.4  Results 
Patient characteristics and cancer specific survival analysis of patients with gastro-
oesophageal cancer (n=152) are shown in Table 2.1.  The minimum follow up period was 
54 months or until date of death, the median follow up for survivors was 81 months, one 
patient was lost to follow up and one patient withdrew from the study.  During this period 
106 (70%) patients died from their disease and 14 (9%) died from co-morbid disease. 
The majority of patients were over the age of 65 years (57%), male (68%) and had 
adenocarcinomas (84%).  The majority of patients presented with weight loss (66%), had 
little or no dysphagia, and a near normal performance status (ECOG-ps, 71%).  The 
majority of patients had EORTC QLQ-C30 function scores above 50 (physical functioning 
100%, role functioning 65%, emotional functioning 74%, cognitive functioning 83%, 
social a functioning 79% and global quality of life 56%) and symptom scores below 50 
(fatigue 69%, nausea/vomiting 85%, pain 86%, dyspnoea 79%, sleep disturbance 69%, 
appetite loss 64%, constipation 76%, diarrhoea 95% and financial difficulties 89%) and 
therefore had apparently normal quality of life (Table 2.1). 
On univariate analysis, age (P<0.01), tumour length (P<0.0001), TNM stage (P<0.0001), 
weight loss (P<0.0001), dysphagia score (P<0.001), performance status (P <0.1) and 
treatment (P<0.0001) were significantly associated with cancer specific survival.  EORTC 
QLQ-C30, physical functioning (P<0.0001), role functioning (P<0.001), cognitive 
functioning (P<0.1), social functioning (P<0.0001), global quality of life (P<0.0001), 
fatigue (P<0.0001), nausea/ vomiting (P<0.01), pain (P<0.001), dyspnoea (P<0.0001), 
appetite loss (P<0.0001) and constipation (P<0.01) were also significantly associated with 
cancer specific survival.  
On multivariate analysis, tumour stage (P<0.001), treatment (P<0.0001) and appetite loss 
(P<0.0001) were significantly independent predictors of cancer specific survival.  The 
relationship between appetite loss and cancer specific survival in patients with gastro-
oesophageal cancer is shown in Figure 2.1. 
  
  58 
When appetite loss was rescaled so that the four categories were represented by an integer 
score of 0 to 3 (rather than a percentage score), the unadjusted hazard ratio comparing 
adjacent categories was 2.06 (95% CI 1.72 – 2.48, p<0.0001).  When adjusted for stage 
and treatment, it was 1.72 (95% CI 1.41 – 2.08, p<0.0001).  When adjusted for stage, 
treatment and remaining clinico-pathological variables, it was 2.07 (95% CI 1.61 – 2.67, 
p<0.0001).  When adjusted for stage, treatment, remaining clinico-pathological variables 
and quality of life and symptom scores, it was 2.03 (95% CI 1.40 – 2.94, P=0.0002). 
In the present study C-reactive protein concentrations, at the time of quality of life 
assessment, were available in 94 patients (57 patients <10mg/l, 37 patients >10mg/l) and 
were significantly associated with poorer cancer specific survival (P<0.0001).  Therefore 
we included C-reactive protein in addition to TNM stage, treatment and appetite loss in the 
multivariate survival model.  TNM stage (HR 1.37, 95%CI 1.01-1.87, P=0.0426), 
treatment (HR 3.67, 95%CI 1.74-7.75, P=0.0006), appetite loss (HR 1.02, 95%CI 1.01-
1.03, P<0.0001) and C-reactive protein (HR 2.15, 95%CI 1.21-3.83, P=0.0091) were 
independently associated with cancer specific survival. 
The relationship between tumour site, clinico-pathological characteristics and quality of 
life in patients with gastro-oesophageal cancer is shown in Table 2.2.  Compared with the 
gastric cancer patients, oesophageal cancer patients were older (P<0.01), had more 
dysphagia (P<0.001) and a poorer ECOG-ps (P<0.05).  In terms of quality of life, 
compared with the gastric cancer patients, oesophageal cancer patients had higher 
emotional functioning (P<0.01), cognitive functioning (P<0.05), less nausea and vomiting 
(P<0.05). 
The relationship between TNM stage and clinico-pathological and quality of life 
characteristics in patients with gastric-oesophageal cancer is shown in Table 2.3.  With 
increasing TNM stage patients had greater weight loss (P<0.01) and were less likely to 
have had surgery (P<0.001).  In terms of quality of life, with increasing TNM stage there 
was poorer physical functioning (P<0.05), emotional functioning (P<0.05), social 
functioning (P<0.01) and global quality of life (P<0.01).  In terms of symptoms, with 
increasing TNM stage there was more fatigue (P<0.01), appetite loss (P<0.001), dyspnoea 
(P<0.05) and constipation (P<0.05).  
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The relationship between appetite loss, clinico-pathological characteristics and quality of 
life in patients with gastric-oesophageal cancer is shown in Table 2.4.  Increasing appetite 
loss was associated with greater tumour length (P<0.05), TNM stage (P<0.001) and the 
operability of the tumour (P<0.001).  Also, increasing appetite loss was associated with 
weight loss (P<0.001) and dysphagia (P<0.001).  In terms of quality of life, increasing 
appetite loss was associated with poorer physical (P<0.001), role (P<0.001), emotional 
(P<0.01), cognitive (P<0.01), social (P<0.001) and global quality of life (P<0.001) 
functioning.  In terms of symptoms, with increasing appetite loss there was more fatigue 
(P<0.01), nausea and vomiting (P<0.001), pain (P<0.001), sleep disturbance (<0.05) and 
constipation (P<0.001). 
The relationship between systemic inflammatory response, as evidenced by elevated C-
reactive protein, clinico-pathological and quality of life characteristics in patients with 
gastric-oesophageal cancer is shown in Table 2.5.  An elevated C-reactive protein was 
associated with greater tumour length (P<0.01), advanced TNM stage (P<0.01) and the 
operability of the tumour (P<0.001) and a poorer ECOG-ps (P<0.05).  In terms of quality 
of life, an elevated C-reactive protein was associated with poorer physical (P<0.01), role 
(P<0.05) and social (P<0.05) functioning.  In terms of symptoms, with an elevated C-
reactive protein was associated with more fatigue (P<0.01), pain (P<0.05) and appetite loss 
(P<0.01).  
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2.5  Discussion 
In the present study tumour site was not associated with major differences in EORTC 
QLQ-C30 quality of life function or symptom scores.  However, there were major 
differences in quality of life and symptom scores with increasing stage of disease.  In 
particular, social functioning, fatigue, appetite loss and global quality of life were all 
impaired with increasing tumour stage. 
As might be expected in view of these associations with tumour stage, the majority of 
quality of life and symptom scores predicted survival on univariate analysis.  It was of 
interest, however, that appetite loss remained an independently significant prognostic 
factor even after adjustment for TNM stage and treatment.  Furthermore, the predictive 
value of appetite loss was maintained even after adjustment for all other clinico-
pathological variables and quality of life and symptom scores.  Taken together the results 
of the present study highlight the importance of appetite loss as a presenting symptom in 
patients with gastro-oesophageal cancer. 
Few studies have examined the relationship between aspects of quality of life and survival 
in patients with gastro-oesophageal cancer.  The results of the present study are consistent 
with the report of Fang and co-workers (2003) who reported that appetite loss was 
associated with poorer survival in 110 patients with oesophageal cancer.  However, the 
association was much weaker than that of the present study and was not significant in 
multivariate analysis.  Furthermore, the follow-up period and the numbers of patients who 
died of their disease was not defined.  Blazeby and colleagues (1995), in a smaller study of 
59 patients with oesophageal cancer, also reported that appetite loss was associated with 
poorer survival (Blazeby et al., 1995). 
The basis of the relationship between appetite loss and poorer cancer specific survival 
cannot be determined by the present cross sectional study.  However, it was of interest that 
appetite loss was closely associated with nausea and vomiting, dysphagia and weight loss 
and therefore it may be that these symptoms result in appetite loss and the consequent loss 
of weight, which has long been recognised to impact on outcome (DeWys et al., 1980). 
A number of workers have implicated the systemic inflammatory response in this process 
(Kotler, 2000; MacDonald, 2007).  O’Gorman and co-workers (1998), in a cross sectional  
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study, showed that in addition to appetite loss and weight loss, the systemic inflammatory 
response was an important factor in determining patients’ quality of life (EORTC QLQ-
C30) in gastro-intestinal cancer patients (O’Gorman et al., 1998).  Therefore, it is of 
interest that two recent studies have shown that the presence of a systemic inflammatory 
response, as evidenced by an elevated C-reactive protein, predicts survival in both operable 
(Crumley et al., 2006a) and inoperable (Crumley et al., 2006b) gastro-oesophageal cancer 
patients.  In the present study C-reactive protein concentrations, at the time of quality of 
life assessment, were available in 94 (62%) patients.  Consistent with previous work an 
elevated C-reactive protein concentration was associated with increased appetite loss and 
when included in the multivariate analysis, an elevated C-reactive protein concentration 
was independently associated with poorer cancer specific survival.  However, even those 
patients without an elevated C-reactive protein concentration reported some appetite loss 
and the independent prognostic value of appetite loss remained, thus confirming the 
importance of appetite loss in the multifactorial nature of weight loss and poor outcome in 
these patients (MacDonald, 2007). 
In summary, in patients with gastro-oesophageal cancer, routinely used prognostic factors 
are based predominantly on clinical and pathological findings.  The present study 
highlights the importance of quality of life (EORTC QLQ-C30) measures, in particular 
appetite loss, as prognostic factors in these patients.  
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Table 2.1 The relationship between clinico-pathological characteristics, quality of life and cancer specific survival in patients with gastro-oesophageal cancer (n=152) 
  Patients 
(n=152) 
Univariate analysis 
HR    (95% CI) 
P-value  Multivariate analysis 
HR    (95% CI) 
P-value 
Age:(<65/65-74/³75)  66/56/30  1.46 (1.14-1.89)  0.0033     
Sex:(male/female)  104/48  0.84 (0.55-1.30)  0.4377     
Tumour type:(adeno/squam)  127/25  1.40 (0.83-2.36)  0.2016     
Tumour site:(oesoph/gastric)  70/82  0.88 (0.60-1.29)  0.5163     
Tumour length:(<5/510/>10cm)  60/70/12  2.37 (1.71-3.27)  <0.0001     
TNM stage:(I/II/III/IV)  28/46/34/41  2.29 (1.84-2.83)  <0.0001  1.65 (1.25-2.18)  <0.0004 
Weight loss:(no/yes)  51/101  3.08 (1.94-4.89)  <0.0001     
Dysphagia score:(1/2/3/4/5)  81/23/32/15/1  1.37 (1.16-1.63)  0.0003     
ECOG:(0-1/2/3-4)  108/38/6  1.61 (1.14-2.27)  0.0069     
Treatment:(operable/inoperable)  69/83  8.12 (5.06-13.03)  <0.0001  5.29 (2.80-9.97)  <0.0001 
           
EORTC QLQ-C30 (0-100)*  Median (range)         
Physical functioning  93 (66.7-100)  0.96 (0.94-0.98)  0.0001     
Role functioning  66.7 (0-100)  0.99 (0.99-1.00)  0.0006     
Emotional functioning  66.7 (0-100  1.00 (0.99-1.00)  0.1302     
Cognitive functioning  83.3 (0-100)  0.99 (0.98-0.99)  0.0051     
Social functioning  83.3 (0-100)  0.99 (0.98-0.99)  <0.0001     
Global quality of life  50 (0-100)  0.98 (0.97-0.99)   <0.0001     
Fatigue  33.3 (0-100)  1.02 (1.01-1.02)  <0.0001     
Nausea and vomiting  16.7 (0-100)  1.01 (1.00-1.02)  0.0067     
Pain  16.7 (0-100)  1.01 (1.01-1.02)  0.0002     
Dyspnoea  0 (0-100)  1.01 (1.01-1.02)  0.0001     
Sleep disturbance  33.3 (0-100)  1.00 (0.99-1.01)  0.1558     
Appetite loss  33.3 (0-100)  1.02 (1.02-1.03)  <0.0001  1.02 (1.01-1.03)  <0.0001 
Constipation  33.3 (0-100)  1.01 (1.00-1.02)  0.0007     
Diarrhoea  0 (0-100)  1.00 (0.99-1.01)  0.9586     
Financial difficulty  0 (0-100)  1.01 (1.00-1.01)  0.0932      
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Table 2.2 The relationship between tumour site, clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer (n=152) 





Age:(<65 yrs/ 65-74yrs/>75 yrs)  41/29/12  25/27/18  0.0041 
Sex:(male/female)  53/29  51/19  0.279 
Type:(squam/adeno)  1/81  24/46  <0.001 
Tumour length:(<5cm/5-10cm/>10cm)  33/33/7  27/37/5  0.724 
Tumour stage:(I/II/III/IV)  22/13/18/28  6/33/16/13  0.528 
Dysphagia score:(1/2/3/4/5)  64/9/8/1/0  17/14/24/1  <0.001 
Weight loss:(yes/no)  53/29  48/22  0.610 
ECOG:(0-1/2/3-4)  64/17/1  44/21/5  0.018 
Treatment:(operable/inoperable)  38/44  31/39  0.800 
       
EORTC QLQ-C30 (0-100)  Median (range)  Median (range)   
Physical functioning  93.3 (66.7-100)  93.3 (66.7-100)  0.733 
Role functioning  66.7 (0-100)  66.7 (0-100)  0.923 
Emotional functioning  66.7 (0-100)  83.3 (0-100)  0.007 
Cognitive functioning  83.3 (0-100)  83.3 (0-100)  0.038 
Social functioning  83.3 (0-100)  75 (0-100)  0.964 
Global quality of life  50 (0-100)  50 (0-100)  0.284 
Fatigue  33.3 (0-100)  22.2 (0-100)  0.077 
Nausea and vomiting  16.7 (0-100)  0 (0-100)  0.036 
Pain  16.7 (0-100)  16.7 (0-100)  0.716 
Dyspnoea  33.3 (0-100)  0 (0-100)  0.123 
Sleep disturbance  33.3 (0-100)  33.3 (0-100)  0.360 
Appetite loss  33.3 (0-100)  33.3 (0-100)  0.624 
Constipation  33.3 (0-100)  33.3 (0-100)  0.031 
Diarrhoea  0 (0-100)  0 (0-100)  0.802 
Financial difficulty  0 (0-100)  0 (0-66.7)  0.098  
  64 
Table 2.3 The relationship between TNM stage and clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer (n=149) 









Age:(<65 yrs/ 65-74yrs/>75 yrs)  15/12/1  23/21/2  18/9/7  18/13/10  0.482 
Sex:(male/female)  17/11  33/13  20/14  31/10  0.387 
Tumour type:(squam/adeno)  2/26  13/33  6/28  4/37  0.576 
Tumour site:(oesophagus/gastric)  6/22  33/13  16/18  13/28  0.528 
Tumour length:(<5cm/5-10cm/>10cm)  19/7/0  21/22/3  10/19/3  8/22/6  <0.001 
Weight loss:(yes/no)  14/14  29/17  23/11  34/7  0.004 
Dysphagia score:(1/2/3/4/5)  22/3/3/0/0  20/10/9/7/0  14/5/9/5/1  23/5/10/3/0  0.130 
ECOG:(0-1/2/3-4)  22/6/0  33/11/2  27/6/1  24/15/2  0.099 
Treatment:(operable/inoperable)  25/3  26/20  15/19  1/40  <0.001 
           
EORTC QLQ-C30 (0-100)  Median (range)  Median (range)  Median (range)  Median (range)   
Physical functioning  93.3 (73.3-100)  100 (66.7-100)  100 (73.3-100)  86.7 (66.7-100)  0.023 
Role functioning  66.7 (0-100)  66.7 (0-100)  66.7 (0-100)  50 (0-100)  0.058 
Emotional functioning  66.7 (8.3-100)  75 (25-100)  83.3 (0-100)  58.3 (0-100)  0.042 
Cognitive functioning  83.3 (50-100)  83.3 (33.3-100)  83.3 (16.7-100)  75 (0-100)  0.042 
Social functioning   100 (33.3-100)  83.3 (0-100)  66.7 (0-100)  50 (0-100)  0.002 
Global quality of life  66.7 (8.3-100)  66.7 (0-100)  50 (16.7-100)  41.7 (0-100)  0.001 
Fatigue  27.8 (0-66.7)  22.2 (0-88.9)  33.3 (0-100)  55.6 (0-100)  0.002 
Nausea and vomiting  16.7 (0-100)  0 (0-100)  16.7 (0-100)  16.7 (0-100)  0.553 
Pain  16.7 (0-66.7)  16.7 (0-100)  33.3 (0-100)  16.7 (0-100)  0.098 
Dyspnoea  16.7 (0-100)  0 (0-100)  0 (0-100)  33.3 (0-100)  0.014 
Sleep disturbance  33.3  (0-100)  33.3 (0-100)  33.3 (0-100)  66.7 (0-100)  0.689 
Appetite loss  0 (0-100)  33.3 (0-100)  33.3 (0-100)  66.7 (0-100)  <0.001 
Constipation  33.3 (0-66.7)  16.7 (0-100)  0 (0-100)  33.3 (0-100)  0.013 
Diarrhoea  0 (0-100)  0 (0-100)  0 (0-33.3)  0 (0-66.7)  0.601 
Financial difficulty  0 (0-66.7)  0 (0-100)  0 (0-66.7)  0 (0-100)  0.306  
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Table 2.4 The relationship between appetite loss, clinico-pathological characteristics and quality of life in patients with gastro-oesophageal cancer (n=152) 
  Not at all 
(n=55) 
A little  
(n=43) 






Age:(<65 yrs/ 65-74yrs/>75 yrs)  27/18/10  18/15/10  8/15/3  13/8/7  0.540 
Sex:(male/female)  43/12  26/17  15/11  20/8  0.312 
Tumour type:(squam/adeno)  7/48  5/38  7/19  6/22  0.138 
Tumour site:(oesophagus/gastric)  25/30  17/26  15/11  13/15  0.603 
Tumour length:(<5cm/5-10cm/ >10cm)  27/20/4  18/21/2  9/15/2  6/14/4  0.016 
TNM stage:(I/II/III/IV)  16/17/13/8  8/17/9/9  3/8/7/8  1/4/5/16  <0.001 
Weight loss:(yes/no)  26/29  27/16  22/4  26/2  <0.001 
Dysphagia score:(1/2/3/4/5)  37/10/6/2/0  24/6/10/3/0  9/4/9/3/1  11/3/7/7/0  <0.001 
ECOG:(0-1/2/3-4)  39/14/2  34/8/1  18/7/1  17/9/2  0.281 
Treatment:(operable/inoperable)  35/20  20/23  11/15  3/25  <0.001 
           
EORTC QLQ-C30 (0-100)  Median (range)  Median (range)  Median (range)  Median (range)   
Physical functioning  100 (73.3-100)   100 (73.3-100)  86.7 (66.7-100)  80 (66.7-100)  <0.001 
Role functioning  100 (0-100)  66.7 (0-100)  58.3 (0-100)  33.3 (0-100)  <0.001 
Emotional functioning  75 (73.3-100)  66.7 (0-100)  83.3 (8.3-100)  58.3 (0-96.7)  0.003 
Cognitive functioning  83.3 (16.7-100)  83.3 (0-100)  83.3 (50-100)  66.7(0-100)  0.001 
Social functioning  100 (0-100)   83.3 (0-100)  66.7 (0-100)  50 (0-100)  <0.001 
Global quality of life  66.7 (16.7-100)  50 (0-100)  45.8(16.7-100)  29.1 (0-66.7)  <0.001 
Fatigue  11.1 (0-88.9)  33.3 (0-83.2)  33.3 (0-100)  77.7 (22.2-100)  <0.001 
Nausea and vomiting  0 (0-100)  16.7 (0-100)  16.7 (0-100)  41.7 (0-100)  <0.001 
Pain  16.7 (0-100)  16.7 (0-83.3)  33.3 (0-100)  25 (0-100)  <0.001 
Dyspnoea  0 (0-66.7)  0 (0-100)  0 (0-100)  50 (0-100)  <0.001 
Sleep disturbance  0 (0-100)  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  0.044 
Constipation  0 (0-100)  33.3 (0-100)  33.3 (0-100)  66.7 (0-100)  <0.001 
Diarrhoea  0 (0-100)  0 (0-66.7)  0 (0-100)  0 (0-100)  0.512 
Financial difficulty  0 (0-66.7)  0 (0-100)  0 (0-100)  0 (0-100)  0.296  
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Table 2.5 The relationship between systemic inflammatory response, as evidenced by elevated C-reactive protein, clinico-pathological and quality of life characteristics in patients with 
gastric-oesophageal cancer (n=94) 





Age:(<65 yrs/65-74yrs/>75yrs)  34/16/7  18/12/7  0.258 
Sex:(male/female)  38/19  27/10  0.520 
Tumour type:(adeno/squam)  48/9  30/7  0.695 
Tumour site:(oesoph/gastric)  23/34  20/17  0.195 
Tumour length:(<5cm/5-10cm/>10cm)  35/17/2  11/20/3  0.005 
Tumour stage:(I/II/III/IV)  15/20/13/8  4/10/10/13  0.006 
Weight loss:(yes/no)  31/16  27/10  0.072 
Dysphagia score:(1/2/3/4/5)  29/14/11/3/0  18/6/10/2/1  0.390 
ECOG:(0-1/2/3-4)  52/5/0  27/10/0  0.019 
Treatment:(operable/inoperable)  40/17  8/29  <0.001 
       
EORTC:(0-100)  Median (range)  Median (range)   
Physical functioning  100 (73-100)  86.7 (66.7-100)  0.001 
Role functioning  66.7 (0-100)  66.7 (0-100)  0.040 
Emotional functioning  66.7 (0-100)  70.8 (0-100)  0.343 
Cognitive functioning  83.3 (16.7-100)  83.3 (33.3-100)  0.875 
Social functioning  83.3 (0-100)  66.7 (0-100)  0.045 
Global quality of life  66.7 (0-100)  50 (0-100)  0.068 
Fatigue  33.3 (0-100)  44.4 (0-88.9)  0.003 
Nausea and vomiting  16.7 (0-100)  16.7 (0-100)  0.152 
Pain  16.7 (0-100)  16.7 (0-100)  0.040 
Appetite loss  33.3 (0-100)  66.7 (0-100)  0.001 
Dyspnoea  0 (0-100)  0 (0-100)  0.055 
Sleep disturbance  33.3 (0-100)  33.3 (0-100)  0.518 
Constipation  0 (0-100)  33.3 (0-100)  0.142 
Diarrhoea  0 (0-66.7)  0 (0-100)  0.304 
Financial difficulty  0 (0-100)  0 (0-100)  0.362 Created by Margaret McKernan     
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Figure 2.1 The relationship between appetite loss (None, A little, Quite a bit, Very much, 
from top to bottom) and cancer specific survival in patients with gastro-oesophageal 














Chapter 3 Created by Margaret McKernan     
3.  A prospective longitudinal study of the impact of treatment on quality of life  (EORTC 
QLQ-C30) in patients with gastric and oesophageal cancer 
3.1  Introduction 
In the United Kingdom gastric and oesophageal cancer are the sixth and fifth most 
common cause of cancer respectively and each year, there are approximately 17,000 new 
cases diagnosed.  Combined gastro-oesophageal cancer is the third commonest cause of 
cancer death in the UK with over 13,000 deaths attributable to the disease.  Overall 
survival is poor with the majority of patients presenting with advanced, inoperable disease 
and less than 15% surviving 5 years (Cancerstats, 2004).  Although there has been 
improvements in survival following surgery long term outcome is still poor.  Even in those 
who undergo potentially curative resection for gastric cancer, less than 30% survive 5 
years (Hundahl et al., 2000).  Survival for oesophageal cancer who undergo potentially 
curative resection has recently been reported to be 40% (Stein et al., 2005). 
Therefore, although surgery confers the greatest chance of long-term cure it should also 
aim to maintain long-term quality of life.  In the last decade or so there has been 
considerable interest in including some measure of quality of life in the assessment and 
follow up of patients with cancer and their continuing aftercare, as it provides information 
on the patient’s perception of their health and the effectiveness and side effects of their 
treatment. 
A number of workers have reported the importance of quality of life as an outcome 
measure, in addition to survival, as debilitating problems with nutrition, pain and fatigue 
are common after surgery.  Furthermore, in patients undergoing palliative treatment 
symptom relief must be weighed against treatment toxicity and therefore recording 
ongoing quality of life in these patients is of considerable importance (Aaronson et al., 
1993; Vickery et al., 2000). 
We have recently reported that in an unselected cohort of patients with gastro-oesophageal 
cancer (McKernan et al., 2008) that appetite loss was a significant prognostic factor even 
after adjustment for TNM stage and the systemic inflammatory response.  Furthermore, 
when the baseline relationship between appetite loss and the other quality of life functions 
or symptom scores were examined, it was clear that appetite loss was closely related to  
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these measures, in particular; appetite loss was closely associated with global quality of 
life, fatigue and dysphagia.  However, the effect of treatment on aspects of quality of life 
including appetite loss has rarely been examined. 
A study by Thybusch-Bernhardt and co-workers (1999) reported that in patients (n=62) 
undergoing gastric surgery, comparing total gastrectomy with extended gastrectomy, the 
global quality of life during the first 12 months was poor; thereafter there were no 
significant differences over the following 2 years (Thybusch-Bernhardt et al., 1999).  
However, in their study there were no baseline pre-operative quality of life measurements 
and therefore it is unclear if the patients already had underlying poor quality of life prior to 
surgery. 
A later study by Blazeby and co-workers (2000) reported similar results in patients (n=55) 
with oesophageal cancer.  They reported that six weeks after oesophagectomy, patients 
reported worse functional, symptom, and global quality of life scores than before 
treatment.  Furthermore, it was reported that quality of life scores returned to preoperative 
levels within 9 months, dysphagia improved after surgery and the improvement was 
maintained until death or for the duration of the study.  In the same study it was reported 
that there was gradual deterioration in most aspects of quality of life until death in patients 
(n=37) undergoing palliative treatment (Blazeby et al., 2000). 
Bamias and colleagues (1996) reported that in oesophageal cancer patients (n=235) 
receiving palliative chemotherapy, the quality of life assessments showed a transient 
deterioration in physical and role functioning and provided good symptomatic control of 
pain (Bamias et al., 1996). 
Glimelius and co-workers (1997) reported that in a randomised trial comparing 
chemotherapy and best supportive care in patients (n=55) with advanced gastric cancer, 
chemotherapy appeared to improve quality of life compared with patients in the supportive 
care group at the four month evaluation (Glimelius et al., 1997). 
The aim of the present longitudinal study was to examine the effect of treatment (surgery, 
oncological treatment or supportive care) on quality of life (EORTC QLQ-C30) in patients 
with gastric and oesophageal cancer.  
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3.2  Patients and methods 
Patients 
Patients presenting with adenocarcinoma or squamous carcinoma of the gastric or 
oesophageal tract at the Royal Infirmary and Southern General Hospital, Glasgow between 
November 1997 and December 2002 (n=160) participated in a quality of life study, using 
the EORTC QLQ-C30 core questionnaire. 
The extent of tumour spread was recorded using the UICC TNM 5th edition classification, 
as this was the edition in use at the commencement of the study (Sobin and Wittekind, 
1997).  Tumours around the gastro-oesophageal junction were further classified according 
to tumour site, using the Siewert system; type 1 and 2 lesions of the gastro-oesophageal 
junction were designated as cancers of the oesophagus.  Type 3 tumours of the cardia were 
designated as gastric cancers (Siewert and Stein, 1998). 
For gastric cancers, tumour node metastasis (TNM) stage I–III tumours were considered to 
be amenable to curative surgical resection.  For oesophageal cancers, TNM stage I–III 
tumours, excluding T4, were deemed to be amenable to curative surgical resection.  
Patients who had TNM stage I and II disease but their performance status and significant 
co-morbid disease was poor were not deemed suitable for surgery and went forward for 
active palliative oncological treatment or supportive care, which included endoscopic 
input.  There were 160 patients included in the study, 35 patients were suitable for 
gastrectomy and 34 patients were suitable for oesophageactomy.  Due to stage of disease 
or co-morbid disease, 91 patients were inoperable of which 38 received chemotherapy, 
radiotherapy or combined treatment, the further 53 patients received supportive care which 
may have included therapeutic endoscopic input. 
The study was approved by the Research Ethics Committee of the Royal Infirmary and 
Southern General Hospital, Glasgow. 
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Methods 
Clinical and demographic variables were recorded at the patient’s initial presentation and 
included age, sex, tumour type (only adenocarcinoma or squamous cancers were included 
in the study), site and length, UICC TNM stage, ECOG performance status, weight loss, 
dysphagia and treatment. 
Following diagnosis but prior to treatment the lead clinician approached patients as to 
whether they would participate in a study to examine their quality of life.  If they gave 
informed consent they were given the EORTC QLQ-C30 questionnaire to complete. 
Different aspects of quality of life were assessed using this cancer specific 30-item 
questionnaire, which has six functional scales (physical, role, emotional, cognitive, social, 
global health status) and several questions relating to a range of physical symptoms 
(Aaronson et al, 1993).  Patients marked to what extent each statement applied to them.  In 
the present study a number of patients (less than 10 patients) were excluded because they 
were unlikely to understand the language, had brain metastases, delirium or confusion.  
Neither age nor performance status were considered when offering the patient 
questionnaire.  Patients were not randomised. 
Questionnaires were completed at baseline 3, 6, 9 and 12 months, then 6 monthly until year 
4 and the last questionnaire was at the end of year 5.  Following the baseline assessment, 
questionnaires were posted out to patients in a self addressed, stamped envelope, with 
covering letter to re-iterate the reason for the assessment, or were conducted whilst the 
patient was attending a clinic or endoscopy appointment.  The dysphagia score was 
recorded at time of the patients’ routine clinic or endoscopic assessment. 
As a result of loss of patients to follow-up, predominantly due to death, those patients who 
underwent surgery had questionnaires at baseline, 3 and 6 months and years 1, 2, 3 and 4 
analysed.  In those patients who received oncological treatment or supportive care had 
questionnaires at baseline, 3 and 6 months analysed. 
 
  
  73 
3.3  Statistics 
Data are presented as the median and range.  Scoring algorithms produced by the EORTC 
Quality of Life Study Group were used.  The sum of items in each category is added and 
the total divided by the number of questions in the category.  A linear transformation is 
then undertaken to convert this to a percentage scale with a higher score representing a 
higher response level.  Thus a high score for functional scale represents a high/healthy 
level of functioning.  A high score for the global health status/quality of life represents a 
high quality of life.  In contrast, a high score for the symptom scale represents a higher 
level of symptoms/ problems (Aaronson et al., 1993). 
Data from different patient groups were tested for statistical significance using ANOVA 
(Kruskal–Wallis) and the Mann-Whitney U-test was used to compare two patient groups.  
Analysis of data from different time periods within each group were tested for statistical 
significance using the Freidman test, and when appropriate comparisons of data from 
different time periods were carried out using the Wilcoxon signed rank test.  Analysis was 
performed using SPSS software (SPSS Inc, Chicago, IL, USA).  
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3.4  Results 
The minimum follow up period was 54 months or until date of death, the median follow up 
for survivors was 81 months, one patient was lost to follow up and one patient withdrew 
from the study.  During this period 112 (70%) patients died from their disease and 18 
(11%) died from co-morbid disease.  Deaths and patients who did not return questionnaires 
at each time point have been reported in each table. 
The relationship between clinico-pathological and quality of life (EORTC QLQ-C30) 
characteristics in patients with operable gastric and oesophageal cancer and inoperable 
gastric and oesophageal cancer are shown in Table 3.1. 
At study entry, there were significant differences in age (P<0.001), sex (P<0.01), tumour 
type (P<0.01), tumour length (P<0.001), TNM stage (P<0.001), dysphagia score 
(P<0.001), weight loss (P<0.001) and performance status (P<0.001) between the 4 groups.  
With reference to quality of life, there were significant differences in physical functioning 
(P<0.01), role functioning (P<0.01), cognitive functioning (P<0.05), social functioning 
(P<0.05), global quality of life (P<0.01), fatigue (P<0.001), nausea and vomiting (P<0.01), 
appetite loss (P<0.001) and dyspnoea (P<0.001) between the 4 groups. 
Patients undergoing gastrectomy or oesophagectomy were more likely to be younger 
(P<0.01) had less advanced TNM stage (P<0.001) and had less dysphagia (P<0.01) and 
weight loss (P<0.001) and better performance status (P<0.001) compared with those 
patients who were inoperable or receiving supportive care.  Furthermore, they reported 
better physical functioning (P<0.01), role functioning (P<0.01), social functioning 
(P<0.01) and global quality life (P<0.01) and less fatigue (P<0.01), nausea and vomiting 
(P<0.05), appetite loss (P<0.001) and dyspnoea (P<0.01) compared with those patients 
who were inoperable or receiving supportive care. 
In those patients amenable to surgery, the patients undergoing oesophagectomy had fewer 
females (P<0.05), more adenocarcinomas (P<0.001), more dysphagia (P<0.001) but better 
emotional (P<0.05) and cognitive functioning (P<0.05) and had better symptom scores for 
fatigue (P<0.01), nausea/vomiting (P<0.01) and dyspnoea (P<0.05) compared with patients 
undergoing gastrectomy.  In those patients deemed inoperable, patients who received 
supportive care were more likely to be older (P<0.001), female (P<0.01), and had poorer  
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performance status (P<0.001) than patients who were offered oncological treatment.  Also 
higher symptom scores for fatigue (P<0.05) was seen in the patients receiving supportive 
care compared with those patients receiving oncological treatment. 
The longitudinal measurement at baseline, 3 and 6 months, 1, 2, 3 and 4 years, of the 
dysphagia score and quality of life EORTC QLQ-C30 in patients who underwent a 
gastrectomy are shown in Table 3.2.  Social functioning (P<0.01) was significantly poorer 
following surgery and persisted throughout the follow-up period.  Also the symptom score 
for pain (P<0.05) increased following surgery and failed to return to pre-treatment levels 
(Figures 3.1-3.2). 
The longitudinal measurement at baseline, 3 and 6 months, 1, 2, 3 and 4 years, of the 
dysphagia score and quality of life EORTC QLQ-C30 in patients who underwent 
oesophagectomy are shown in Table 3.3.  Physical (P<0.001), role (P<0.001) and social 
(P<0.01) functioning and global quality of life (P<0.05) were significantly poorer 
following surgery and persisted throughout most of the follow-up period, gradually 
returning to near baseline levels after 2 years.  Following oesophagectomy dysphagia 
(P<0.001) improved, fatigue (P<0.001) increased following surgery and failed to return to 
pre-treatment levels.  However, following surgery there was a transient increase in nausea 
and vomiting (P<0.05), dyspnoea (P<0.01) and diarrhoea (P<0.01), which appeared to 
resolve slowly during follow-up (Figures 3.3-3.11). 
The longitudinal measurement at baseline, 3 and 6 months, of the dysphagia score and 
quality of life EORTC QLQ-C30 in patients who had oncological treatment are shown in 
Table 3.4.  Dysphagia (P<0.01) resolved gradually, physical functioning (P<0.001) had a 
transient change at 3 months and fatigue (P<0.01) increased during the follow-up period 
(Figures 3.12-3.14). 
The longitudinal measurement at baseline, 3 and 6 months, of the dysphagia score and 
quality of life EORTC QLQ-C30 in patients who were offered supportive care are shown 
in Table 3.5.  Dysphagia (P<0.05) and cognitive functioning (P<0.05) were shown to be 
significant during the follow-up period (Figures 3.15-3.16). 
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3.5  Discussion 
In the present cross sectional and longitudinal study, patients who underwent surgery had, 
at study entry, better global quality life including better physical and role functioning and 
less fatigue and appetite loss compared with those patients who did not receive surgery.  
Furthermore, the effect of oesophageal surgery on global quality of life appeared to be 
more profound and persistent, in particular patients went on to have poorer physical and 
role functioning and more fatigue.  In contrast, in patients with inoperable disease, the poor 
quality of life measures at study entry remained poor on follow-up whether patients 
received oncological input or supportive care.  Therefore, these longitudinal data from an 
unselected cohort of patients with gastric and oesophageal cancer further inform the 
treatment decision making process.  In particular, it is clear that oesophageal surgery has a 
profound and long lasting effect on quality of life. 
We have previously reported (McKernan et al., 2008) that appetite loss at study entry was 
independently associated with poorer survival and associated with other quality of life 
parameters such as global quality of life, fatigue and dysphagia.  In the present longitudinal 
study appetite loss did not appear to be significantly altered on follow-up or on whether 
patients had gastric or oesophageal cancer or were operable or not.  Even in those patients 
with oesophagectomy who reported an improvement in their dysphagia there was only a 
transient alteration in appetite loss.  Therefore, it would appear that the degree of appetite 
loss is determined at an early stage in the disease process and is not related simply to 
obstruction of the gastro-oesophageal tract. 
The results of the present study are consistent with the previous studies of Thybusch-
Bernhardt and co-workers (1999) in gastric cancer patients.  Similarly the results of the 
present study are consistent with those of Viklund and co-workers (2006) who compared 
oesophageal cancer patients (n=282) undergoing resection to the general population and 
reported that, at 6 months following oesophagectomy, patients had significantly worse 
quality of life including most functioning and symptom scales (Viklund et al., 2006).  
However, similar to the Thybusch-Bernhardt study there were no baseline pre-operative 
quality of life measurements recorded. 
In the present study there were persistent reductions in physical, role and social functioning 
and fatigue in oesophageactomy patients up to 4 years following surgery.  There are, to our  
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knowledge, no studies which have examined the effect of surgery on quality of life beyond 
3 years.  Previous studies by (Blazeby et al., 2000 and 2005; Reynolds et al., 2006) in 
oesophageal cancer patients have reported transient changes in dysphagia and some 
functional scales and global quality of life in the first year following oesophagectomy.  
Blazeby and co-workers also reported that patients who died within 2 years of surgery did 
not appear to regain their quality of life. 
In the present study, in the oncological treatment and supportive care patient groups most 
function and symptom scales were poor at study entry and remained poor during the 
follow-up period.  However, in a larger palliative cohort of oesophageal cancer patients 
(n=209) receiving brachytherapy or stent Homs and co-workers (2004) reported that there 
was a deterioration in all functional scales and an increase in symptom scales particularly 
pain. 
In summary, the results of the present study suggest that surgery for oesophageal cancer, 
compared with that for gastric cancer, has a more profound and long lasting effect on 
quality of life, especially physical, role and social functioning and fatigue symptoms.  In 
contrast, patients with inoperable gastro-oesophageal cancer have poor quality of life and 
oncological treatment or supportive care appears to have little further impact on their 
quality of life.  
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Table 3.1: The relationship between clinico-pathological and quality of life (EORTC QLQ-C30) characteristics in patients with operable gastric and oesophageal cancer and inoperable 
gastric and oesophageal cancer 




  Inoperable Oncology 
(n=38) 
Inoperable Supportive care 
(n=53) 
P value 
Age:(<65yrs/65-74yrs/>75yrs)  16/7/2  21/10/3  22/13/3  9/22/22***  <0.001 
Sex:(male/female)  19/16  27/7*  33/5  32/21**  0.005 
Type:(squam/adeno)  0/35  23/11***  11/27  7/46  0.001 
Tumour length:(<5cm/5-10cm/>10cm)  20/11/1  22/11/0  6/25/7  14/27/6  <0.001 
Tumour stage:(I-II/III/IV)  29/4/1  22/11/0  11/12/13  15/9/28  <0.001 
Dysphagia score:(1/2/3/4/5)  30/3/2/0/0  12/10/9/3/0***  15/8/9/5/1  26/4/14/9/0  <0.001 
Weight loss:(yes/no)  18/17  15/19  32/6  43/10  <0.001 
ECOG:(0-1/2/3-4)  30/5/0  29/5/0  27/11/0  23/24/6***  <0.001 
           
EORTC: QLQ-C30 (0-100)           
Physical functioning  100 (73.3-100)  100 (73.3-100)  86.7 (66.7-100)  86.7 (66.7-100)  0.006 
Role functioning  66.7 (0-100)  100 (0-100)  66.7 (0-100)  50 (0-100)  0.003 
Emotional functioning  66.7 (8.3-100)  83.3 (33.3-100)*  75 (0-100)  66.7 (0-100)  0.191 
Cognitive functioning  83.3 (16.7-100)  100 (50.100)*  83.3 (16.7-100)  83.3 (0-100)  0.037 
Social functioning  91.6 (0-100)  100 (0-100)  66.7 (0-100)  66.7 (0-100)  0.013 
Global quality of life  50 (8.3-100)  66.7 (25-100)  50 (0-100)  50 (0-100)  0.002 
Fatigue  33.3 (0-83.2)  11.1 (0-88.9)**  33.3 (0-100)  44.4 (0-100) *  <0.001 
Nausea and vomiting  16.7 (0-100)  0 (0-50)**  16.7 (0-100)  16.7 (0-100)  0.002 
Pain  16.7 (0-83.3)  16.7 (0-66.7)  16.7 (0-100)  16.7 (0-100)  0.444 
Appetite loss  33.3 (0-100)  0 (0-100)  33.3 (0-100)  66.7 (0-100)  <0.001 
Dyspnoea  0 (0-100)  0 (0-66.7) *  33.3 (0-100)  33.3 (0-100)  <0.001 
Sleep disturbance  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  0.715 
Constipation  0 (0-100)  0 (0-100)  33.3 (0-100)  33.3 (0-100)  0.104 
Diarrhoea  0 (0-100)  0 (0-33.3)  0 (0-100)  0 (0-100)  0.881 
Financial difficulty  0 (0-100)  0 (0-100)  0 (0-100)  0 (0-100)  0.444 
* p<0.05, ** p<0.01, ***p<0.001 compared with gastrectomy         * p<0.05, ** p<0.01, ***p<0.001 compared with inoperable oncology  
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Table 3.2  Longitudinal dysphagia score and quality of life EORTC QLQ-C30 in patients after gastrectomy at baseline, 3 and 6 months, 1, 2, 3 and 4 years. 




















P-  value 
Dysphagia score (1-5)  1 (1-3)  1 (1-3)  1 (1-2)  1 (1-2)  1 (1-2)  1 (1-3)  1 (1)  0.228 
                 
EORTC:(0-100)                 
Physical functioning  100 (73.3-100)  86.7 (66.7-100)  80 (66.7-100)  86.7 (66.7-100)  80 (60-100)  86.7 (66.7-100)  86.7 (73.3-100)  0.822 
Role functioning  66.7 (0-100)  41.6 (0-100)  41.6 (0-100)  58.3 (0-100)  50 (0-100)
   50 (0-100)
   33.3 (16.7-100)  0.253 
Emotional functioning  66.7 (8.3-100)  66.7 (0-100)  70.8 (16.7-100)  50 (0-100)  66.7 (8.3-100)  83.3 (8.3-100)  66.7 (0-100)  0.787 
Cognitive functioning  83.3(16.7-100)  83.3 (0-100)  75 (16.7-100)  58.3 (0-100)  66.7 (16.7-100)  83.3 (16.7-100)  66.7 (16.7-100)  0.112 
Social functioning  91.6 (0-100)  50 (0-100)**  66.7 (0-100)*  66.7 (0-100)***  66.7 (0-100)**  66.7 (16.7-100)
 n/s  50 (0-100)**  0.008 
Global quality of life  50 (8.3-100)  50 (0-100)  58.3 (16.7-100)  50 (0-83.3)  58.3 (0-83.3)  50 (0-100)  50 (8.3-75)  0.541 
Fatigue  33.3 (0-83.2)  50 (0-100)  50 (0-100)  44.4 (0-100)  38.3 (0-100)  44.4 (0-77.8)  33.3 (11.1-100)  0.513 
Nausea and vomiting  16.7 (0-100)  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  16.7 (0-100)  16.7 (0-100)  33.3 (0-83.3)  0.098 
Pain  16.7 (0-88.3)  33.3 (0-100)**  33.3 (0-100)*  33.3 (0-100)**  33.3 (0-83.3)*  33.3 (0-83.3)**  50 (0-100)**  0.021 
Appetite loss  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  0.260 
Dyspnoea  0 (0-100)  33.3 (0-100)  16.5 (0-100)  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  0.350 
Sleep disturbance  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  66.7 (0-100)  33.3 (0-100)  33.3 (0-100)  66.7 (0-100)  0.718 
Constipation  0 (0-100)  0 (0-100)  0 (0-33.3)  0 (0-66.7)*  0 (0-33.3)
   0 (0-100)
   0 (0-33.3)  0.473 
Diarrhoea  0 (0-100)  33.3 (0-100)  33.3 (0-100)  0 (0-66.7)  0 (0-100)  0 (0-100)  33.3 (0-100)  0.306 
Financial difficulty  0 (0-100)  33.3 (0-100)  0 (0-100)  0 (0-100)  33.3 (0-100)  33.3 (0-66.7)  0 (0-100)  0.276 
 
a. 7 not returned 
b. 1 too ill to complete questionnaire, 8 not returned 
c. 2 patients died, 5 too ill to complete questionnaire, 4 not returned 
d. 8 further patients died, 4 not returned 
e. 2 further patients died, 1 not returned 
f. 3 further patients died, 5 not returned 
 
* p<0.05, ** p<0.01, ***p<0.001 compared with baseline 
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Table 3.3  Longitudinal dysphagia score and quality of life EORTC QLQ-C30 in patients after oesophagectomy at baseline, 3 and 6 months, 1, 2, 3 and 4 years. 






















Dysphagia score (1-5)  2 (1-4)  2 (1-3)*  2 (1-3)**  1 (1-3)**  1 (1)**  1 (1)**  1 (1)**  <0.001 
                 
EORTC:(0-100)                 
Physical functioning  100 (73.3-100)  86.7 (53.3-100)***  86.7 (66.7-100)***  86.7 (66.7-100)**  93.3 (73.3-100)*  93.3 (73.3-100)*  93.3 (73.3-100)*  <0.001 
Role functioning  100 (0-100)  33.3 (0-100)**  33.3 (0-100)**  66.7 (0-100)
n/s  66.7 (0-100)
 n/s  83.3 (0-100)
 n/s  91.7 (0-100)
 *  <0.001 
Emotional functioning  83.3 (33.3-100)  83.3 (16.7-100)  83.3 (0-100)  91.7 (25-100)  91.7 (0-100)  100 (0-100)  95.8 (0-100)  0.447 
Cognitive functioning  100 (50-100)  83.3 (50-100)  91.7 (0-100)  100 (33.3-100)  100 (33.3-100)  83.3 (0-100)  100 (0-100)  0.523 
Social functioning  100 (0-100)  41.7 (0-100)***  66.7 (0-100)**  75 (25-100)*  66.7 (0-100)*  83.3 (0-100)*  91.7 (0-100)*  0.002 
Global quality of life  66.7 (25-100)  58.3 (16.7-91.7)**  54.1 (0-91.7)**  66.7 (33.3-100)
 n/s  75 (33.3-100)
 n/s  66.7 (33.3-100)
 n/s  75 (33.3-100)
 n/s  0.033 
Fatigue  11.1 (0-88.9)  33.3 (0-88.9)***  33.3 (0-100)***  33.3 (0-88.9)**  33.3 (0-100)**  33.3 (0-77.8)**  33.3 (0-88.9)**  <0.001 
Nausea and vomiting  0 (0-50)  16.7 (0-100)**  16.7 (0-100)**  16.7 (0-66.7)
 n/s  0 (0-100)
 n/s  0 (0-66.7)
 n/s  0 (0-83.3)
 n/s  0.018 
Pain  16.7 (0-66.7)  33.3 (0-100)  33.3 (0-100)  16.7 (0-100)  33.3 (0-100)  16.7 (0-100)  8.3 (0-83.3)  0.638 
Appetite loss  0 (0-100)  33.3 (0-100)  33.3 (0-100)  0 (0-66.7)  0 (0-100)  0 (0-66.7)  0 (0-66.7)  0.182 
Dyspnoea  0 (0-66.7)  33.3 (0-100)***  33.3 (0-100)**  33.3 (0-100)**  33.3.(0-100)**  0 (0-100)*  16.7 (0-100)*  0.009 
Sleep disturbance  33.3 (0-100)  33.3 (0-100)  50 (0-100)  0 (0-100)  33.3 (0-100)  0 (0-100)  0 (0-100)  0.790 
Constipation  0 (0-66.7)  0 (0-100)  0 (0-100)  0 (0-100)  0 (0-100)  0 (0-33.3)  0 (0-100)  0.893 
Diarrhoea  0 (0-33.3)  33.3 (0-100)**  33.3 (0-100)**  0 (0-66.7)**  0 (0-66.7)
 n/s  33.3 (0-66.7)
 n/s  0 (0-33.3)
 n/s  0.003 
Financial difficulty  0 (0-100)  16.7 (0-100)  33.3 (0-100)  0 (0-100)  0 (0-100)  0 (0-100)  0 (0-100)  0.103 
 
a. 3 patients died, 2 too ill to complete questionnaire, 4 not returned 
b. 1 further patient died, 1 too ill to complete questionnaire, 6 not returned 
c. 4 further patients died, 1 too ill to complete questionnaire, 2 not returned 
d. 5 further patients died, 2 not returned 
e. 3 further patients died, 1 too ill to complete questionnaire, 2 not returned 
f. 1 further patient died, 1 too ill to complete questionnaire, 2 not returned 
 
* p<0.05, ** p<0.01, ***p<0.001 compared with baseline 
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Table 3.4  Longitudinal dysphagia score and quality of life EORTC QLQ-C30 in patients with gastro-oesophageal cancer receiving oncological treatment at baseline, 3 and 6 months. 










Dysphagia (1-5)  1 (1-5)  1 (1-2)*  1 (1-2)**  0.007 
         
EORTC:(0-100)         
Physical functioning  86.7 (66.7-100)  80 (66.7-100)***  86.7 (66.7-100)**  <0.001 
Role functioning  66.7 (0-100)  33.3 (0-100)  66.7 (0-100)  0.191 
Emotional functioning  75 (0-100)  75 (25-100)  91.7 (0-100)  0.846 
Cognitive functioning  83.3 (16.7-100)  66.7 (16.7-100)  50 (16.7-100)  0.052 
Social functioning  66.7 (0-100)  66.7 (0-100)  66.7 (0-100)  0.281 
Global quality of life  50 (0-100)  50 (0-83.3)  50 (0-91.7)  0.813 
Fatigue  33.3 (0-100)  50 (0-100)**  55.6 (11.1-100)*  0.005 
Nausea and vomiting  16.7 (0-100)  16.7 (0-100)  16.7 (0-66.7)  0.756 
Pain  16.7 (0-100)  33.3-(0-100)  33.3-(0-100)  0.102 
Appetite loss  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  0.614 
Dyspnoea  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  0.091 
Sleep disturbance  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  0.223 
Constipation  33.3 (0-100)  33.3 (0-100)  0 (0-100)  0.784 
Diarrhoea  0 (0-100)  0 (0-66.7)  0 (0-66.7)  0.646 
Financial difficulty  0 (0-100)  16.7 (0-100)  33.3 (0-100)  0.507 
 
a. 6 patients died, 1 too ill to complete questionnaire, 
b. 6 further patients died, 6 too ill to complete questionnaire, 5 not returned 
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Table 3.5  Longitudinal dysphagia score and quality of life EORTC QLQ-C30 in patients with gastro-oesophageal cancer receiving supportive care at baseline, 3 and 6 months. 










Dysphagia (1-5)  1 (1-4)  1 (1-3)**  1 (1-4)*  0.025 
         
EORTC:(0-100)         
Physical functioning  86.7 (66.7-100)  80 (66.7-100)  80 (66.7-100)  0.214 
Role functioning  50 (0-100)  41.7 (0-100)  33.3 (0-100)  0.562 
Emotional functioning  66.7 (0-100)  66.7 (0-100)  66.7 (0-100)  0.337 
Cognitive functioning  83.3 (0-100)  83.3 (33.3-100)
n/s  83.3 (0-100)
 n/s  0.050 
Social functioning  66.7 (0-100)  50 (0-100)  66.7 (0-100)  0.717 
Global quality of life  50 (0-100)  50 (0-83.3)  50 (0-83.3)  0.590 
Fatigue  44.4 (0-100)  61.1 (0-100)  66.7 (11.1-100)  0.500 
Nausea and vomiting  16.7 (0-100)  16.7 (0-66.7)  0 (0-100)  0.508 
Pain  16.7 (0-100)  33.3-(0-100)  33.3-(0-100)  0.519 
Appetite loss  66.7 (0-100)  33.3 (0-100)  33.3 (0-100)  0.368 
Dyspnoea  33.3 (0-100)  66.7 (0-100)  66.7 (0-100)  0.121 
Sleep disturbance  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  0.394 
Constipation  33.3 (0-100)  33.3 (0-100)  33.3 (0-100)  0.834 
Diarrhoea  0 (0-100)  0 (0-66.7)  0 (0-100)  0.368 
Financial difficulty  0 (0-100)  0 (0-100)  0 (0-100)  0.779 
 
a. 19 patients died, 6 too ill to complete questionnaire, 5 not returned 
b. 8 further patients died, 6 too ill to complete questionnaire, 7 not returned 
 
* p<0.05, ** p<0.01, ***p<0.001 compared with baseline  
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Figure 3.2.  Changes in quality of life following gastrectomy; pain  
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Figure 3.5  Changes in quality of life following oesophagectomy;  
social functioning 
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Figure 3.6  Changes in quality of life following oesophagectomy;  


















































Figure 3.8  Changes in quality of life following oesophagectomy; fatigue 
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Figure 3.14  Changes in quality of life following oncological treatment; dysphagia 
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4.  CONCLUSIONS 
4.1  Introduction 
In Chapter 1 the aims of this thesis were defined as follows: 
1. To examine the relationship between quality of life (EORTC QLQ-C30) and survival in 
patients with gastro-oesophageal cancer. 
2. To examine the longitudinal impact of treatment on quality of life (EORTC QLQ-C30) 
in patients with gastric and oesophageal cancer. 
4.2  Aim 1 
It had been previously reported that few aspects of quality of life had a role in predicting 
survival in an unselected cohort of patients with gastro-oesophageal cancer. 
Fang and co-workers (2003) reported that there was evidence to support the correlation of 
patient-reported QOL scores with survival; in particular physical functioning might be a 
surrogate marker of an unrecognised biological prognostic factor.  In contrast, Chau and 
colleagues (2004) reported that no aspect of the quality of life (QLQ-C30) had independent 
prognostic value when performance status was considered. 
The results of the present work (Chapter 2) demonstrate there were major differences in 
quality of life and symptom scores with increasing stage of disease.  In particular, social 
functioning, fatigue, appetite loss and global quality of life were all impaired with 
increasing tumour stage.  Furthermore, appetite loss remained an independently significant 
prognostic factor even after adjustment for TNM stage and treatment.  It was of interest 
that appetite loss was closely associated with nausea and vomiting, dysphagia and weight 
loss and therefore it may be that these symptoms result in appetite loss and the consequent 
loss of weight, which has long been recognised to impact on outcome.  These findings are 
consistent with Blazeby (1995) who reported that appetite loss was associated with poorer 
survival. 
A number of workers (O’Gorman et al., 1998; Kotler, 2000; Scott et al., 2003; MacDonald, 
2007).  Previously reported the systemic inflammatory response also had an important      
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factor in determining patients’ quality of life (QLQ-C30) in gastro-intestinal and lung 
cancer patients.  Consistent with previous work, the present study suggests that an elevated 
C-reactive protein concentration was associated with increased appetite loss.  Nevertheless, 
even those patients without an elevated C-reactive protein concentration, reported some 
appetite loss and both were independently associated with poorer cancer specific survival. 
In order to take this work forward it will be important to examine the effect of targeting the 
systemic inflammatory response, using anti-inflammatory agents (MacDonald, 2007), 
targeting appetite loss using appetite stimulants (McMillan et al., 1998; Goldberg and 
Loprinzi, 1999; Tomiska et al., 2003) and quality of life in patients with gastric and 
oesophageal cancer. 
4.3  Aim 2 
There are, to our knowledge, no studies, which have examined the effect of surgery on 
quality of life beyond 3 years.  Therefore, the aim of the present longitudinal study was to 
examine the effect of treatment (surgery, oncological treatment or supportive care) on 
quality of life. 
In the present work (Chapter 3), at study entry, patients who underwent surgery had better 
quality of life (QLQ-C30) scores, in particular; physical, role and social functioning and 
global quality life and less fatigue, nausea and appetite loss, compared with those patients 
with inoperable disease, where the poor quality of life measures at study entry remained 
poor on follow-up, whether patients received oncological input or supportive care. 
The effect of oesophageactomy reported persistent and profound reductions in physical, 
role and social functioning and fatigue in patients up to 4 years following surgery.  In 
contrast, in patients with inoperable disease, the poor quality of life measures at study entry 
remained poor on follow-up whether patients received oncological input or supportive 
care. 
Furthermore, in the present longitudinal study appetite loss did not appear to be 
significantly altered on follow-up, even in those patients with oesophagectomy there was 
only a transient alteration in appetite loss.  Therefore, it would appear that the degree of      
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appetite loss is determined at an early stage in the disease process and is not related simply 
to obstruction of the gastro-oesophageal tract. 
In conclusion, the results of the present thesis show that host (appetite loss, systemic 
inflammation), tumour (stage, type), and treatment (surgery, chemotherapy) factors are 
important in determining quality of life in patients with gastric and oesophageal cancer.  It 
is therefore important that these factors are taken into account when considering how to 
improve quality of life. 
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Appendix 1.1 
TNM classification of gastric tumours 
T – Primary Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ: intraepithelial tumour without invasion of the lamina propria 
T1 Tumour invades lamina propria or submucosa 
T2 Tumour invades muscularis propria or subserosa 
T3 Tumour penetrates serosa (visceral peritoneum) without invasion of adjacent structures 
T4 Tumour invades adjacent structures 
 
N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1 to 6 regional lymph nodes 
N2 Metastasis in 7 to 15 regional lymph nodes 
N3 Metastasis in more than 15 regional lymph nodes 
 
M – Distant Metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
 
Stage Grouping 
Stage 0   Tis     N0     M0 
Stage IA   T1     N0     M0 
Stage IB   T1     N1     M0 
                 T2     N0     M0 
Stage II   T1     N2     M0 
                T2     N1     M0 
                T3     N0     M0 
Stage IIIA   T2     N2     M0 
                    T3     N1     M0 
                    T4     N0     M0 
Stage IIIB   T3     N2     M0 
Stage IV   T4     N1, N2, N3  M0 
                 T1, T2, T3   N3     M0 
                 Any T    Any N    M1     
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Appendix 1.1 continued 
TNM classification of oesophageal tumours 
T – Primary Tumour 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour invades lamina propria or submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades adjacent structures 
 
N – Regional Lymph Nodes 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 
M – Distant Metastasis 
MX Distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis-For tumours of lower thoracic oesophagus 
M1a Metastasis in coeliac lymph nodes 
M1b Other distant metastasis-For tumours of upper thoracic oesophagus 
M1a Metastasis in cervical lymph nodes 
M1b Other distant metastasis-For tumours of mid-thoracic oesophagus 
M1a Not applicable 
M1b Non-regional lymph node or other distant metastasis 
 
Stage Grouping 
Stage 0   Tis     N0     M0 
Stage I   T1     N0     M0 
Stage IIA   T2     N0     M0 
T3     N0     M0 
Stage IIB   T1     N1     M0 
T2     N1     M0 
Stage III   T3     N1     M0 
T4     Any N    M0 
Stage IVA   Any T    Any N    M1a 
Stage IVB   Any T    Any N    M1b      
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Appendix 2.1 
EORTC QLQ-C30 (version 2.0) 
 
We are interested in some things about you and your health. Please answer all of the questions 
yourself by circling the number that best applies to you. There are no "right" or "wrong" answers. 
The information that you provide will remain strictly confidential. 
Please fill in your initials:                _________ 
Your birth date (Day, Month, Year): ________ 
Today's date (Day, Month, Year):   _________ 
_________________________________________________________________________
                    No  Yes 
1. Do you have any trouble doing strenuous activities  
    like carrying a heavy shopping bag or a suitcase?         1      2 
2. Do you have any trouble taking a long walk?          1      2 
3. Do you have any trouble taking a short walk outside of the house?     1      2 
4. Do you need to stay in bed or a chair during the day?        1      2 
5. Do you need help with eating, dressing, washing yourself or using the toilet?    1      2 
 
During the past week:            Not at       A       Quite   Very 
                   All      Little    a Bit    Much 
6. Were you limited in doing either your work or other  
     daily activities?                  1          2             3        4 
7. Were you limited in pursuing your hobbies or other 
     leisure time activities?                1          2           3          4 
8. Were you short of breath?                1          2           3          4 
9. Have you had pain?                  1          2           3          4 
10. Did you need to rest?                1          2           3          4 
11. Have you had trouble sleeping?              1          2           3          4 
12. Have you felt weak?                1          2           3          4 
13. Have you lacked appetite?                1          2           3          4 
14. Have you felt nauseated?                1          2           3         4 
15. Have you vomited?                 1          2           3          4 
16. Have you been constipated?               1          2           3          4 
Please go on to the next page      
  114 
 
Appendix 2.1 continued 
During the past week:            Not at      A       Quite   Very 
                   All      Little    a Bit    Much 
 
17. Have you had diarrhea?               1          2           3          4 
18. Were you tired?                 1          2           3          4 
19. Did pain interfere with your daily activities?          1          2           3          4 
20. Have you had difficulty in concentrating on things, 
      like reading a newspaper or watching television?         1          2           3          4 
21. Did you feel tense?                 1          2           3          4 
22. Did you worry?                 1          2           3          4 
23. Did you feel irritable?               1          2          3          4 
24. Did you feel depressed?               1          2          3          4 
25. Have you had difficulty remembering things?         1          2          3          4 
26. Has your physical condition or medical treatment 
      interfered with your family life?             1          2          3          4 
27. Has your physical condition or medical treatment 
      interfered with your social activities?           1          2          3          4 
28. Has your physical condition or medical treatment 
      caused you financial difficulties?             1          2          3          4 
 
For the following questions please circle the number between 1 and 7 that best applies to you 
 
29. How would you rate your overall health during the past week? 
         1              2              3              4              5              6              7 
Very poor                 Excellent 
 
30. How would you rate your overall quality of life during the past week? 
         1              2              3              4              5              6              7 




© Copyright 1995 EORTC Quality of Life Group. All rights reserved. Version 3.0 
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Appendix 2.2 
WHO/ECOG Performance Status: 
 
Code  Description 
0  Fully active, able to carry on all pre-disease performance without 
restriction 
 
1  Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, eg light 
housework, office work 
 
2  Ambulatory and capable of self care but unable to carry out any 
work activities: up and about more than 50% of waking hours 
 
3  Capable of only limited self care, confined to bed or chair more 
than 50% of waking hours 
 
4  Completely  disabled,  cannot  carry  on  any  self  care,  totally 
confined to bed or chair 
 
9  Unknown (not recorded) 
      
  116 
Appendix 2.3 
Dysphagia Score: 
0 = able to eat normal diet / no dysphagia. 
1 = able to swallow some solid foods 
2 = able to swallow only semi solid foods 
3 = able to swallow liquids only 
4 = unable to swallow anything / total dysphagia      
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Appendix 3.1 
EORTC QLQ-C30 Scoring Sheet 
Physical functioning (PF) = (Q1+Q2+Q3+Q4+Q5)/5 
Linear transformation to convert to a 0 to 100 scale (XPF) =100 - [(PF-1) × 100] 
 
Role functioning (RF) = (Q6+Q7)/2 
Linear transformation to convert to a 0 to 100 scale (XRF) =100 - [(RF-1) ×100/3] 
 
Emotional functioning (EF) = (Q21+Q22+Q23+Q24)/4 
Linear transformation to convert to a 0 to 100 scale (XEF) =100 - [(EF-1) ×100/3] 
 
Cognitive functioning (CF) = (Q20+Q25)/2 
Linear transformation to convert to a 0 to 100 scale (XCF) =100 - [(CF-1) ×100/3] 
 
Social functioning (SF) = (Q26+Q27)/2 
Linear transformation to convert to a 0 to 100 scale (XSF) =100 - [(SF-1) × 100/3] 
 
Quality of Life (QL) = (Q29+Q30)/2 
Linear transformation to convert to a 0 to 100 scale (XQL) = (QL-1) × 100/6 
 
Fatigue (FA) = (Q10+Q12+Q18)/3 
Linear transformation to convert to a 0 to 100 scale (XFA) = (FA-1) × 100/3 
 
Nausea and Vomiting (NV) = (Q14+Q15)/2 
Linear transformation to convert to a 0 to 100 scale (XNV) = (NV-1) × 100/3 
 
Pain (PA) = (Q9+Q19)/2 
Linear transformation to convert to a 0 to 100 scale (XPA) = (PA-1) × 100/3 
 
The remaining questions are single items and are also converted to a 0-100 scale 
 
Dyspnoea (Q8=DY)      Linear transformation (XDY) = (DY-1) × 100/3 
Sleep Disturbance (Q11=SL)  Linear transformation (XSL) = (SL-1) × 100/3 
Appetite loss (Q13=AP)     Linear transformation (XAP) = (AP-1) × 100/3 
Constipation (Q16=CO)     Linear transformation (XCO) = (CO-1) × 100/3 
Diarrhoea (Q17=DI)      Linear transformation (XDI) = (DI-1) × 100/3 
Financial Difficulty (Q28=FI)  Linear transformation (XFI) = (FI-1) × 100/3      
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Appendix 4.1                                                                      Quality of life in gastric and oesophageal cancer patients at baseline 


















disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
1  66.7  0  8.3  50  33.3  0  100  50  66.7  100  66.7  0  66.7  0  66.7  1 
2  93.3  66.7  100  100  100  100  11.1  16.7  0  66.7  0  0  66.7  0  0  1 
3  100  50  91.7  100  83.3  66.7  22.2  0  0  0  100  0  100  0  0  1 
4  100  0  0  100  33.3  25  55.6  33.3  100  0  0  100  0  0  0  1 
5  100  66.7  83.3  100  83.3  83.3  22.2  16.7  0  0  33.3  33.3  33.3  0  33.3  4 
6  100  100  100  83.3  100  83.3  11.1  0  16.7  0  0  0  33.3  0  33.3  1 
7  100  100  41.7  100  100  667  0  0  0  0  33.3  0  0  0  0  2 
8  93.3  100  100  83.3  100  100  0  33.3  16.7  0  0  0  0  0  33.3  3 
9  100  100  91.7  100  100  50  33.3  66.7  50  0  66.7  33.3  100  0  0  1 
10  100  100  91.7  83.3  100  83.3  0  0  0  0  0  0  0  33.3  0  1 
11  93.3  16.7  50  50  33.3  50  55.6  0  33.3  33.3  0  0  0  0  33.3  1 
12  73.3  0  8.3  16.7  0  16.7  77.8  16.7  100  33.3  100  100  100  0  33.3  3 
13  66.7  0  25  33.3  0  16.7  88.9  66.7  66.7  100  100  100  100  33.3  100  1 
14  100  100  75  100  100  50  22.2  16.7  0  33.3  33.3  33.3  0  0  0  1 
15  100  100  100  50  100  100  22.2  0  16.7  66.7  0  0  66.7  0  0  1 
16  100  66.7  0  0  33.3  0  55.6  50  33.3  66.7  33.3  0  33.3  0  100  1 
17  86.7  66.7  66.7  66.7  66.7  33.3  33.3  0  33.3  33.3  66.7  66.7  33.3  33.3  0  1 
18  73.3  33.3  41.7  16.7  66.7  66.7  77.8  16.7  0  100  33.3  0  0  0  33.3  1 
19  86.7  83.3  41.7  66.7  33.3  41.7  44.4  0  0  33.3  100  33.3  *  *  66.7  4 
20  86.7  33.3  66.7  83.3  50  33.3  55.6  66.7  50  0  33.3  66.7  66.7  0  33.3  1 
21  100  83.3  83.3  100  100  50  11.1  50  0  0  33.3  100  0  *  0  4 
22  100  0  91.7  100  0  41.7  22.2  0  50  0  33.3  33.3  33.3  0  0  3 
23  93.3  66.7  100  100  66.7  58.3  22.2  0  0  0  0  33.3  66.7  0  0  3 
24  86.7  50  25  83.3  66.7  41.7  66.7  83.3  66.7  100  100  0  66.7  0  0  1 
25  93.3  0  100  100  33.3  50  44.4  16.7  0  0  33.3  0  33.3  0  0  3 
26  100  83.3  66.7  83.3  66.7  33.3  33.3  0  33.3  0  0  0  33.3  33.3  0  2 
27  73.3  16.7  66.7  66.7  50  50  77.8  66.7  100  33.3  100  33.3  66.7  0  66.7  4 
28  100  100  91.7  100  100  58.3  0  0  33.3  0  33.3  33.3  33.3  0  0  2      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
29  86.7  33.3  91.7  66.7  83.3  58.3  44.4  0  66.7  0  66.7  0  33.3  0  0  1 
30  93.3  33.3  66.7  100  16.7  100  33.3  16.7  0  0  66.7  100  0  33.3  0  4 
31  93.3  66.7  50  66.7  100  50  55.6  50  16.7  66.7  0  100  33.3  100  0  1 
32  100  83.3  50  100  16.7  41.7  11.1  0  16.7  0  0  333  33.3  33.3  0  3 
33  100  33.3  83.3  100  83.3  66.7  0  16.7  16.7  0  66.7  0  33.3  0  0  3 
34  100  0  66.7  66.7  16.7  16.7  77.8  16.7  83.3  33.3  66.7  100  33.3  33.3  33.3  1 
35  66.7  0  91.7  100  0  16.7  100  83.3  16.7  100  100  0  33.3  33.3    4 
36  100  0  83.3  100  100  83.3  11.1  16.7  0  0  66.7  0  0  0  0  4 
37  100  0  75  66.7  0  33.3  22.2  66.7  0  0  0  33.3  0  0  0  4 
38  100  100  100  100  100  100  0  0  0  0  0  0  0  0  0  4 
39  86.7  66.7  66.7  66.7  50  50  55.6  0  33.3  100  33.3  0  33.3  0  0  3 
40  73.3  33.3  41.7  33.3  16.7  16.7  77.8  16.7  16.7  100  100  0  66.7  0  66.7  4 
41  86.7  50  66.7  100  83.3  41.7  55.6  16.7  0  33.3  100  0  66.7  0  0  1 
42  100  0  0  0  0  0  100  100  100  33.3  100  100  33.3  0  0  3 
43  73.3  66.7  8.3  50  83.3  8.33  22.2  100  33.3  0  66.7  66.7  66.7  33.3  66.7  1 
44  66.7  0  41.7  50  0  0  66.7  50  100  100  66.7  66.7  0  0  66.7  3 
45  86.7  16.7  *  100  83.3  83.3  22.2  0  16.7  33.3  0  0  33.3  0  0  1 
46  80  33.3  50  66.7  66.7  66.7  77.8  0  100  33.3  100  66.7  33.3  0  33.3  1 
47  93.3  83.3  25  50  50  33.3  44.4  33.3  33.3  33.3  66.7  66.7  33.3  *  33.3  1 
48  86.7  0  75  66.7  33.3  50  44.4  0  16.7  100  100  100  66.7  0  0  1 
49  100  50  100  100  100  66.7  11.1  0  16.7  0  0  33.3  33.3  0  0  1 
50  86.7  50  100  100  16.5  50  55.6  50  0  33.3  33.3  66.7  33.3  0  *  1 
51  100  100  83.3  83.3  100  83.3  22.2  0  16.7  0  66.7  33.3  0  0  0  2 
52  86.7  100  91.7  83.3  100  91.7  33.3  0  0  0  33.3  33.3  0  0  0  3 
53  93.3  50  33.3  66.7  50  25  66.7  100  66.7  33.3  100  33.3  100  0  33.3  1 
54  100  33.3  100  66.7  83.3  66.7  0  0  16.7  0  0  0  0  33.3  0  1 
55  86.7  16.7  58.3  *  66.7  41.7  66.7  33.3  83.3  0  33.3  0  33.3  0  0  1      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
56  100  100  83.3  100  100  66.7  0  50  0  0  33.3  0  0  0  0  3 
57  93.3  100  25  83.3  100  66.7  55.6  8  0  0  0  33.3  100  0  33.3  1 
58  73.3  16.7  *  *  *  16.7  22.2  33.3  16.7  66.7  0  66.7  *  *  *  1 
59  86.7  100  66.7  83.3  100  50  33.3  0  0  33.3  33.3  0  0  33.3  0  1 
60  80  83.3  33.3  83.3  100  33.3  33.3  16.7  33.3  0  33.3  66.7  33.3  0  0  1 
61  93.3  100  91.7  100  100  83.3  0  0  0  0  0  0  0  33.3  0  1 
62  100  100  100  83.3  100  100  0  0  0  0  0  0  33.3  0  0  1 
63  93.3  33.3  83.3  83.3  66.7  50  55.6  0  16.7  0  100  33.3  33.3  0  0  2 
64  100  0  91.7  100  100  100  11.1  16.7  16.7  *  0  33.3  0  33.3  0  2 
65  80  66.7  33.3  83.3  66.7  66.7  88.9  16.7  50  66.7  0  66.7  66.7  33.3  33.3  1 
66  100  100  58.3  100  100  66.7  22.2  16.7  16.7  0  100  0  0  0  0  3 
67  100  100  75  83.3  100  66.7  0  0  16.7  33.3  33.3  0  33.3  0  0  1 
68  100  100  41.7  83.3  66.7  66.7  33.3  16.7  33.3  33.3  33.3  33.3  33.3  0  0  1 
69  80  66.7  66.7  66.7  100  33.3  44.4  0  33.3  66.7  0  33.3  33.3  0  66.7  1 
70  86.7  16.7  75  100  66.7  33.3  33.3  33.3  0  66.7  100  66.7  33.3  0  0  4 
71  100  100  66.7  66.7  100  41.7  11.1  0  16.7  0  33.3  0  0  0  33.3  3 
72  86.7  66.7  75  83.3  83.3  66.7  33.3  66.7  33.3  33.3  33.3  0  0  33.3  0  3 
73  100  100  83.3  83.3  100  83.3  0  0  16.7  0  0  0  0  0  0  2 
74  86.7  100  91.7  100  100  50  33.3  66.7  50  100  66.7  0  66.6  0  33.3  3 
75  80  66.7  100  66.7  66.7  50  44.4  0  50  0  66.7  33.3  66.7  33.3  33.3  4 
76  100  100  100  100  100  100  0  0  0  0  0  0  33.3  0  0  1 
77  100  100  100  100  66.7  41.7  33.3  0  50  0  66.7  66.7  33.3  0  0  3 
78  100  100  66.7  100  100  66.7  11.1  0  16.7  33.3  0  33.3  0  0  0  3 
79  86.7  100  91.7  100  100  66.7  11.1  0  0  0  0  0  0  0  0  1 
80  86.7  33.3  66.7  100  50  50  66.7  16.7  33.3  33.3  66.7  33.3  33.3  0  0  3 
81  86.7  33.3  58.3  83.3  33.3  25  66.7  16.7  66.7  *  66.7  66.7  66.7  0  0  3 
82  73.3  16.7  91.7  50  33.3  16.7  77.8  66.7  50  66.7  100  100  66.7  33.3  66.7  3 
83  100  0  91.7  100  50  33.3  11.1  16.7  33.3  0  66.7  66.7  66.7  0  0  2      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
84  93.3  66.7  75  83.3  100  83.3  44.4  0  0  33.3  0  66.7  0  0  0  1 
85  100  33.3  58.3  83.3  100  50  55.6  16.7  16.7  100  33.3  66.7  33.3  0  33.3  1 
86  100  100  16.7  50  100  66.7  22.2  0  0  0  0  66.7  33.3  0  33.3  1 
87  100  100  75  83.3  83.3  66.7  33.3  16.7  50  0  0  33.3  33.3  0  33.3  1 
88  100  100  58.3  100  66.7  83.3  0  0  0  0  0  0  0  0  0  2 
89  100  100  66.7  100  100  83.3  44.4  33.3  0  0  0  0  33.3  0  0  1 
90  100  66.7  83.3  100  100  91.7  33.3  16.7  50  0  33.3  0  0  0  0  1 
91  100  0  83.3  100  0  33.3  0  0  16.7  0  0  0  0  0  0  1 
92  86.7  83.3  66.7  100  66.7  50  55.6  33.3  50  0  66.7  66.7  66.7  0  0  2 
93  100  100  83.3  100  100  83.3  0  0  0  0  0  33.3  0  0  0  1 
94  73.3  66.7  58.3  50  33.3  33.3  44.4  0  33.3  33.3  0  66.7  33.3  0  33.3  1 
95  86.7  66.7  58.3  66.7  83.3  50  33.3  0  66.7  33.3  0  33.3  33.3  0  33.3  2 
96  100  100  66.7  83.3  100  75  0  0  0  0  0  0  0  0  0  1 
97  100  100  83.3  100  83.3  83.3  11.1  16.7  16.7  0  0  0  0  0  0  1 
98  100  66.7  91.7  83.3  100  33.3  33.3  16.7  0  33.3  100  0  0  0  0  4 
99  100  100  50  83.3  0  33.3  11.1  0  16.7  0  33.3  66.7  0  0  0  3 
100  100  100  66.7  83.3  100  50  11.1  *  16.7  33.3  0  33.3  0  0  33.3  1 
101  86.7  50  83.3  83.3  66.7  33.3  33.3  0  33.3  33.3  66.7  33.3  0  0  0  3 
102  80  0  41.6  83.3  0  50  83.2  100  16.7  66.7  33.3  33.3  100  0  33.3  1 
103  100  100  91.6  83.3  100  83.3  0  0  0  0  0  0  0  0  0  1 
104  80  50  58.3  83.3  100  0  77.8  50  0  100  100  0  100  0  0  1 
105  100  66.7  33.3  83.3  66.7  33.  22.2  16.7  16.7  0  33.3  0  0  33.3  33.3  4 
106  100  100  66.7  66.7  83.3  66.7  33.3  16.7  0  33.3  33.3  33.3  33.3  33.3  33.3  1 
107  93.3  83.3  66.7  50  66.7  41.7  33.3  50  0  33.3  33.3  0  33.3  0  66.7  1 
108  86.7  0  66.7  33.3  50  0  88.9  50  16.7  100  100  33.3  33.3  100  0  2 
109  66.7  0  66.7  100  0  0  88.9  50  66.7  100  66.7  33.3  33.3  100  100  1 
110  86.7  66.7  91.7  66.7  33.3  33.3  33.3  0  33.3  0  66.7  0  0  0  33.3  3 
111  100  100  100  100  100  66.7  11.1  0  16.7  33.3  33.3  0  0  33.3  0  2      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
112  86.7  33.3  83.3  83.3  83.3  83.3  33.3  33.3  16.7  33.3  33.3  66.7  33.3  0  33.3  2 
113  100  100  100  83.3  100  91.7  0  0  0  0  0  33.3  0  0  33.3  2 
114  100  100  100  100  66.7  91.7  0  0  0  0  0  0  0  0  0  1 
115  80  66.7  75  83.3  83.3  50  55.6  0  0  33.3  66.7  0  33.3  66.7  0  2 
116  93.3  0  83.3  66.7  16.7  41.7  44.4  0  0  33.3  66.7  33.3  100  0  33.3  5 
117  100  100  100  100  100  100  0  0  0  0  0  0  0  0  0  3 
118  100  33.3  58.3  66.7  0  33.3  33.3  16.7  0  0  33.3  33.3  33.3  0  0  1 
119  86.7  66.7  50  83.3  33.3  50  55.6  33.3  50  0  33.3  66.7  66.7  0  33.3  3 
120  80  0  41.7  83.3  33.3  66.7  44.4  0  33.3  33.3  33.3  100  33.3  0  0  2 
121  73.3  100  50  50  16.7  25  44.4  0  0  0  0  66.7  0  0  0  2 
122  80  66.7  75  33.3  66.7  0  66.7  33.3  33.3  33.3  100  0  33.3  0  0  4 
123  100  100  83.3  83.3  100  100  0  0  16.7  0  33.3  33.3  0  0  0  1 
124  73.3  16.7  66.7  83.3  33.3  41.7  55.6  100  16.7  66.7  0  100  0  0  0  3 
125  100  100  100  100  100  91.7  0  0  0  0  0  0  0  0  0  1 
126  73.3  33.3  0  50  66.7  0  77.8  100  66.7  66.7  100  100  100  66.7  33.3  2 
127  100  100  66.7  100  100  83.3  11.1  0  0  0  0  0  0  33.3  0  2 
128  100  100  83.3  100  100  100  0  16.7  16.7  0  33.3  0  0  0  0  1 
129  100  50  75  83.3  83.3  66.7  22.2  16.7  16.7  0  100  0  0  0  0  1 
130  86.7  83.3  8.33  66.7  66.7  50  33.3  33.3  0  33.3  33.3  66.7  0  0  33.3  1 
131  80  83.3  58.3  83.3  50  41.7  11.1  0  0  33.3  0  66.7  33.3  0  33.3  2 
132  93.3  83.3  0  66.7  83.3  66.7  11.1  0  33.3  0  33.3  100  *  0  33.3  2 
133  86.7  83.3  75  83.3  100  83.3  11.1  0  33.3  33.3  33.3  0  33.3  0  0  1 
134  86.7  83.3  91.7  100  83.3  83.3  33.3  0  16.7  0  66.7  100  33.3  0  0  1 
135  80  33.3  0  16.7  33.3  16.7  100  100  100  66.7  100  100  0  0  66.7  3 
136  86.7  100  41.7  83.3  50  16.7  33.3  16.7  0  0  33.3  0  66.7  0  33.3  1 
137  80  0  0  66.7  0  0  88.9  66.7  66.7  100  100  100  100  0  0  3 
138  80  33.3  100  *  *  16.7  22.2  66.7  66.7  0  0  33.3  66.7  0  *  1 
139  73.3  0  16.7  50  16.7  0  88.9  83.3  100  66.7  100  100  66.7  66.7  100  3      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
140  100  66.7  83.3  100  100  66.7  22.2  33.3  16.7  0  33.3  0  33.3  0  0  1 
141  80  66.7  66.7  66.7  83.3  50  22.2  0  16.7  33.3  0  33.3  33.3  0  33.3  1 
142  73.3  33.3  83.3  50  83.3  50  66.7  100  33.3  0  100  66.7  66.7  0  33.3  1 
143  100  66.7  91.7  100  66.7  58.3  22.2  0  0  33.3  0  0  0  0  0  1 
144  100  100  66.7  100  100  83.3  22.2  66.7  16.7  0  0  0  0  0  0  1 
145  100  0  33.3  16.7  0  25  55.6  16.7  50  0  0  100  66.7  0  66.7  2 
146  80  16.7  25  50  16.7  33.3  77.8  33.3  16.7  66.7  100  33.3  0  0  0  1 
147  86.7  66.7  83.3  66.7  100  50  44.4  66.7  16.7  33.3  66.7  66.7  33.3  0  33.3  3 
148  86.7  33.3  100  100  100  100  11.1  33.3  0  33.3  0  33.3  33.3  33.3  0  1 
149  86.7  66.7  100  100  100  50  66.7  0  0  33.3  33.3  66.7  66.7  0  0  1 
150  100  66.7  66.7  83.3  33.3  50  22.2  16.7  33.3  0  33.3  33.3  0  0  0  3 
151  73.3  16.7  33.3  66.7  0  0  66.7  0  0  100  33.3  33.3  0  66.7  0  1 
152  100  50  58.3  100  100  91.7  0  0  0  0  0  0  0  0  0  1 
153  100  100  100  100  83.3  91.7  0  16.7  0  100  33.3  33.3  33.3  66.7  0  4 
154  100  33.3  67  83.3  83.3  66.7  16.7  33.3  16.7  33.3  33.3  *  0  0  0  2 
155  100  100  91.7  100  100  83.3  0  16.7  0  100  0  0  0  0  0  2 
156  80  83.3  91.7  100  100  *  22.2  33.3  16.7  83.1  33.3  0  0  0  0  0 
157  80  0  100  83.3  33.3  33.3  33.3  33.3  50  0  66.7  33.3  66.7  0  33.3  3 
158  100  66.7  66.7  100  100  75  33.3  0  16.7  66.7  0  0  33.3  0  0  1 
159  86.7  83.3  83.3  100  100  66.7  11.1  0  0  33.3  33.3  33.3  66.7  0  66.7  3 








100  0-100  0-100  0-100  0-100  0-100  0-100  0-100 
0-
100  0-100  0-100  0-100  0-100  0-100  0-100  1-5 
* not obtained/ patient deceased      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
1  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
2  86.7  0  50  33.3  83.3  41.7  66.7  0  33.3  100  33.3  66.7  100  0  0  1 
3  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
4  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
5  80  100  83.3  100  33.3  66.7  33.3  0  16.7  0  0  0  33.3  0  33.3  1 
6  86.7  50  50  83.3  100  50  66.7  16.7  66.7  0  100  33.3  0  100  0  1 
7  100  100  66.7  100  100  66.7  11.1  0  16.7  0  0  0  0  0  0  2 
8  73.3  0  100  66.7  50  58.3  77.8  66.7  83.3  100  33.3  33.3  66.7  33.3  0  3 
9  66.7  0  91.7  33.3  0  50  100  0  0  0  66.7  0  66.7  0  0  1 
10  100  33.3  66.7  100  50  50  66.7  16.7  0  33.3  100  0  33.3  0  0  1 
11  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
12  73.3  0  66.6  33.3  33.3  41.6  100  33.3  100  33.3  33.3  100  33.3  0  66.6  3 
13  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
14  93.3  100  91.7  100  100  50  0  0  16.7  33.3  0  33.3  0  0  0  1 
15  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
16  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
17  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
18  93.3  50  75  50  66.7  66.7  33.3  66.7  0  0  33.3  33.3  33.3  0  66.7  1 
19  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
20  86.7  66.7  66.7  33.3  100  83.3  33.3  16.7  16.7  66.7  100  66.7  66.7  0  0  1 
21  100  66.7  100  100  100  75  0  0  0  0  33.3  33.3  0  100  0  1 
22  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
23  80  0  91.7  83.3  66.7  50  55.6  0  50  66.7  33.3  66.7  0  0  0  1 
24  80  33.3  0  0  0  33.3  44.4  100  100  66.7  100  33.3  100  66.7  66.7  1 
25  86.7  50  100  100  66.7  75  22.2  33.3  16.7  0  0  33.3  0  0  33.3  3 
26  93.3  16.7  0  16.7  50  41.7  77.8  16.7  66.7  33.3  66.7  0  66.7  667  *  4 
27  86.7  0  16.7  33.3  0  0  100  66.7  100  66.7  100  100  100  0  33.3  4 
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
28  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
29  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
30  73.3  50  33.3  83.3  50  16.7  22.2  16.7  0  0  66.7  66.7  0  0  0  3 
31  86.7  50  66.7  50  83.3  41.7  77.8  100  50  33.3  100  100  33.3  33.3  33.3  1 
32  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
33  80  83.3  75  100  66.7  58.3  44.4  0  66.7  0  66.7  0  100  0  0  2 
34  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
35  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
36  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
37  80  0  100  100  0  41.7  77.8  33.3  33.3  66.7  33.3  0  33.3  0  0  2 
38  73.3  100  *  *  *  0  11.1  50  0  0  0  0  0  0  0  1 
39  73.3  0  58.3  50  33.3  50  100  66.7  50  100  66.7  33.3  33.3  0  0  1 
40  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  3 
41  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
42  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
43  80  16.7  16.7  33.3  50  16.7  77.8  50  100  0  33.3  66.7  0  33.3  33.3  1 
44  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
45  73.3  33.3  25  66.7  16.7  58.3  66.7  50  66.7  33.3  66.7  100  33.3  66.7  66.7  1 
46  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
47  80  66.7  41.7  66.7  50  25  66.7  33.3  66.7  66.7  66.7  33.3  33.3  0  33.3  2 
48  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
49  100  66.7  100  100  100  66.7  0  33.3  0  33.3  33.3  0  33.3  33.3  0  3 
50  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
51  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
52  73.3  83.3  66.7  66.7  33.3  50  88.9  16.7  0  100  100  100  33.3  0  0  1 
53  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
54  86.7  66.7  91.7  100  66.7  75  22.2  0  33.3  0  0  33.3  0  0  0  2 
55  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
56  86.7  0  16.7  100  16.7  25  77.8  33.3  50  66.7  66.7  100  33.3  0  100  1 
57  86.7  50  41.7  83.3  83.3  50  44.4  16.7  50  0  33.3  66.7  0  66.7  0  1 
58  73.3  33.3  *  *  *  *  100  16.7  66.7  66.7  33.3  33.3  *  *  *  3 
59  80  0  66.7  66.7  100  66.7  77.8  33.3  33.3  100  33.3  33.3  33.3  66.7  0  1 
60  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
61  93.3  100  100  100  100  83.3  11.1  16.7  0  33.3  0  0  0  33.3  0  1 
62  100  100  100  100  83.3  75  0  33.3  16.7  0  33.3  33.3  0  0  0  1 
63  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
64  100  100  91.7  833  100  66.7  22.2  16.7  0  33.3  0  0  0  0  0  1 
65  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
66  86.7  0  66.7  83.3  33.3  50  55.6  33.3  33.3  66.7  33.3  66.7  0  33.3  0  1 
67  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
68  86.7  50  41.7  66.7  66.7  58.3  33.3  16.7  33.3  0  0  0  0  0  0  1 
69  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
70  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
71  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  3 
72  80  33.3  66.7  83.3  83.3  50  77.8  50  83.3  66.7  100  33.3  0  66.7  0  2 
73  93.3  0  66.7  100  50  50  33.3  16.7  0  0  33.3  0  0  0  0  2 
74  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
75  80  16.7  100  66.7  33.3  50  55.6  50  66.7  33.3  0  33.3  33.3  66.7  66.7  1 
76  93.3  *  100  100  100  58.3  33.3  0  0  66.7  0  0  100  0  0  1 
77  80  0  91.7  66.7  0  16.7  88.9  33.3  66.7  100  66.7  33.3  0  33.3  33.3  1 
78  66.7  33.3  25  33.3  16.7  41.7  88.9  16.7  33.3  100  66.7  100  33.3  0  100  3 
79  73.3  0  91.7  100  0  50  55. 6  0  16.7  33.3  66.7  0  33.3  33.3  0  1 
80  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
81  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
82  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
83  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
84  80  50  75  100  100  50  55.6  0  33.3  100  0  33.3  0  0  33.3  1 
85  100  66.7  100  83.3  66.7  83.3  33.3  0  16.7  33.3  0  66.7  0  0  0  1 
86  80  33.3  41.7  66.7  16.7  41.7  44.4  66.7  66.7  33.3  100  33.3  33.3  33.3  66.7  1 
87  86.7  16.7  41.7  50  16.7  33.3  100  33.3  100  100  0  66.7  33.3  33.3  66.7  1 
88  93.3  66.7  100  100  83.3  83.3  33.3  0  0  0  0  0  0  33.3  33.3  2 
89  73.3  0  0  83.3  0  0  100  100  100  0  66.7  100  0  33.3  100  1 
90  86.7  83.3  91. 7  100  66.7  75  44.4  16.7  50  0  33.3  0  33.3  0  0  1 
91  80  0  83.3  100  16.7  41.7  55.6  33.3  50  0  33.3  0  0  33.3  66.7  1 
92  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
93  86.7  66.7  91.7  66.7  83.3  66.7  33.3  0  0  0  0  0  33.3  0  66.7  1 
94  66.7  33.3  66.7  66.7  0  50  55.6  66.7  66.7  66.7  66.7  66.7  33.3  66.7  33.3  1 
95  86.7  33.3  58.3  50  33.3  50  66.7  0  33.3  66.7  33.3  33.3  33.3  66.7  66.7  2 
96  86.7  66.7  66.7  66.7  66.7  66.7  33.3  16.7  33.3  33.3  33.3  33.3  33.3  0  33.3  2 
97  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
98  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
99  86.7  50  75  83.3  33.3  66.7  33.3  0  33.3  0  100  33.3  0  0  0  1 
100  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
101  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
102  86.7  0  33.3  66.7  0  33.3  77.8  83.3  66.7  66.7  0  33.3  0  100  100  1 
103  93.3  100  75  66.7  83.3  75  33.3  0  0  33.3  33.3  0  33.3  0  0  1 
104  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
105  80  0  33.3  33.3  0  16.7  77.8  100  83.3  0  66.7  33.3  0  0  100  1 
106  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
107  73.3  0  41.7  33.3  16.7  8.33  88.9  50  66.7  66.7  100  33.3  0  100  33.3  1 
108  80  33.3  91.7  33.3  83.3  25  77.8  16.7  33.3  100  100  33.3  100  0  0  3 
109  73.3  0  100  100  0  58.3  66.7  0  0  100  0  0  0  0  0  1 
110  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
111  80  33.3  100  100  50  33.3  44.4  16.7  16.7  100  66.7  0  0  33.3  66.7  1 
112  86.7  33.3  100  83.3  50  66.7  55.6  83.3  16.7  33.3  66.7  33.3  33.3  66.7  33.3  1 
113  100  66.7  100  83.3  66.7  66.7  22.2  0  33.3  33.3  33.3  33.3  0  66.7  0  1 
114  80  33.3  66.7  50  50  50  44.4  16.7  33.3  33.3  66.7  33.3  0  0  100  1 
115  73.3  33.3  83.3  83.3  33.3  41.7  66.7  33.3  33.3  33.3  33.3  0  0  100  33.3  1 
116  86.7  100  91.7  50  66.7  33.3  66.7  0  50  33.3  0  33.3  66.7  33.3  0  1 
117  86.7  100  100  100  66.7  91.7  33.3  16.7  33.3  33.3  0  0  0  33.3  0  2 
118  93.3  66.7  66.7  83.3  83.3  58.3  33.3  16.7  0  0  33.3  33.3  33.3  0  0  1 
119  73.3  33.3  33.3  33.3  33.3  50  100  66.7  66.7  33.3  100  100  66.7  33.3  66.7  1 
120  73.3  0  58.3  66.7  0  33.3  66.7  66.7  100  66.7  33.3  100  100  0  100  1 
121  66.7  50  50  50  66.7  25  44.4  0  33.3  33.3  0  66.7  0  0  0  2 
122  73.3  0  0  50  0  0  100  66.7  100  66.7  100  100  33.3  33.3  0  1 
123  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
124  73.3  0  33.3  33.3  16.7  16.7  100  33.3  100  100  0  0  66.7  33.3  33.3  1 
125  93.3  100  75  100  100  66.7  33.3  16.7  16.7  0  0  66.7  0  0  0  1 
126  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
127  53.3  33.3  33.3  50  33.3  33.3  66.7  33.3  0  100  66.7  66.7  0  33.3  66.7  1 
128  100  66.7  83.3  66.7  100  75  44.4  0  66.7  0  66.7  0  0  0  0  1 
129  66.7  0  66.7  50  16.7  41.6  88.9  66.7  33.3  0  66.7  66.7  33.3  33.3  100  1 
130  73.3  66.7  33.3  66.7  66.7  66.7  33.3  0  0  33.3  0  66.7  0  0  0  1 
131  80  16.7  25  50  50  50  44.4  66.7  33.3  33.3  33.3  100  667  0  33.3  1 
132  86.7  83.3  75  83.3  83.3  66.7  33.3  0  0  0  0  0  0  0  0  1 
133  66.7  33.3  66.7  66.7  50  66.7  44.4  16.7  33.3  66.7  33.3  33.3  66.7  33.3  66.7  1 
134  66.7  0  83.3  100  0  33.3  100  50  33.3  100  100  66.7  100  0  100  1 
135  80  66.7  50  33.3  83.3  41.7  77.8  83.3  16.7  66.7  100  100  100  100  0  3 
136  73.3  33.3  25  33.3  66.7  33.3  77.8  0  50  0  0  100  33.3  0  66.7  1 
137  73.3  33.3  8.33  66.7  33.3  33.3  44.4  50  16.7  33.3  100  66.7  33.3  33.3  100  1 
138  73.3  16.7  50  50  33.3  0  88.9  100  83.3  66.7  100  66.7  33.3  0  66.7  3      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
139  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
140  93.3  100  100  83.3  100  100  22.2  0  0  0  0  0  0  33.3  0  1 
141  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
142  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
143  100  100  91.7  100  83.3  66.7  11.1  0  0  0  0  66.7  0  0  0  1 
144  100  83.3  100  83.3  66.7  100  33.3  0  0  0  0  0  0  0  0  1 
145  66.7  0  16.7  16.7  0  16.7  100  83.3  33.3  66.7  66.7  0  33.3  100  100  1 
146  73.3  33.3  66.7  66.7  16.7  33.3  55.6  16.7  0  0  66.7  33.3  66.7  0  66.7  1 
147  73.3  33.3  16.7  0  50  50  55.6  50  0  33.3  100  100  0  0  66.7  1 
148  100  100  75  83.3  100  100  0  0  0  0  0  0  0  33.3  0  1 
149  86.7  100  100  100  100  100  33.3  0  0  0  0  0  0  0  0  1 
150  86.7  66.7  66.7  83.3  16.7  41.7  44.4  50  33.3  0  33.3  33.3  0  33.3  0  1 
151  86.7  50  83.3  100  50  16.7  33.3  0  0  66.7  0  33.3  0  66.7  0  1 
152  66.7  0  16.7  66.7  16.7  25  88.9  100  66. 7  100  66.7  100  0  100  100  1 
153  93.3  83.3  100  100  100  66.7  0  0  33.3  0  0  100  0  0  0  2 
154  93.3  83.3  75  100  100  75  22.2  33.3  16.7  33.3  33.3  0  0  0  0  2 
155  100  100  91.7  100  100  83.3  22.2  0  16.7  0  0  0  33.3  0  0  2 
156  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
157  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  3 
158  100  66.7  75  83.3  83.3  66.7  33.3  33.3  0  33.3  0  0  0  0  0  2 
159  86.7  83.3  91.7  100  0  83.3  22.2  0  16.7  33.3  33.3  0  0  0  0  3 








100  0-100  0-100  0-100  0-100  0-100  0-100  0-100 
0-
100  0-100  0-100  0-100  0-100  0-100  0-100  1-4 
* not obtained/ patient deceased      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
1  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
2  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
3  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
4  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
5  86.7  100  91.7  100  100  83.3  22.2  0  0  0  0  33.3  0  0  0  2 
6  93.3  83.3  100  83.3  83.3  66.7  11.1  0  0  0  0  0  0  66.7  0  1 
7  100  100  75  100  100  91.7  0  0  0  0  0  0  33.3  0  0  1 
8  86.7  33.3  100  100  16.7  66.7  100  100  33.3  33.3  100  100  0  100  0  3 
9  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
10  100  100  100  100  100  66.7  33.3  0  0  0  66.7  0  0  0  0  1 
11  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
12  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  3 
13  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
14  100  100  75  100  100  50  11.1  0  16.7  33.3  0  33.3  33.3  0  0  1 
15  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
16  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
17  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
18  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
19  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
20  80  33.3  100  83.3  50  25  66.7  0  50  100  33.3  33.3  33.3  0  66.7  1 
21  66.7  0  41.7  33.3  0  0  100  33.3  100  100  100  33.3  100  0  33.3  1 
22  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
23  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
24  80  33.3  33.3  66.7  66.7  50  88.9  16.7  33.3  66.7  33.3  66.7  0  33.3  66.7  1 
25  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
26  86.7  50  55.5  100  16.7  50  33.3  0  33.3  0  33.3  0  100  0  0  2 
27  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
28  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  4      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
29  86.7  33.3  75  50  66.7  33.3  66.7  0  66.7  0  100  33.3  66.7  0  0  2 
30  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
31  80  16.7  33.3  66.7  50  41.7  88.9  100  66.7  66.7  33.3  66.7  33.3  0  0  1 
32  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
33  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
34  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
35  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
36  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
37  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
38  80  33.3  100  100  66.7  91.7  55.6  16.7  0  33.3  33.3  66.7  0  0  0  1 
39  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
40  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  3 
41  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
42  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
43  73.3  0  25  16.7  33.3  25  77.8  33.3  83.3  100  33.3  66.7  33.3  0  66.7  1 
44  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
45  80  33.3  41.7  50  33.3  33.3  55.6  33.3  50  66.7  33.3  66.7  33.3  33.3  100  1 
46  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
47  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
48  73.3  16.7  83.3  66.7  0  58.3  55.6  0  50  66.7  100  66.7  0  0  0  1 
49  100  83.3  91.7  100  83.3  66.7  0  0  0  0  33.3  33.3  0  33.3  0  3 
50  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
51  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
52  73.3  0  66.7  50  83.3  50  77.8  0  0  66.7  100  0  33.3  33.3  0  1 
53  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
54  86.7  66.7  *  *  *  0  0  0  16.7  0  0  0  0  0  *  1 
55  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
56  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
57  93.3  66.7  25  66.7  66.7  50  22.2  0  50  0  33.3  66.7  0  66.7  33.3  1 
58  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
59  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
60  73.3  33.3  75  83.3  83.3  66.7  44.4  0  33.3  33.3  0  33.3  0  33.3  0  1 
61  100  83.3  100  100  100  83.3  11.1  0  16.7  0  0  0  0  0  0  1 
62  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
63  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
64  100  100  91.7  100  100  66.7  11.1  16.7  0  0  0  33.3  0  33.3  0  1 
65  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
66  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
67  66.7  0  41.7  83.3  0  0  100  83.3  100  100  100  100  100  100  66.7  1 
68  80  0  16.7  33.3  16.7  25  100  50  100  0  66.7  100  0  100  33.3  1 
69  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
70  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
71  73.3  0  66.7  66.7  66.7  91.7  11.1  33.3  33.3  33.3  100  33.3  0  33.3  0  1 
72  73.3  33.3  66.7  66.7  50  8.3  88.9  16.7  83.3  66.7  100  66.7  33.3  33.3  0  1 
73  93.3  33.3  91.7  100  66.7  50  33.3  16.7  0  0  33.3  33.3  0  33.3  0  2 
74  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
75  80  33.33  100  83.3  66.7  33.3  33.3  0  33.3  0  0  33.3  0  66.7  33.3  2 
76  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
77  93.3  16.7  83.3  83.3  0  33.3  88.9  66.7  33.3  66.7  100  33.3  0  33.3  0  1 
78  66.7  16.7  66.7  50  50  50  100  33.3  66.7  66.7  100  100  100  0  33.3  3 
79  86.7  16.7  91.7  66.7  33.3  33.3  33.3  0  0  66.7  66.7  0  33.3  66.7  33.3  1 
80  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
81  86.7  16.7  83.3  100  33.3  50  88.9  0  66.7  33.3  33.3  33.3  0  100  33.3  1 
82  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
83  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
84  73.3  50  50  100  100  58.3  44.4  16.7  66.7  66.7  100  66.7  0  0  33.3  1      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
85  100  100  66.7  83.3  100  58.3  33.3  16.7  50  0  0  33.3  0  0  0  1 
86  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
87  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
88  93.3  66.7  100  100  66.7  83.3  33.3  16.7  50  0  0  0  33.3  33.3  33.3  1 
89  86.7  33.3  91.7  66.7  50  66.7  88.9  83.3  83.3  0  66.7  100  0  0  66.7  1 
90  100  83.3  91.7  100  100  66.7  44.4  16.7  16.7  0  0  0  33.3  33.3  0  1 
91  80  66.7  75  100  50  58.3  55.6  0  33.3  0  0  0  0  33.3  66.7  1 
92  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
93  100  100  91.7  100  100  83.3  11.1  33.3  33.3  0  0  0  0  0  0  1 
94  66.7  0  0  16.7  0  0  100  66.7  100  66.7  100  100  0  33.3  66.7  1 
95  86.7  66.7  66.7  66.7  50  66.7  33.3  33.3  50  33.3  33.3  0  33.3  33.3  66.7  2 
96  93.3  66.7  66.7  66.7  66.7  66.7  33.3  33.3  0  33.3  33.3  33.3  0  33.3  33.3  2 
97  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
98  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
99  93.3  50  41.7  100  50  58.3  33.3  0  16.7  0  66.7  0  0  0  0  1 
100  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
101  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
102  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
103  100  100  91.7  83.3  100  83.3  22.2  0  0  0  0  0  0  0  0  1 
104  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
105  86.7  83.3  50  50  50  25  55.6  33.3  0  33.3  33.3  33.3  0  0  100  1 
106  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
107  73.3  0  33.3  33.3  0  16.7  88.9  66.7  66.7  66.7  100  66.7  0  66.7  0  2 
108  80  16.7  91.7  50  66.7  33.3  77.8  16.7  50  100  100  0  33.3  0  33.3  1 
109  73.3  16.7  75  100  0  50  66.7  16. 7  33.3  100  0  33.3  0  0  0  1 
110  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
111  86.7  66.7  91.7  100  83.3  66.7  11.1  50  33.3  33.3  0  33.3  0  33.3  0  1 
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
112  66.7  50  33.3  33.3  33.3  33.3  55.6  66. 7  33.3  33.3  66. 7  66.7  33.3  33.3  33.3  2 
113  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
114  93.3  66.7  66.7  83.3  83.3  58.3  33.3  16.7  16.7  33.3  0  33.3  0  0  0  1 
115  80  33.3  91.7  83.3  66.7  50  66.7  66.7  16.7  0  100  33.3  33.3  33.3  0  1 
116  86.7  66.7  100  100  83.3  66.7  33.3  0  0  33.3  0  33.3  0  0  0  1 
117  100  100  91.7  100  100  91.7  22.2    16.7  0  0  0  0  66.7  0  1 
118  86.7  66.7  83.3  83.3  66.7  75  33.3  0  0  0  0  33.3  33.3  0  0  1 
119  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
120  73.3  0  58.3  66.7  50  50  66.7  66.7  100  66.7  66.7  100  66.7  33.3  100  1 
121  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
122  73.3  0  0  0  0  41.7  100  100  0  66.7  100  66.7  33.3  0  0  * 
123  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
124  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
125  100  83.3  75  100  100  58.3  33.3  50  83.3  0  100  33.3  0  0  33.3  1 
126  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
127  100  33.3  83.3  83.3  33.3  50  44.4  33.3  50  0  33.3  33.3  0  66.7  66.7  1 
128  100  100  100  100  100  91.7  22.2  0  0  0  33.3  0  0  0  0  1 
129  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
130  73.3  0  0  16.67  0  0  100  66.7  100  66.7  100  0  0  0  33.3  1 
131  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
132  86.7  50  66.7  66.7  66.7  75  33.3  0  33.3  0  0  33.3  33.3  0  0  1 
133  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
134  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
135  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  3 
136  80  33.3  33.3  50  66.7  41.7  55.6  0  33.3  0  0  66.7  0  0  33.3  1 
137  80  0  0  33.3  16.7  0  77.8  33.3  33.3  100  33.3  66.7  0  33.3  100  1 
138  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
139  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
140  100  100  100  100  100  100  0  0  0  0  0  0  0  0  0  1 
141  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
142  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *   
143  86.7  66.7  100  100  50  66.7  33.3  0  0  0  66.7  33.3  66.7  0  0  1 
144  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
145  80  16.7  66.7  33.3  0  33.3  88.9  50  33.3  66.7  33.3  33.3  33.3  66.7  100  1 
146  66.7  0  33.3  16.7  0  0  100  66.7  66.7  66.7  100  33.3  0  66.7  66.7  1 
147  80  33.3  25  16.7  50  66.7  55.6  33.3  33.3  33.3  100  33.3  0  33.3  66.7  1 
148  93.3  50  66.7  66.7  66.7  33.3  44.4  33.3  33.3  33.3  0  33.3  0  33.3  33.3  1 
149  93.3  100  83.3  83.3  100  100  11.1  0  0  0  0  0  0  0  0  1 
150  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
151  86.7  66.7  75  83.3  33.3  50  33.3  0  0  33.3  0  33.3  0  33.3  0  1 
152  86.7  0  0  0  33.3  16.7  100  66.7  66.7  100  33.3  100  33.3  100  100  2 
153  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
154  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
155  100  100  83.3  100  100  75  22.2  0  33.3  0    *  33.3  0  0  1 
156  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
157  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
158  86.7  66.7  83.3  100  100  66.7  33.3  16.7  0  33.3  *  *  33.3  0  0  2 
159  66.7  0  33.3  16.7  0  16.7  88.9  33.3  100  66.7  *  *  0  0  66.7  * 








100  0-100  0-100  0-100  0-100  0-100  0-100  0-100 
0-
100  0-100  0-100  0-100  0-100  0-100  0-100  1-4 
* not obtained/ patient deceased      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
1  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
2  100  66.7  100  83.3  91.7  91.7  11.1  0  0  33.3  0  0  0  0  0  1 
3  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
4  86.7  66.7  50  33.3  33.3  33.3  44.4  16.7  66.7  100  66.7  33.3  33.3  0  0  1 
5  66.7  0  0  33.3  0  0  100  66.7  100  66.7  100  100  100  *  100  1 
6  86.7  83.3  83.3  83.3  66.7  66.7  22.2  0  16.7  0  0  0  0  66.7  0  2 
7  100  100  75  100  91.7  91.7  0  0  0  0  0  0  33.3  0  0  1 
8  80  33.3  75  83.3  58.3  58.3  55.6  33.3  66.7  33.3  33.3  33.3  66.7  33.3  0  1 
9  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
10  100  83.3  100  100  75  75  33.3  0  0  0  33.3  0  33.3  0  0  1 
11  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
12  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
13  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
14  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
15  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
16  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
17  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
18  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
19  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
20  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
21  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
22  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
23  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
24  86.7  33.3  41.7  66.7  33.3  33.3  66.7  33.3  66.7  66.7  33.3  66.7  33.3  33.3  33.3  1 
25  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
26  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
27  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
28  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
29  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
30  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
31  86.7  66.7  41.7  50  58.3  58.3  44.4  50  33.3  66.7  66.7  100  66.7  0  0  1 
32  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
33  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
34  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
35  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
36  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
37  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
38  73.3  50  91.7  100  91.7  91.7  44.4  0  0  66.7  0  0  0  0  0  1 
39  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
40  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
41  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
42  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
43  73.3  0  8.33  0  8.33  8.33  100  83.3  100  100  100  100  33.3  0  66.7  1 
44  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
45  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
46  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
47  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
48  66.7  0  91.7  16.7  41.7  41.7  100  0  100  33.3  100  0  0  0  0  2 
49  80  16.7  83.3  100  58.3  58.3  33.3  0  33.3  0  0  100  0  0  0  3 
50  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
51  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
52  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
53  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
54  100  66.7  100  83.3  66.7  66.7  0  0  0  0  0  0  0  0  0  1 
55  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
56  100  83.3  91.7  100  50  50  22.2  16.7  16. 7  33.3  33.3  0  0  0  66.7  1 
57  80  50  25  50  50  50  33.3  0  33.3  0  0  100  0  33.3  0  1 
58  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
59  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
60  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
61  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
62  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
63  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
64  100  100  100  83.3  75  75  0  16.7  0  0  0  0  0  33.3  0  1 
65  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
66  66.7  66.7  58.3  66.7  50  50  55.6  33.3  50  66.7  33.3  33.3  100  33.3  33.3  1 
67  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
68  86.7  66.7  50  50  66.7  66.7  33.3  16.7  33.3  0  0  33.3  0  0  33.3  1 
69  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
70  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
71  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
72  73.3  0  50  100  58.3  58.3  100  100  33.3  100  33.3  100  0  33.3  0  1 
73  93.3  66.7  100  100  83.3  83.3  33.3  0  0  0  0  33.3  0  0  0  1 
74  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
75  73.3  33.3  91.7  66.7  66.7  66.7  33.3  0  66.7  33.3  0  0  0  33.3  33.3  1 
76  100  100  100  100  100  100  0  0  0  0  0  0  0  0  0  1 
77  73.3  16.7  75  33.3  33.3  33.3  88.9  66.7  100  33.3  33.3  100  0  0  33.3  1 
78  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
79  86.7  83.3  100  100  66.7  66.7  33.3  0  0  33.3  33.3  0  0  0  0  2 
80  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
81  86.7  33.3  100  100  50  50  44.4  0  50  0  33.3  33.3  0  66.7  0  1 
82  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
83  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
84  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *   
85  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
86  93.3  50  33.3  66.7  50  50  77.8  33.3  0  66.7  100  0  0  66.7  33.3  1 
87  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
88  100  100  91.7  100  91.7  91.7  22.2  16.7  16.7  0  0  0  0  33.3  0  1 
89  80  0  8.33  83.3  0  0  77.8  100  100  33.3  66.7  66.7  0  33.3  66.7  1 
90  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
91  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
92  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  2 
93  100  100  100  100  66.7  66.7  22.2  0  16.7  0  0  0  0  0  33.3  1 
94  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
95  86.7  33.3  83.3  66.7  66.7  66.7  11.1  33.3  33.3  33.3  66.7  33.3  33.3  66.7  33.3  1 
96  100  100  100  100  66.7  66.7  0  0  0  0  33.3  33.3  0  0  0  1 
97  93.3  83.3  100  66.7  83.3  83.3  33.3  0  16.7  33.3  0  0  0  33.3  0  1 
98  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
99  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
100  86.7  66.7  75  66.7  50  50  33.3  33.3  50  66.7  33.3  66.7  0  0  0  1 
101  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
102  80  33.3  0  33.3  25  25  55.6  50  50  66.7  33.3  66.7  0  66.7  33.3  1 
103  100  100  100  83.3  83.3  83.3  22.2  0  0  0  0  0  0  0  0  1 
104  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
105  93.3  33.3  58.3  66.7  33.3  33.3  22.2  0  0  66.7  0  0  0  0  100  1 
106  86.7  83.3  100  50  50  50  11.1  33.3  0  33.3  0  33.3  0  0  33.3  1 
107  80  33.3  75  50  33.3  33.3  66.7  16.7  33.3  33.3  66.7  66.7  0  66.7  0  1 
108  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
109  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
110  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
111  93.3  66.7  91.7  100  58.3  58.3  11.1  0  50  33.3  0  33.3  0  33.3  0  1 
112  80  33.3  25  16.7  16.7  16.7  88.9  83.3  66.7  33.3  100  66.7  0  0  66.7  1 
113  100  100  100  83.3  100  100  0  16.7  16.7  0  33.3  0  0  33.3  0  1 
114  100  100  58.3  100  83.3  83.3  33.3  0  16.7  33.3  0  33.3  0  0  33.3  1 
115  73.3  50  58.3  83.3  25  25  55.6  50  33.3  33.3  66.7  100  0  0  0  1 
116  86.7  66.7  83.3  100  66.7  66.7  22.2  0  0  33.3  0  0  0  0  0  1 
117  93.3  66.7  100  100  100  100  22.2  33.3  33.3  33.3  0  33.3  0  0  0  1 
118  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
119  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
120  86.7  50  83.3  83.3  75  75  33.3  33.3  66.7  33.3  0  100  0  0  33.3  1 
121  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
122  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
123  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
124  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
125  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
126  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
127  86.7  66.7  83.3  100  66.7  66.7  33.3  16.7  16.7  66.7  0  0  0  33.3  66.7  1 
128  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
129  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
130  86.7  33.3  16.7  66.7  50  50  66.7  33.3  0  66.7  66.7  100  0  33.3  0  1 
131  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
132  66.7  0  25  33.3  0  0  100  83.3  100  66.7  100  33.3  100  0  0  1 
133  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
134  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
135  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
136  80  33.3  33.3  66.7  50  50  66.7  0  66.7  0  66.7  66.7  0  0  0  1 
137  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
138  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
139  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
140  93.3  100  8.33  50  50  50  11.1  0  50  0  0  0  33.3  0  0  1 
141  86.7  50  50  66.7  66.7  66.7  44.4  0  33.3  66.7  0  100  0  0  0  1 
142  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
143  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
144  100  100  100  83.3  83.3  83.3  33.3  16.7  0  0  33.3  0  33.3  0  0  1 
145  86.7  66.7  16.7  50  25  25  100  33.3  50  33.3  66.7  66.7  0  66.7  100  1 
146  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
147  66.7  0  0  33.3  16.7  16.7  100  66.7  33.3  33.3  100  33.3  0  33.3  33.3  1 
148  93.3  100  50  100  50  50  33.3  0  0  0  33.3  66.7  0  0  0  1 
149  93.3  100  91.7  83.3  83.3  83.3  22.2  0  0  0  0  0  0  0  0  1 
150  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
151  86.7  66.7  83.3  83.3  50  50  22.2  0  0  33.3  0  33.3  0  33.3  0  1 
152  86.7  0  25  33.3  50  50  77.8  66.7  16.7  100  33.3  66.7  0  33.3  100  2 
153  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
154  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
155  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
156  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
157  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
158  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
159  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 








100  0-100  0-100  0-100  0-100  0-100  0-100  0-100 
0-
100  0-100  0-100  0-100  0-100  0-66.7  0-100  1-3 
* not obtained/ patient deceased      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
1  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
2  100  83.3  100  83.3  100  75  0  0  0  33.3  0  0  0  0  0  1 
3  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
4  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
5  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
6  86.7  83.3  83.3  83.3  50  50  33.3  0  0  0  33.3  33.3  33.3  66.7  0  1 
7  100  100  66.7  100  100  83.3  0  0  0  0  0  0  0  0  33.3  1 
8  86.7  16.7  25  33.3  33.3  33.3  100  100  66.7  100  33.3  66.7  0  0  0  1 
9  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
10  73.3  0  100  100  66.7  0  100  33.3  0  100  100  0  33.3  66.7  0  1 
11  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
12  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
13  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
14  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
15  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
16  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
17  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
18  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
19  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
20  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
21  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
22  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
23  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
24  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
25  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
26  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
27  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
28  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
29  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
30  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
31  80  50  50  50  33  33.3  77.8  100  50  100  33.3  100  0  100  0  1 
32  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
33  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
34  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
35  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
36  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
37  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
38  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
39  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
40  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
41  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
42  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
43  80  83.3  41.7  100  66.7  25  33.3  0  50  33.3  0  66.7  0  0  33.3  1 
44  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
45  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
46  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
47  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
48  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
49  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
50  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
51  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
52  93.3  66.7  100  83.3  66.7  75  33.3  0  50  0  33.3  33.3  0  0  0  1 
53  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
54  93.3  66.7  100  83.3  66.7  75  33.3  0  50  0  33.3  33.3  0  0  0  1 
55  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
56  86.7  33.3  75  83.3  33.3  41.7  55.6  16.7  50  66.7  100  33.3  33.3  0  66.7  1      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
57  93.3  66.7  41.7  66.7  66.7  66.7  44.4  0  33.3  0  66.7  33.3  0  0  33.3  1 
58  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
59  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
60  66.7  50  75  83.3  66.7  33.3  33.3  0  16.7  33.3  33.3  33.3  0  33.3  0  1 
61  100  100  100  100  100  100  0  0  0  0  0  33.3  0  0  0  1 
62  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
63  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
64  93.3  100  100  100  100  75  22.2  33.3  0  0  0  66.7  33.3  33.3  0  1 
65  73.3  0  91.7  100  0  50  88.9  16.7  100  100  33.3  66.7  100  0  66.7  1 
66  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
67  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
68  80  50  41.7  66.7  50  58.3  33.3  16.7  50  0  0  66.7  0  0  33.3  1 
69  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
70  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
71  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
72  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
73  93.3  66.7  100  100  66.7  83.3  33.3  0  0  0  0  33.3  0  0  0  1 
74  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
75  80  33.3  91.7  66.7  33.3  50  55.6  16.7  50  0  0  33.3  33.3  66.7  33.3  1 
76  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
77  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
78  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
79  80  66.7  100  100  33.3  50  33.3  0  0  33.3  0  0  0  33.3  0  1 
80  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
81  80  16.7  83.3  100  16.7  33.3  77.8  33.3  83.3  66.7  33.3  66.7  0  66.7  0  1 
82  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
83  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
84  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
85  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
86  80  33.3  8.33  50  0  66.7  77.8  33.3  50  33.3  100  0  33.3  100  100  1 
87  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
88  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
89  80  66.7  33.3  33.3  0  33.3  77.8  50  83.3  0  33.3  100  33.3  0  100  1 
90  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
91  100  83.3  83.3  100  66.7  75  33.3  0  16.7  33.3  0  0  0  0  33.3  1 
92  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
93  100  100  100  100  100  83.3  33.3  0  0  0  0  33.3  0  0  0  1 
94  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
95  86.7  100  100  83.3  83.3  83.3  33.3  16.7  33.3  33.3  33.3  0  33.3  33.3  0  1 
96  100  100  100  100  100  83.3  0  0  0  0  0  0  0  0  0  1 
97  100  100  100  83.3  100  83.3  11.1  0  16.7  0  0  0  0  33.3  0  1 
98  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
99  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
100  86.7  50  91.7  83.3  50  50  44.4  33.3  33.3  33.3  33.3  66.7  33.3  0  33.3  1 
101  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
102  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
103  100  100  100  83.3  100  100  0  0  0  0  0  0  0  0  0  1 
104  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
105  86.7  66.7  83.3  100  66.7  33.3  33.3  0  0  66.7  0  0  0  0  66.7  1 
106  93.3  100  100  50  66.7  66.7  33.3  33.3  0  0  33.3  33.3  0  33.3  33.3  1 
107  73.3  33.3  41.7  16.7  0  16.7  100  16.7  83.3  66.7  66.7  100  0  66.7  0  1 
108  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
109  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
110  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
111  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
      
  148 
Appendix 4.5 continued                                           Quality of life in gastric and oesophageal cancer patients at 2 years 


















disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
112  80  50  33.3  50  100  41.7  66.7  66.7  50  66.7  66.7  33.3  33.3  33.3  33.3  1 
113  100  100  100  100  100  83.3  0  0  0  0  0  0  0  0  0  1 
114  100  50  66.7  66.7  66.7  75  33.3  0  33.3  33.3  0  0  0  0  66.7  1 
115  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
116  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
117  100  100  83.3  100  100  100  11.1  0  33.3  66.7  0  0  0  66.7  0  1 
118  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
119  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
120  86.7  50  75  100  66.7  66.7  33.3  16.7  33.3  33.3  0  100  100  0  66.7  1 
121  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
122  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
123  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
124  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
125  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
126  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
127  100  66.7  91.7  83.3  100  66.7  44.4  0  16.7  33.3  0  33.3  0  33.3  33.3  1 
128  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
129  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
130  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
131  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
132  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
133  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
134  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
135  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
136  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
137  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
138  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
139  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
140  100  83.3  100  83.3  100  83.3  0  0  16.7  0  0  0  0  0  0  1 
141  80  33.3  33.3  33.3  50  58.3  77.8  0  50  100  33.3  100  33.3  33.3  0  1 
142  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
143  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
144  100  100  75  83.3  83.3  66.7  0  16.7  0  0  33.3  0  33.3  0  0  1 
145  60  16.7  33.3  33.3  0  16.7  77.8  33.3  50  66.7  66.7  66.7  0  66.7  100  1 
146  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
147  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
148  100  100  66.7  83.3  100  66.7  11.1  0  0  33.3  0  0  0  0  0  1 
149  93.3  83.3  83.3  66.7  100  83.3  11.1  0  0  0  0  0  0  0  0  1 
150  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
151  86.7  66.7  83.3  83.3  66.7  50  22.2  0  0  33.3  0  33.3  0  33.3  33.3  1 
152  86.7  16.7  0  33.3  16.7  50  66.7  66.7  66.7  66.7  33.3  100  66.7  33.3  100  1 
153  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
154  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
155  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
156  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
157  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
158  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
159  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 










100  0-100 
16.7 
-100  0-100  0-100  0-100  0-100 
0-
100  0-100  0-100  0-100  0-100  0-100  0-100  1 
* not obtained/ patient deceased      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
1  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
2  86.7  83.3  83.3  83.3  66.7  58.3  33.3  0  33.3  66.7  0  33.3  0  0  33.3  1 
3  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
4  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
5  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
6  86.7  50  66.7  83.3  33.3  50  44.4  0  33.3  0  33.3  33.3  0  33.3  0  1 
7  100  100  66.7  100  100  83.3  11.1  0  16.7  33.3  0  0  33.3  0  0  1 
8  73.3  0  0  0  0  33.3  77.8  50  100  66.7  33.3  100  33.3  33.3  66.7  1 
9  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
10  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
11  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
12  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
13  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
14  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
15  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
16  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
17  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
18  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
19  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
20  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
21  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
22  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
23  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
24  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
25  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
26  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
27  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
28  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
29  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
30  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
31  86.7  50  33.3  50  83.3  25  55.6  33.3  66.7  100  66.7  33.3  0  100  0  1 
32  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
33  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
34  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
35  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
36  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
37  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
38  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
39  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
40  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
41  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
42  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
43  80  0  25  167  50  0  77.8  100  83.3  66.7  100  66.7  0  0  33.3  1 
44  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
45  73.3  16.7  33.3  66.7  33.3  50  66.7  50  50  33.3  33.3  66.7  0  33.3  66.7  1 
46  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
47  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
48  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
49  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
50  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
51  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
52  100  83.3  100  100  100  100  0  0  16.7  0  0  0  0  0  0  1 
53  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
54  100  83.3  100  100  100  100  0  0  16.7  0  0  0  0  0  0  1 
55  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
56  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
57  86.7  50  8.3  66.7  66.7  50  66.7  0  50  100  33.3  66.7  0  66.7  33.3  1 
58  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
59  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
60  66.7  0  83.3  100  100  33.3  55.6  33.3  50  66.7  33.3  33.3  0  33.3  0  3 
61  100  100  100  100  100  83.3  0  0  0  0  0  0  0  0  0  1 
62  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
63  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
64  93.3  100  100  83.3  100  75  33.3  16.7  0  0  0  33.3  0  33.3  0  1 
65  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
66  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
67  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
68  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
69  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
70  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
71  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
72  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
73  93.3  83.3  100  100  83.3  83.3  33.3  0  0  0  0  33.3  0  0  0  1 
74  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
75  80  33.3  100  83.3  33.3  58.3  44.4  0  33.3  0  0  0  33.3  33.3  66.7  1 
76  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
77  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
78  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
79  80  50  100  100  50  50  44.4  0  0  0  33.3  0  0  33.3  0  1 
80  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *   
81  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *   
82  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *   
83  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
84  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
85  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
86  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
87  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
88  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
89  80  8.33  8.33  66.7  16.7  16.7  55.6  66.7  50  0  66.7  100  33.3  33.3  66.7  1 
90  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
91  100  100  91.7  100  66.7  83.3  11.1  0  16.7  0  0  0  0  0  66.7  1 
92  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
93  100  100  100  83.3  100  83.3  33.3  0  0  0  0  0  33.3  0  0  1 
94  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
95  80  66.7  66.7  66.7  33.3  58.3  44.4  33.3  50  66.7  66.7  33.3  0  66.7  33.3  1 
96  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
97  86.7  83.3  100  83.3  100  66.7  22.2  0  33.3  0  33.3  0  0  33.3  0  1 
98  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
99  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
100  86.7  33.3  91.7  83.3  100  83.3  22.2  33.3  33.3  33.3  33.3  33.3  0  0  33.3  1 
101  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
102  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
103  100  100  100  83.3  100  100  0  0  0  0  0  0  0  0  0  1 
104  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
105  93.3  66.7  66.7  100  66.7  50  33.3  0  0  66.7  33.3  33..3  0  33.3  66.7  1 
106  86.7  66.7  100  50  66.7  66.7  11.1  0  0  0  0  33.3  0  0  33.3  1 
107  73.3  33.3  50  33.3  33.3  16.7  77.8  50  33.3  66.7  100  66.7  0  33.3  33.3  1 
108  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
109  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
110  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
111  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
112  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
113  100  100  100  100  100  83.3  0  16.7  0  0  0  0  0  33.3  0  1 
114  100  66.7  83.3  83.3  100  33.3  33.3  16.7  0  33.3  0  0  0  0  33.3  1 
115  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
116  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
117  100  100  83.3  100  100  83.3  11.1  0  0  33.3  0  0  0  33.3  0  1 
118  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
119  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
120  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
121  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
122  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
123  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
124  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
125  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
126  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
127  100  66.7  75  100  83.3  66.7  33.3  0  33.3  0  0  66.7  0  0  66.7  1 
128  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
129  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
130  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
131  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
132  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
133  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
134  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
135  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
136  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
137  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
138  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
139  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
140  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
141  86.7  33.3  41.7  66.7  66.7  50  44.4  16.7  33.3  66.7  0  33.3  100  0  33.3  1 
142  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
143  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
144  100  66.7  100  83.3  100  83.3  33.3  33.3  16.7  0  33.3  33.3  66.7  0  0  1 
145  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  1 
146  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
147  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
148  100  100  100  83.3  100  100  22.2  16.7  0  33.3  0  33.3  0  0  0  1 
149  93.3  100  100  100  100  100  0  0  0  0  0  0  0  0  0  1 
150  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
151  80  50  66.7  83.3  66.7  50  44.4  16.7  16.7  66.7  33.3  33.3  33.3  33.3  33.3  1 
152  86.7  16.7  16.7  16.7  66.7  50  66.7  66.7  33.3  100  0  100  33.3  0  100  1 
153  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
154  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
155  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
156  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
157  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
158  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
159  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 








100  0-100  0-100  0-100  0-100  0-100  0-100  0-100 
0-
100  0-100  0-100  0-100  0-100  0-100  0-100  1-3 
* not obtained/ patient deceased 
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
1  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
2  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
3  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
4  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
5  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
6  86.7  50  75  83.3  33.3  50  33.3  0  66.7  0  0  33.3  0  66.7  0  1 
7  100  100  66.7  100  83.3  83.3  11.1  0  0  0  0  0  33.3  0  0  1 
8  73.3  0  8.3  0  0  33.3  88.9  16.7  33.3  66.7  66.7  100  100  0  33.3  1 
9  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
10  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
11  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
12  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
13  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
14  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
15  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
16  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
17  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
18  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
19  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
20  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
21  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
22  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
23  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
24  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
25  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
26  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
27  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
28  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
29  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
30  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
31  80  16.7  25  66.7  83.3  50  66.7  33.3  66.7  33.3  33.3  66.7  0  66.7  0  1 
32  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
33  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
34  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
35  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
36  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
37  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
38  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
39  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
40  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
41  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
42  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
43  80  16.7  16.7  33.3  50  25  100  83.3  100  66.7  66.7  100  33.3  0  33.3  1 
44  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
45  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
46  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
47  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
48  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
49  73.3  0  91.7  100  0  66.7  22.2  0  83.3  0  0  33.3  0  0  0  1 
50  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
51  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
52  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
53  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
54  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
55  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
56  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
57  86.7  66.7  50  66.7  50  33.3  33.3  16.7  50  0  0  100  0  66.7  33.3  1 
58  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
59  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
60  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
61  100  100  83.3  100  100  83.3  11.1  16.7  16.7  0  0  0  0  0  0  1 
62  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
63  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
64  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
65  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
66  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
67  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
68  86.7  50  66.7  83.3  50  75  11.1  0  16.7  33.3  0  66.7  0  0  0  1 
69  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
70  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
71  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
72  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
73  93.3  83.3  100  100  100  83.3  33.3  0  0  0  0  0  0  0  0  1 
74  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
75  80  16.7  66.7  50  50  50  66.7  50  33.3  33.3  66.7  66.7  33.3  33.3  33.3  1 
76  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
77  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
78  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
79  80  50  100  100  66.7  50  33.3  0  16.7  33.3  0  0  0  0  0  1 
80  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
81  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
82  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
83  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
84  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
  159 
Appendix 4.7 continued                                            Quality of life in gastric and oesophageal cancer patients at 4 years 


















disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
85  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
86  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
87  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
88  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
89  86.7  33.3  25  66.7  16.7  8.33  77.8  50  66.7  0  100  100  33.3  0  100  1 
90  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
91  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
92  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
93  100  100  100  100  100  83.3  33.3  0  0  0  0  0  0  33.3  0  1 
94  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
95  86.7  66.7  66.7  66.7  66.7  58.3  66.7  50  33.3  100  33.3  66.7  33.3  33.3  33.3  1 
96  100  100  100  100  100  100  0  0  0  0  0  0  0  0  0  1 
97  93.3  100  100  83.3  100  66.7  22.2  0  0  33.3  0  0  0  33.3  0  1 
98  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
99  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
100  86.7  16.7  66.7  50  33.3  33.3  66.7  33.3  83.3  33.3  66.7  100  33.3  0  33.3  1 
101  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
102  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
103  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
104  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
105  93.3  66.7  91.7  83.3  66.7  33.3  33.3  0  0  33.3  33.3  33.3  0  0  66.7  1 
106  86.7  50  100  50  66.7  58.3  22.2  0  0  33.3  33.3  0  0  0  33.3  1 
107  80  33.3  50  16.7  0  25  88.9  33.3  50  100  100  100  0  100  0  1 
108  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
109  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
110  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
111  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
112  86.7  33.3  66.7  50  50  41.7  66.7  33.3  50  33.3  66.7  66.7  33.3  33.3  33.3  1 
113  100  100  100  100  100  83.3  0  0  0  0  0  0  0  0  0  1 
114  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
115  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
116  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
117  100  100  75  100  100  100  33.3  0  33.3  33.3  0  0  0  33.3  0  1 
118  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
119  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
120  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
121  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
122  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
123  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
124  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
125  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
126  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
127  100  100  100  100  100  83.3  0  0  0  0  0  0  0  0  0  1 
128  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
129  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
130  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
131  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
132  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
133  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
134  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
135  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
136  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
137  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
138  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
139  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *      
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disturbance  Constipation  Diarrhoea 
Financial 
difficulty  Dysphagia 
140  86.7  33.3  58.3  33.3  66.7  50  33.3  0  50  100  33.3  33.3  0  66.7  0  1 
141  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
142  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
143  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
144  100  100  100  66.7  100  66.7  33.3  50  0  0  33.3  0  33.3  33.3  0  1 
145  73.3  16.7  41.7  33.3  0  33.3  77.8  33.3  33.3  66.7  66.7  100  0  66.7  100  1 
146  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
147  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
148  100  100  66.7  83.3  100  66.7  11.1  0  0  33.3  0  0  0  0  0  1 
149  93.3  100  100  100  100  66.7  11.1  0  0  0  0  0  33.3  0  0  1 
150  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
151  73.3  16.7  50  50  16.7  50  66.7  33.3  0  100  0  100  33.3  3.3  66.7  1 
152  86.7  33.3  0  16.7  0  50  77.8  83.3  50  100  0  100  0  33.3  100  1 
153  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
154  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
155  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
156  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
157  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
158  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 
159  *  *  *  *  *  *  *  *  *  *  *  *  *  *  *  * 








100  0-100  0-100  0-100  0-100  8.3-100  0-100  0-83.3 
0-
100  0-100  0-100  0-100  0-100  0-100  0-100  1-3 
* not obtained/ patient deceased 